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Abstract 
 
 G protein-coupled receptors (GPCRs) are a class of integral membrane receptor 
proteins that are characterized by a signature seven-transmembrane (7TM) configuration. 
These receptors comprise a large and diverse gene family found in fungi, plants, and the 
animal kingdom. Recent studies with GPCRs have begun to elucidate their importance in 
many physiological processes, thus various human diseases are associated with GPCR 
pathology. Although the overall 3D structure of these receptors carry similar features, 
binding of an extraordinarily diverse array of ligands trigger many different biological 
pathways.     
 The α-factor receptor (Ste2p) of Saccharomyces cerevisiae belongs to the GPCR 
family. Upon the α-factor binding to Ste2p, a signal is transduced via an associated 
guanine-nucleotide binding protein initiating a cascade of events that leads to the mating 
of haploid yeast cells. As only two GPCRs and two G proteins are encoded in the S. 
cerevisiae genome, this yeast presents a relatively simple system to study GPCR signal 
transduction in comparison to mammalian cells that possess hundreds of GPCRs and tens 
of G proteins. Part I of this dissertation is an overview of GPCRs in general with specific 
emphasis on the peptide pheromone α-factor and its receptorSte2p.  
 Part II of this dissertation details the design and characterization of a number of 
iodinatable α-factor pheromone analogs containing the photo-cross-linkable 4-benzoyl-L-
phenylalanine (Bpa) group. One of these analogs [Bpa1, Y3, R7, Nle12, F13] was 
radioiodinated for detection and used as a probe for cross-linking studies with Ste2p. 
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Chemical (with CNBr & BNPS-skatole) and enzymatic (with Trypsin) cleavage of the 
receptor/analog complex after the cross-linking was examined to determine the 
interaction between the α-factor probe and a fragment of the receptor. Data from these 
digestions indicated that the position one of the α-factor interacts with residues 251 to 
294 in the receptor.  
 Similarly Part III of this dissertation describes the design and synthesis of five 
photoactivatable α-factor analogs that carry Bpa at positions one, three, five, eight, or 
thirteen. All of these analogs were biotinylated at the ε-amine of the Lys7 for detection 
and purification purposes. The biological activity (growth arrest assay) and binding 
affinities of all analogs for Ste2p were determined. Two of the analogs tested, Bpa1 and 
Bpa5, showed three- to four-fold lower affinity compared to α-factor, whereas Bpa3 and 
Bpa13 had seven- to twelve-fold lower affinities, respectively. Bpa8 competed poorly with 
[3H]α-factor for Ste2p. All of the analogs tested had detectable halos in the growth arrest 
assay indicating that these analogs are α-factor agonists. Cross-linking studies 
demonstrated that [Bpa1]α-factor, [Bpa3]α-factor, [Bpa5]α-factor and [Bpa13]α-factor 
were cross-linked to Ste2p; the biotin tag on the pheromone was detected by a 
NeutrAvidin-HRP conjugate on Western blots. Digestion of Bpa1, Bpa3, and Bpa13 cross-
linked receptors with chemical and enzymatic reagents suggested that the N-terminus of 
the pheromone interacts with a binding domain consisting of residues from the 
extracellular ends of TM5, TM6, and TM7 and portions of EL2 and EL3 close to these 
TMs. Additionally it was concluded that there is a direct interaction between the position 
13 side chain and a region of Ste2p (F55-R58) at the extracellular end of TM1.  Parts II 
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and III of this dissertation indicate that Bpa-containing α-factor probes are useful in 
determining contacts between α-factor and Ste2p and initiating mapping of the ligand 
binding site of the GPCR for its peptide ligand. 
 This dissertation (Part IV) also presents the application of different purification 
methods and the use of two mass spectrometry instruments for identification of ligand-
receptor interactions at the molecular level. Results presented in this part showed that 
although a single step purification was enough for western blot analyses of the cross-
linked receptor fragments, at least a two-step purification and enrichment of the 
biotinylated peptide fragments were necessary for mass spectrometric studies. MALDI-
TOF experiments showed that the affinity purification of the biotinylated fragments by 
monomeric avidin beads was successful. Data obtained from CNBr fragments of Bpa1 
cross-linked membranes were in agreement with the previous results discussed in Parts II 
and III of this dissertation suggesting the cross-linking between position one of α-factor 
and a region of Ste2p covering residues 251 to 294. This part also illustrated that the 
analyses of the MS/MS data from the cross-linked fragments were more complex than the 
fragmentation data obtained from biotinylated α-factor; the presence of multiple charge 
states of fragment ions and unusual fragmentation of branched peptides indicated the 
necessity of using an instrument with higher resolution. In addition, analyses of the 
MS/MS data with a customized algorithm would be required to deconvolute the sequence 
of the cross-linked fragment(s) to identify the cross-linked residue(s) on Ste2p.   
 The final part of this dissertation reviews the overall conclusions and discussion. 
This part also contains suggestions for future experiments that could help identification of 
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contact points between Ste2p and its peptide ligand α-factor.  Additional studies on this 
GPCR system employing high-resolution mass spectral characterization of fragments 
should allow identification of residue-to-residue interactions between the analogs used in 
this study and Ste2p. Such information will aid the mapping of the ligand-binding site of 
the pheromone receptor and has the potential to provide key insights into peptide ligand 
mediated activation of GPCRs. This and similar studies may ultimately lead to the 
discovery of how peptide ligands initiate signal transduction through GPCRs.   
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PART I 
 
 
General Introduction 
 2
CHAPTER 1 
G Protein-coupled Receptors: An overview 
 
 A class of integral membrane receptor proteins that are characterized by a 
signature seven-transmembrane (7TM) configuration consists of large and diverse gene 
families found in fungi, plants, and the animal kingdom. Members of this class of 
receptors are coupled to heterotrimeric guanine nucleotide-binding proteins (G proteins); 
thus they are called G protein-coupled receptors (GPCRs) [1]. GPCRs are located at the 
cell surface and are responsible for the transduction of an extracellular signal into an 
intracellular response [2].  The natural ligands of this receptor superfamily are 
extraordinarily diverse, embracing biogenic amines (for example, adrenaline, dopamine, 
histamine, and serotonin), peptide and protein hormones (such as angiotensin, bradykinin, 
endothelin, and melanocortin), peptide pheromones (i.e. α-factor, a-factor of various 
fungi species), nucleosides and nucleotides (adenosine, adenosine triphosphate, uridine 
triphosphate), and lipids and eicosanoids (cannabinoids, leukotrienes, prostaglandins, and 
thromboxanes) [3]. Furthermore, the awareness of exogenous stimuli, such as light, odor, 
and taste, is also mediated via this class of receptors [3-5].  
 Heterotrimeric G proteins transduce ligand binding to GPCRs into intracellular 
responses. These proteins are composed of three subunits (α, βγ-dimer) and each subunit 
plays important roles in determining the specificity and temporal characteristics of the 
cellular responses to signals [6]. Activation of GPCRs by agonists induces a 
conformational change in the associated G protein α-subunit leading to release of GDP 
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followed by binding of GTP [7]. This change initiates the dissociation of the α-subunit 
from the receptor and the βγ-dimer. Both the GTP bound α-subunit and the released βγ-
dimer can mediate the stimulation or inhibition of a diverse collection of effector 
enzymes and ion channels, including adenylate cyclase, guanylyl cyclase, phospholipase 
C, mitogen-activated protein kinases (MAPKs), Ca+2, and K+ channels. Thus, stimulation 
of different cell-surface GPCRs with specific agonists results in changes in levels of a 
wide variety of second-messenger molecules [8, 9]. G protein deactivation is rate-limiting 
for turnoff of the cellular response and occurs when the Gα subunit hydrolyzes GTP to 
GDP.    
 Considering the wide variety of biological pathways regulated by GPCRs it is not 
surprising that irregularities of signaling by these receptors are at the root of disorders 
that affect tissues and organs in the human body [10]. So widespread are the 
physiological processes controlled by GPCRs that it has been estimated approximately 
50% of all modern prescription drugs and 25% of the top-selling drugs directly or 
indirectly affect GPCRs [2, 11] (Table 1). In contrast, only a very small portion of the 
known GPCRs represent targets of currently marketed drugs. With the completion of the 
human genome it has been estimated that hundreds of genes code for the GPCR family 
[12] of which only approximately 30 represent targets of currently marketed drugs. 
Hundreds of so-called ‘orphan receptors’ have been identified within the human genome, 
for which the ligand and the (patho)physiological function is unknown [13], and the 
GPCR target family represents approximately a quarter of the portfolio of many 
pharmaceutical companies [14]. It is thus clear that future studies of GPCRs should make 
a dramatic impact on understanding and treatment of a variety of diseases.   
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Table 1: GPCR-based drugs among the 200 best-selling prescriptions in 2000 and 
their GPCR targets*. 
GPCR target Drug Disease Company 2000 sales(US $m) 
Zantac  Ulcers    GlaxoSmithKline  870 
Pepcid  Ulcers  Merck  850 
Claritin  Allergies    Schering-Plough  3,000 
Histamine 
receptors  
Allegra  Allergies    Aventis  1,100 
Risperdal  Psychosis    Johnson & Johnson  1,600 
Imitrex  Migraine   GlaxoSmithKline  1,100 
BuSpar  Anxiety    Bristol-Myers Squibb  714 
5-HT receptors  
Zyprexa  Schizophrenia    Eli Lilly  2,400 
Angiotensin 
receptors  Cozaar  Hypertension    Merck  1,700 
Toprol-XL Hypertension    AstraZeneca  580 
Coreg  Congestive heart failure  GlaxoSmithKline  250 Adrenoceptors 
Serevent  Asthma  GlaxoSmithKline  940 
Muscarinic 
acetylcholine 
receptors 
Atrovent  COPD  Boehringer Ingelheim  600 
GnRH receptors  Zoladex  Cancer  AstraZeneca  740 
Dopamine 
receptors  Requip  
Parkinson’s 
diseases  GlaxoSmithKline  90 
Prostaglandin 
(PGE1) receptors  Cytotec  Ulcers  Pharmacia  100 
ADP receptors  Plavix  Stroke  Bristol-Myers Squibb  900 
*Source: McKinsey Analysis “http://www.predixpharm.com/market_table.htm”.  
Abbreviations: COPD, chronic obstructive pulmonary disease; 5HT, 5-
hydroxytryptamine (serotonin); GnRH, Gonadotrophin-releasing-hormone  
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Classification of GPCRs:  
 Despite the wide variety of agonists that stimulate the diverse secondary-
messenger pathways activated by the GPCR family, these receptors share structure 
similarities [8]. All members of the superfamily contains seven transmembrane-spanning 
α-helical segments connected by alternating intracellular and extracellular loops (IL and 
EL, respectively), with the amino terminus located on the extracellular side of the 
cytoplasmic membrane and the carboxy terminus on the intracellular side. Although 
GPCRs share common membrane topological features, they are diverse in sequence and 
vary especially in size of the extracellular amino-terminal tails, extracellular and 
intracellular loops, and carboxy-terminal tails. Currently several classification systems 
based on these differences have been used to sort out the GPCR superfamily. Some 
systems group the receptors by their ligand, and others have used both physiological and 
structural features. Today one of the most commonly used systems classifies GPCRs into 
six distinct families (A to F clans). This A-F system is designed to cover all GPCRs, in 
both vertebrates and invertebrates with regard to their sequence similarity. According to 
this classification a ‘Superfamily’ is a collection of proteins with structural and functional 
characteristics in common, but which lack obvious sequence similarity. A GPCR ‘Clan’ 
is a collection of receptors, within a superfamily, whose protein sequences share greater 
then 20% sequence identity in their transmembrane regions, and is presumed to have 
evolved from a common ancestor. A ‘Family’ within a clan shares obvious common 
biochemical properties [15, 16] (Table 2).  
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Table 2: Sequence-based groupings within the G-protein-coupled receptors. 
 
 
 
Table adapted from Flower et al. [17] 
Clan A: Rhodopsin-like receptors 
Family I 
Olfactory receptors, adenosine receptors, melanocortin receptors, 
and others 
Family II Biogenic amine receptors 
Family III Vertebrate opsins and neuropeptide receptors 
Family IV Invertebrate opsins 
Family V Chemokine, chemotactic, somatostatin, opioids and others 
Family VI Melatonin receptors and others 
  
Clan B: Calcitonin and related receptors 
Family I Calcitonin, calcitonin-like, and CRF receptors 
Family II PTH/PTHrP receptors 
Family III Glucagon, secretin receptors and others 
Family IV Latrotoxin receptors and others 
  
Clan C: Metabotropic glutamate and related receptors 
Family I Metabotropic glutamate receptors 
Family II Calcium receptors 
Family II GABA-B receptors 
Family IV Putative pheromone receptors 
  
Clan D: STE2 pheromone receptors 
  
Clan E: STE3 pheromone receptors 
  
Clan F: cAMP and archaebacterial opsin receptors 
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According to A-F classification the rhodopsin-like family (Clan A) has the largest 
number of receptors and is by far the most studied. This group contains receptors for 
odorants, small molecules such as the catecholamines and amines, some peptides and 
glycoprotein hormones [18]. The overall sequence identity among all type A receptors is 
low compared to the sequence identity among the members of other clans, and restricted 
to a number of highly conserved motifs such as NSxxNPxxY motif in transmembrane 
domain seven (TMVII) and the DRY motif or D(E)-R-Y(F) at the border between TMIII 
and IL2[19]. Clan B is presently the next largest family, with around 25 distinct 
members, including receptors for a variety of gastrointestinal peptide hormones (secretin, 
glucagons, vasoactive intestinal peptide, and growth-hormone-releasing hormone), 
calcitonin, corticotrophin-releasing hormone and parathyroid hormone [1]. Receptors in 
this clan do not contain any of the structural features characterizing Clan A receptors 
except the presence of a disulfide bridge between the second (EL2) and third extracellular 
loops (EL3). The most noticeable characteristic of this clan is that the amino terminus 
contains several cysteines, presumably forming a network of disulfide bridges [20]. Clan 
C on the other hand is relatively a smaller group, containing the metabotropic glutamate 
and γ-amino-butyric acid receptors, the calcium receptors, the vomeronasal, mammalian 
pheromone receptors, as well as some taste receptors [5]. All receptors in this clan have a 
very large extracellular amino terminus (500-600 amino acids) that seems to be crucial 
for ligand binding and activation [21, 22]. Clan D is the STE2 yeast pheromone 
receptors, and clan E is the STE3 yeast pheromone receptors. These two groups will be 
discussed in the next section (Chapter 2). Finally Clan F comprises the receptors that are 
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related to slime mold cyclic adenosine monophosphate (cAMP) receptors and 
archaebacterial opsins.  
 
The tertiary structure of GPCRs:  
 Information about the tertiary structure of a GPCR is crucial for the understanding 
of its function and for the design of drugs to correct possible problems caused by failure 
of this function. Currently methods used to understand the interactions between the 
ligand and its receptor at the atomic level include X-ray crystallography, electron 
microscopy or diffraction, NMR spectroscopy and molecular modeling. One of the 
advantages for NMR spectroscopy compared to the other methods is that dynamic 
information can be obtained. However, for solving structures by this method, high 
concentrations of dissolved protein (fairly pure) are needed; unfortunately at these high 
concentrations GPCRs are mostly insoluble. Except for several studies where single 
helices were measured in a membrane, using solid state NMR, technical problems have 
precluded NMR studies from giving structural information on GPCRs [23]. Electron 
diffraction has so far been successful in obtaining information on structure of one GPCR-
like molecule (bacterio-rhodopsin) at medium high resolution (3.5 A) [24], and one l 
GPCR (rhodopsin) at low resolution (9.0 A) [25, 26]. These studies with the addition of 
further biochemical and theoretical studies led to structural information about other 
members of the superfamily through homology-modeling studies [27-34].  
 Similar to NMR studies, X-ray studies of GPCRs are hampered by poor solubility 
and suboptimal purification methods of integral membrane proteins. Thus, so far there is 
only one high-resolution 3D GPCR structure determined by X-ray crystallography. The 
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3D structural determination of the dark-adapted bovine rhodopsin by X-ray 
crystallography provides deep insight into the structure of the rhodopsin family of 
GPCRs and related GPCRs in general [35, 36](see review [37]). Remarkably, the X-ray 
structure of rhodopsin was generally in good agreement with the models of various 
GPCRs derived from low-resolution structures of rhodopsin.  
 The crystal structure of rhodopsin revealed a highly organized heptahelical 
transmembrane bundle with 11-cis-retinal as a key cofactor involved in maintaining 
rhodopsin in the ground state. The EL2 is connected to TM3 via a disulfide bridge and 
fits tightly into this helix bundle [38]. A significant feature, from the crystal structure, is 
that the transmembrane helices in rhodopsin are not regular α-helices [39]. The helices 
are bent and contain segments with 310- or π-helical conformation. One of the strongest 
distortions is in TM6 induced by the presence of Pro 267 (a highly conserved residue 
among GPCRs). It has been shown that mutations at this residue can have long range 
effects such as conformational changes on IL3 [27]. In addition a pronounced kink is 
observed in TM2, caused by flexibility in the Gly-Gly sequence in the middle of this 
helix. The crystal structure also revealed a short 8th helix, which runs parallel to the 
cytoplasmic membrane. This helix and the generated fourth cytoplasmic loop cover part 
of the binding site for the C-terminus of the Gα subunit and plays a role in Gγ binding. A 
set of residues including portions of IL3 and the 8th helix likely undergoes a 
conformational change upon photoactivation of the chromophore that leads to the 
receptor activation and signal transduction (see review[40]).  
 It is generally agreed that 3D models of rhodopsin guided by the crystal structure 
will provide a general picture of the other GPCR classes, especially rhodopsin-like 
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GPCRs (Clan A) (see review[41]). Comparisons of the tertiary structures of homologous 
proteins have shown that three-dimensional structures have been better conserved in 
evolution than primary structures, indicating the feasibility of model-building by 
homology. However differences between 3D structures increase with decreasing 
sequence identity and accordingly the accuracy of models built by homology decreases. 
Unfortunately the sequence similarity between different clans of GPCRs is very low, thus 
homology modeling is difficult for GPCRs in non-rhodopsin like families. In case of low 
homology (≤ 25% sequence identity) the alignment of the sequences is the main 
bottleneck for model building, and large errors are often generated. To overcome this 
problem development of secondary structure predictions and ab initio 3D modeling 
techniques with experimental constraints are being used [42, 43].    
 
Ligand binding and receptor activation:  
 The family of G protein-coupled receptors binds and is activated by a wide 
variety of ligands, ranging in size from small molecules to large glycoproteins. Much of 
the current emphasis on receptor research is focused on identification of the binding 
domains for these structurally divergent ligands, using genetic, biochemical, and 
biophysical approaches [8]. Receptor mutagenesis (site-directed or random), domain 
swapping, and use of fluorescence probes are the most commonly used methods for 
elucidating structure-function relationship between GPCRs and their ligands.  The 
binding sites of endogenous “small-molecule” ligands in family A receptors, such as for 
the retinal chromophore in rhodopsin and for catecholamines in the adrenergic receptors 
are the most widely studied and well characterized of these receptor-binding domains 
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(see reviews [44-46]). Recent studies on several peptide receptors such as the receptors 
for angiotensin [47-49], parathyroid hormone [50, 51], secretin [52], bradykinin B2 [53, 
54], gonadotropin-releasing hormone [55], opioids [56, 57], neurokinin (NK) [58, 59], 
vasopressin/oxytocin [60-62], cholecystokinin/gastrin [63, 64], and neurotensin 1 [65] 
supplied valuable information on the binding domains for other classes of GPCRs. 
Although the specific ligand receptor interactions vary, certain similarities are observed 
in ligand GPCR interactions. Large ligands, such as proteins, bind to extracellular loops, 
while small molecules, including pharmacological agents, bind within the transmembrane 
region of receptor. Peptides on the other hand can exhibit a combined binding mode 
whereby they bind primarily to the extracellular loops while part of the structure 
penetrates the transmembrane region and interacts with residues buried in lipids  [66-69]. 
 Photo-affinity cross-linking is one of the few direct methods applied to identify 
the contact regions between the peptide ligands and their GPCRs, thus providing 
information on how the ligand interacts with its receptor. Benzophenones have been used 
extensively as photophysical probes to identify and map peptide-protein interactions [70]. 
In contrast to other cross-linkers, like aryl azides, diazoesters, and diazarenes, they are 
chemically stable under ambient light and could be activated by low energy UV (at 350-
360 nm) minimizing protein damage. They preferentially react with carbon-hydrogen 
bonds resulting in a covalent adduct, which would be stable to chemical and enzymatic 
peptide cleavage [71]. Furthermore, relative to other photo cross-linkers, benzophenones 
do not photo-dissociate and their photo-excited state readily relaxes in the absence of a 
suitable C-H bond. This relaxed state could be excited again which will result in higher 
cross-linking yields upon repeated excitation by long-wavelength UV light [72]. This 
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dissertation will mainly focus on the use of photoactivatable analogs carrying 4-benzoyl-
L-phenylalanine (Bpa), for cross-linking the pheromone to its GPCR, and analysis of the 
results by the aid of other techniques such as site-directed mutagenesis, use of analogs 
and mass spectrometry. The discussions of these methodologies are expanded in parts 2, 
3, and 4 of this dissertation. 
  
Conformational Changes Involved in Agonist Induced GPCR Activation:  
 Several studies on GPCR activation by agonist binding suggested that relative 
movements of the transmembrane domains are the key to transfer the extracellular signal 
to the heterotrimeric G protein. Spin-labeling studies on cysteine-substituted mutants of 
rhodopsin showed that a rigid body motion of TM6 relative to TM3 accompanied by anti-
clockwise rotation (as viewed from the extracellular side) (Figure 1) [73]. Disulfide 
cross-linking of these helices prevented activation of transducin, thus suggesting the 
importance of this movement for activation of rhodopsin. More detailed analysis of 
conformational changes in TM6 of the β2-adrenergic receptor (β2AR) provides evidence 
for a rigid body motion similar to that observed upon activation of rhodopsin [74, 75]. 
Additional support for movement of TM3 and TM6 in the β2AR comes from zinc cross-
linking studies [76] and chemical reactivity measurements in constitutively active β2AR 
mutants [77, 78]. Cysteine cross-linking studies in the muscarinic acetylcholine M3 
receptor provided evidence for the movement of the cytoplasmic ends of TM5 and TM6.  
These results indicated that there are intermolecular interactions allowing the receptor to 
undergo conversion between its inactive and active state. 
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Figure 1: A model for the structure of inactive rhodopsin (dark) and light-
dependent changes (activated) in the relative positions.  Figure adapted from Farrens 
et al. [73].
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 There are currently two widely accepted models for GPCR activation. One of 
these models is the extended ternary complex model (often referred to simply as two-
state model) [79]. According to this model the receptor exists in an equilibrium between 
an inactive conformation (R) and an active conformation (R*). In the absence of agonist, 
the inactive R state is predominant; however, the energy required to convert R to R* is 
sufficiently low, allowing a certain fraction of the receptors spontaneously to assume the 
R* state. In 1994, it was demonstrated that a G protein coupled receptor can be 
spontaneously active in the absence of agonists and that ligands, which were previously 
considered as neutral antagonists, can act as inverse agonist by inhibiting spontaneous 
activity[80]. This concept, originally demonstrated for the β2AR, was then extended to 
many GPCRs including the 5-HT2c serotonin [81], δ-pioid [82] and V2-vasopressin 
receptors [83]. In fact, spontaneous activity and inverse agonism are now considered to 
be general properties of GPCRs that may have physiological implications (reviewed in: 
[84] and [85]). These observations were rationalized by proposing that receptors 
spontaneously isomerize between inactive (R) and active (R*) conformations and that 
inverse agonists and agonists function by stabilizing R and R*, respectively. Agonists are 
predicted to bind with highest affinity to the R* conformation and in this way shift the 
equilibrium and increase the ratio of receptor in R* (conformational selection). On the 
other hand, inverse agonists (also called negative antagonists) have higher affinity to the 
R state, thus bind and stabilize the inactive state shifting the equilibrium away from R*. 
Neutral antagonists, according to this model, are defined as compounds that bind with the 
same affinity to both R and R* thus cause no change in the equilibrium. This model can 
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explain the basal activity of GPCRs in the absence of agonist and the action of inverse 
agonists that inhibit the activity of constitutively-activated receptors. 
The second model for GPCR activation is called multi-state model and suggests 
that the receptor alternates spontaneously between multiple active and inactive 
conformations [86]. This model is becoming more popular due to the limitations of the 
two-state model to explain the complex behavior of GPCRs. Several experiments have 
provided strong support that GPCRs may exist in multiple conformational states. For 
example, a two-state model cannot explain how mutation of certain residues of the 
dopamine D2 receptor can lead to loss of functional coupling in response to some 
agonists, but only had modest effect on the others [87].  Likewise, different 
constitutively-active mutants of the α1b-receptor are differentially phosphorylated and 
internalized although they express a similar agonist-independent activity to the receptor, 
which suggests the existence of more then one active receptor state [88]. Furthermore, 
direct structural evidence has been obtained by fluorescence spectroscopy analysis of the 
purified β2AR[89]. This study indicated that most ligands promote alterations in receptor 
structure consistent with the existence of multiple ligand specific conformation states. 
The most critical point in this model is that the biological response to a given ligand is 
determined by the conformation to which the ligand binds with highest affinity. Thus this 
model is considered as an extension of conformational selection in which ligand binding 
depends on the conformational status of receptor. However, there is evidence suggesting 
that ligand might have an active role of inducing conformational changes in the receptor 
([90-92] for review see [93]).  
 16
It has been recently shown that norepinephrine binds to the β2AR in a sequential 
manner and can induce at least two kinetically and functionally distinct conformational 
states [94]. Similarly studies on µ-opioid receptor demonstrates that different ligands 
induce distinct conformational states that differ in promoting G protein activation and 
receptor internalization [95]. Time-resolved peptide binding studies on the neurokinin 
receptor revealed that an agonist peptide binds with biphasic kinetics. The rapid binding 
component was associated with a cellular calcium response, whereas the slow component 
was required for cAMP signaling [96]. More recently it has been shown that compounds 
which act as inverse agonists on the β-adrenergic-stimulated adenylyl cyclase pathway 
are partial agonists for the receptor-stimulated MAP-kinase activity [83]. These data, 
which support a multi-state model of receptor activation, indicate that different receptor 
conformations lead to the activation of distinct signaling pathways and that ligands can 
selectively activate one while inhibiting the other. Thus, it is likely that a single agonist 
can induce or stabilize multiple functionally distinct conformational states will be 
generalizable to other GPCRs, particularly those activated by peptides and protein 
hormones where there are a larger number of sites of interaction between receptor and 
agonist. A better understanding of this conformational heterogeneity will facilitate the 
design of more effective and selective pharmaceuticals. 
 
 17
CHAPTER 2 
 
α-factor Pheromone and its G Protein-coupled Receptor (Ste2p) in 
Saccharomyces cerevisiae 
 
 One of the biggest challenges facing GPCR research is the complexity of 
eukaryotic systems. The presence of receptor subtypes, known and unknown, within the 
same biological system and cross-talk between different types of receptors regulating 
many different pathways complicate biochemical and physiological studies. S. cerevisiae 
is a species of budding yeast which is most widely known to mankind both for its use 
since ancient times in baking and brewing, and for being one of the most intensively 
studied eukaryotic model organisms in molecular and cell biology. The simplicity of 
single-celled yeast and widely studied mitogen-activated protein kinase (MAPK) system 
regulated by the mating pathway made it a perfect model system for the study of GPCRs.  
After the completion of the sequencing of its genome it is now known that S. cerevisiae 
has only three GPCRs. Two of these are the pheromone receptors (either Ste2p or Ste3p) 
and the other is the Gpr1p which is a carbohydrate sensor. While the pheromone and 
carbohydrate-sensing pathways share some down-stream components, there is no cross-
talk between the two systems as the pheromone receptors and the Gpr1p couple to two 
different G-proteins (Gpa1p and Gpa2p, respectively) [97, 98]. Thus S. cerevisiae 
provides an ideal system to study the relation between a peptide ligand and its GPCR in 
the absence of interfering biological complexities. 
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Mating in yeast, Saccharomyces cerevisiae:  
 S. cerevisiae, commonly referred to as Brewer’s or Baker’s yeast, can grow as a 
haploid or diploid [99, 100]. Haploid cells exist in two mating cell types MATa and 
MATα. The secretion and reciprocal detection of peptide pheromones (α-factor and a-
factor) by GPCRs (Ste2p and Ste3p, respectively) initiate mating and eventual fusion of 
two haploids. a-cells secrete a-factor, a hydrophobic farnesylated, carboxymethylated, 
dodecapeptide with the sequence YIIKGVFWDPAC(Farnesyl)-OCH3 while α-cells 
secrete α-factor, a tridecapeptide with the sequence WHWLQLKPGQPMY (see Figure 2 
for schematic representation).  
 Pheromone binding to its GPCR and activation of the G protein induces initiation 
of the downstream MAPK cascade which, in turn, activates the transcription of genes 
involved in the production of pheromone itself, pheromone receptor and the proteins of 
the signaling pathway. Also components mediating cellular adhesion (sex-specific 
agglutinins), arresting the cell cycle in the G1 phase by eliminating the function of G1 
cyclin complex and Cdc28 protein kinase, inducing cell and nuclear fusion and also genes 
reducing the reactivity of the cell to pheromone and those releasing the cell cycle arrest 
(desensitization) are activated [101, 102] (Figure 3).  The activation of cells by 
pheromone results in morphological changes. First, conjugation projections are formed to 
facilitate connection of the cells. By the action of agglutinins, the tips of the projections 
fuse forming a conjugation bridge. Next, the nuclei migrate into the bridge and 
subsequently fuse to produce a diploid nucleus of the zygote. All these morphological 
processes occur with an involvement of cytoskeletal components, i.e., microtubules and 
actin structures, and the cell wall [103]. 
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Figure 2: Pheromone mediated mating in Saccharomyces cerevisiae. Schematic representation of pheromone/receptor mediated 
communication between MATa and MATα haploid cells prior to mating. 
 
MAT a MATα 
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Figure 3: Saccharomyces cerevisiae mating pathway. Binding of the pheromone to its 
GPCR stimulates downstream responses such as transcriptional activation of pheromone 
induced genes, cell cycle arrest, and polarization of the cytoskeleton. (Adapted from 
Madden and Snyder [103]). Ste5p is the scaffold protein, Ste20p is mitogen-activated 
quadruple protein kinase (MKKKK), Ste11p is MKKK, Ste7p is MKK, Fus3p and Kss1p 
are MAPK. 
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Structure-function analysis of α-factor pheromone:   
The α-factor is a tridecapeptide secreted by MATα cells and has the sequence of 
WHWLQLKPGQPMY. Extensive analyses of α-factor analogs in combination with 
receptor mutagenesis have provided insights into the structural basis of α-factor activity 
[104-108]. These studies aided the discovery of several antagonists, partial agonists and a 
ligand with novel function which is able to enhance the activity of α-factor but, alone, 
has no agonistic activity termed a synergist. Additionally biochemical and biophysical 
analysis of α-factor and its analogs have suggested structural and functional information. 
Briefly the results of these studies indicated that residues near the amino terminus play an 
important role in receptor activation, the carboxyl terminus of the peptide contributes 
mostly to the binding affinity and the central residues of the peptide form a β-turn around 
the Pro8-Gly9 bound aiding the orientation of the signaling and the binding domains of 
the pheromone (Figure 4) [109-111].  
Several of the D-Ala series analogs, near the N-terminus, specifically [D-Ala2]α-
factor, [D-Ala3]α-factor and [D-Ala4]α-factor had no measurable biological activity 
[107]. However, these peptides bound relatively strongly to Ste2p and antagonized the 
biological activity of wild type ligand (α-factor pheromone). Previous studies from our 
laboratory showed that most of the antagonists discovered involved changes in residues 
near the amine terminus. Based on these findings it seems clear that residues near this 
region play an important role in triggering cell signaling through Ste2p or in stabilizing 
the activated state of this receptor. 
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Figure 4: Functional domains of α-factor ligand. Studies of α-factor analogs have 
revealed two regions according to their major contributions to activity and binding 
affinity. The residues at the N-terminus appeared to mainly function in activation of the 
receptor signaling, the residues at the C-terminus strongly contribute to the binding 
affinity. However the two functions cannot be completely separated. The loop domain 
corresponds to residues of the peptide which are thought to induce a bend in the ligand 
structure. (Figure adapted from Abel et al. [107])  
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 On the other hand the residues at the carboxyl terminus of α-factor strongly 
influence the binding. Replacement of these residues by either L- or D-Ala caused 
decreases in affinity of up to 3000-fold [107]. Moreover, these carboxy-terminal residues 
are not sufficient to cause signaling as evidenced by the total absence of agonist activity 
in [D-Ala3]α-factor. Removal of the carboxyl terminal residues result in pheromones 
with drastically reduced receptor affinity and, in some cases, also with complete loss of 
affinity. Similar observations for other peptide receptors, where the functional domains 
for binding and activity are separated, have been reported [112-115].  
 As mentioned above, the central residues of α-factor contains a Pro-Gly sequence. 
This sequence has been associated with a high probability of β-turns, in particular Type II 
β-turns [116, 117]. Studies on desTrp1-α-factor analogs indicated that a turn at this 
position was involved in biological activity of the pheromone [118]. Additional studies 
with L- or D-Ala α-factor analogs suggested that this region of the peptide may lead to 
create the proper overall conformation for the pheromone [107].  
 
Interactions between α-factor pheromone and its GPCR, Ste2p: 
 The yeast α-factor pheromone receptor is one of the most extensively studied 
GPCRs. While many techniques have been applied to study the structure-function 
relationship for this receptor, much of our knowledge comes from the characterization of 
mutant receptors and α-factor analogs. Today several research groups (5 in the United 
States) are working with Ste2p as a model system. Mutagenesis studies carried out by 
these groups cover almost 70-80% of all the residues present in this 431 amino acid 
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receptor. Although it is not possible to summarize all of these mutational analyses in the 
context of this dissertation, studies relevant to our results will be discussed in parts 2 & 3.  
 In addition to the mutagenesis studies, chimeric receptors between S. cerevisiae 
and S. kluyveri α-factor receptors also supplied important information to understand the 
ligand receptor interaction(s) [119, 120]. These studies helped the identification of three 
small regions that are mostly contributing to the specificity of the two receptors to their 
wild type ligands. A substitution at residues 47-49 (region of N-terminus connected to 
TM1) affected specificity for pheromone binding but not for pheromone activation of 
response. Substitution of residues 267-269 (extracellular portion of TM6) affected 
pheromone specificity for activation of cellular responses, but not for pheromone 
binding. Finally substitution of residues 104-123 (part of EL1 attached to TM2) modestly 
affected both types of specificity.   
 
Regulation of Ste2p in Saccharomyces cerevisiae: 
 The coordination of complex cellular processes, from growth and differentiation 
to responses of environmental changes, often depend on careful regulation of GPCRs. 
Like many other GPCRs, Ste2p is highly regulated by several control mechanisms. The 
most well characterized regulation of Ste2p are: rapid phosphorylation and 
desensitization [121]; internalization and recycling [122]; and down-regulation and 
degradation [123, 124]. GPCRs often become less responsive (desensitize) after 
prolonged agonist exposure. In many eukaryotic systems a highly conserved mechanism 
involving multiple protein-protein interactions, receptor phosphorylation [by G-protein 
coupled receptor kinases (GRKs)] and receptor endocytosis (internalization) is 
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responsible for this desensitization [125]. Phosphorylation by GRKs and trafficking 
events are usually associated with acute desensitization as the immediate occurrence of 
these events coincides with the rapid desensitization observed with most receptors. On 
the other hand receptor down-regulation results in an overall reduction in receptor levels 
in the cell, which usually has a longer term effect on signaling [126].    
 The mating process in yeast is further regulated by the control of the expression 
levels or the activities of the downstream elements in the signaling pathway (i.e. subunits 
of the G protein or/and MAPK). One of the well characterized regulators is Sst2p, a yeast 
homologue of regulators of G protein signaling (RGS), which effect the G protein 
signaling by accelerating the GTP hydrolysis and promoting re-association of the 
heterotrimer [127, 128]. Additionally, expression of some proteases like Bar1p (Sst1p), 
which specifically cleaves α-factor pheromone, adds further complexity to the regulation 
of mating [129]. Furthermore, several different types of post-translational modifications 
have been described for the heterotrimeric G protein subunits, which may be involved in 
signal regulation. Details of these modifications are beyond the scope of this study, 
however a few of the well characterized modifications are: 1) palmitoylation [130], 
myristoylation [131, 132] and ubiquitination of the Gα (Gpa1p) [133]; 2) isoprenylation 
[134], farnesylation [135] and palmitoylation of the Gγ (Ste18p) [136]; and 3) 
phosphorylation of the Gβ (Ste4p) [137]. 
 Although the S. cerevisiae mating signal transduction pathway is one of the best 
defined MAPK pathways, the mechanism that triggers this pathway is poorly understood. 
The lack of information how the peptide pheromone interacts with its GPCR and causes 
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conformational changes leading to the dissociation of the G protein limits our 
understanding of α-factor receptor activation. Mapping the α-factor binding region(s) in 
Ste2p could supply great insights for understanding the overall mechanism of GPCR 
activation by peptide ligands. This dissertation mainly describes the use of novel α-factor 
ligand analogs as tools and probes to study receptor binding and activation. Parts II and 
III detail the construction, characterization and use of α-factor probes that contain the 
photo-cross-linkable group, 4-benzoyl-L-phenylalanine (Bpa), for use in determining 
ligand-receptor contact sites. Part III also introduces the use of biotin for detection of the 
ligand as an alternative to radioactive ligand. Part IV describes the methods applied for 
cross-linked sample preparation for mass spectrometry (MS) analysis. This part also 
covers some of the preliminary MS results that support our findings presented in part II 
and III. Finally part IV is an overall evaluation of these studies, contributions to the 
working model of α-factor-Ste2p interaction and future studies that could be performed 
to refine this model, thus aiding us to better understand how peptide ligands interact with 
their GPCRs.   
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CHAPTER 1 
Introduction 
 
 G protein-coupled receptors (GPCRs) comprise one of the largest super-families 
of proteins with over 1000 members represented in the human genome alone [1, 2]. One 
of the key steps in understanding the mechanisms of action of these diverse GPCRs is to 
elucidate the structure of their ligand binding sites. With this information in hand, the 
mechanism of activation of the GPCR can begin to be understood.  
 While there has been considerable data published on the GPCR ligand binding 
sites for biogenic amines (see [3] for a review), much less information exists concerning 
the binding sites of peptide-responsive GPCRs. Recently, several reports have addressed 
this issue with the use of 4-benzoyl-L-phenylalanine (Bpa) photoreactive chemical groups 
[4-10]. Incorporation of Bpa into the first position of parathyroid hormone (PTH) and its 
use as a cross-linkable probe resulted in evidence that the N-terminal residue of PTH 
interacts with the extracellular end of transmembrane helix 6 of its receptor PTH1-Rc 
[11]. A recent study by Mouledous et al. [8] investigating the interaction between the 
heptadecapeptide nociceptin and the opioid receptor-like (ORL1) GPCR made use of 
[Bpa10, Tyr14]nociceptin and found that the photoactivatable Bpa moiety cross-linked to a 
six amino acid fragment (amino acids 296-302). These studies and others using Bpa-
containing peptides have allowed for the identification of interacting receptor fragments 
and in some cases even specific contact residues [5-7, 9]. Identification of these cross-
linked receptor fragments is a first but critical step in the elucidation of direct residue to 
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residue contacts between ligand and receptor and has the potential to provide significant 
insight into the mechanism of activation of GPCRs by peptide ligands.  
 GPCRs can bind a variety of molecules including biogenic amines, peptides, and 
sugars. The unicellular yeast Saccharomyces cerevisiae contains two GPCRs used by 
haploid cells in the detection and response to peptide pheromones secreted by cells of the 
opposite mating type during sexual reproduction (see [12, 13]for reviews). One of these 
receptors, Ste2p, responds to the α-factor peptide pheromone (WHWLQLKPGQPMY) 
while the other receptor, Ste3p, responds to the post-translationally modified a-factor 
peptide (YIIKGVFWDPAC[S-farnesyl]-OCH3).  
 The study of the pheromone receptors in S. cerevisiae has led to many critical 
findings concerning the biology of GPCRs, such as the discovery of the Regulator of G-
protein Signaling (RGS) family of proteins [14, 15]. Additionally, Ste2p serves as a 
model protein for the study of GPCRs, as (i) its transmembrane domains (TMDs) appear 
to be arranged similarly to those of other GPCRs, (ii) interactions between the fifth and 
sixth transmembrane domains appear to be critical for proper signal transduction to the G 
protein, and (iii) close packing of the fifth and sixth TMDs appears to be structurally 
similar to that of rhodopsin [16]. All of these factors suggest that while most GPCRs do 
not share sequence homology, they do have strong structural and functional similarities. 
Therefore, elucidation of contact residues between receptor and ligand should provide 
insight into structure-function relationships in binding and activation of peptide-
responsive GPCRs.  
 Part II of this dissertation describes the synthesis, the chemical, and biochemical 
characterization of iodinatable Bpa-containing α-factor analogs. One of the analogs, 
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[Bpa1, (125I)Tyr3, Arg7, Phe13]α-factor, was specifically cross-linked into the α-factor 
binding pocket of Ste2p and used to determine direct contacts between the pheromone 
and the receptor. Biochemical analysis localized the cross-link site within residues 251-
294 of the Ste2p receptor.  
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CHAPTER 2 
Materials and Methods 
 
Organisms: 
  S. cerevisiae DK102 [MATa ste2::HIS3 bar1 leu2 ura3 lys2 ade2 his3 trp1] 
transformed with pNED1[STE2] [17] was used in binding studies and in the growth arrest 
assays of various α-factor analogs. Strain LM23-3AZ [MATa FUS1::lacZ bar1-1] from 
Lorraine Marsh, Albert Einstein College of Medicine, New York, NY, was used in 
FUS1-lacZ gene induction assays. Strain BJ2168 [MATa prc1-407 prb1-1122 pep4-3 
leu2 trp1 ura3-52] transformed with pNED1[STE2] [17] and BJS21 [MATa ste2::kanR 
prc1-407 prb1-1122 pep4-3 leu2 trp1 ura3-52] transformed with pJL147 [STE2-T7] were 
used in cross-linking assays. Strain BJS21 was constructed by deleting STE2 from strain 
BJ2168 using the kanamycin deletion cassette. pJL147 (a gift from J. Konopka, [16]) 
encoded Ste2p containing the T7 epitope (Met-Ala-Ser-Met-Thr-Gly-Gly-Gln-Gln-Met-
Gly) introduced between Ste2p residues 303 and 304. All strains used had similar binding 
of α-factor. However, the BJ2168pNED and BJS21 strains lacked several peptidases, so 
they were used to increase the yield of Ste2p in experiments involving cross-linking.  
 
Chemical Reagents: 
  All reagents and solvents used for the solid-phase peptide synthesis of the 
photoactivatable peptides were analytical grade and were purchased from Advanced 
Chem Tech (Louisville, KY), VWR Scientific (Piscataway, NJ), or Aldrich Chemical Co. 
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(Milwaukee, WI). High-performance liquid chromatography (HPLC) grade 
dichloromethane (CH2Cl2), acetonitrile (ACN), methanol (MeOH), and water were 
purchased from VWR Scientific and Fisher Scientific (Springfield, NJ).  
 
Synthesis of Bpa-Containing [Nle12]α-Factor Analogs: 
  Automated syntheses were carried out on an Applied Biosystem 433A peptide 
synthesizer (Applied Biosystem, Foster City, CA) using preloaded Wang resins (0.70 
mmol/g, Advanced ChemTech) for most of the peptides. Two series of peptides were 
synthesized. In the first series, 4-benzoyl-L-phenylalanine (Bpa) was systematically used 
to replace the wild-type residue in all positions of the tridecapeptide except for Gly9. The 
latter residue was not replaced because previous studies had concluded that substitution 
of Gly9 by an L-residue results in a marked decrease in activity and affinity [18, 19]. In 
the second series of peptides, Tyr13 was replaced by Phe, Bpa was substituted at either 
position 1, 3, or 5, and a Tyr residue was substituted at either position 1 or 3. The goal of 
the second series of analogs was to prepare a photo-cross-linkable peptide which could 
also be followed by autoradiography. In most peptides, L-norleucine (Nle), which is 
isosteric with L-methionine, was incorporated at position 12 to replace the naturally 
occurring L-methionine to prevent oxidation of the sulfur atom of this amino acid during 
peptide synthesis and purification. Replacement of Met by Nle was shown previously to 
result in an analogue with equal activity and receptor affinity to those of the native 
pheromone [20]. Since all analogs have Nle in place of Met12, this residue is eliminated 
from the abbreviated names for simplicity. The 0.1 mmol FastMoc chemistry of Applied 
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Biosystems was used for the elongation of the peptide chain with an HBTU/HOBt/DIEA-
catalyzed, single coupling step using 10 equiv of protected amino acids for 30 min.  
 
Cleavage of Peptide: 
  The N-α-deprotected peptidyl resin was washed thoroughly with 1-methyl-2-
pyrrolidinone and dichloromethane and dried in vacuum for 2 h. The peptide was cleaved 
from the resin support with simultaneous side chain deprotection using a cleavage 
cocktail containing trifluoroacetic acid (10 mL), crystalline phenol (0.75 g), thioanisole 
(0.5 mL), and water (0.5 mL) at room temperature for 1.5 h with the omission of 1,2-
ethanedithiol in the cleavage reaction, because it was known to transform Bpa-containing 
peptides to cyclic dithioketal derivatives [21]. The filtrates from the cleavage reaction 
were collected, combined with trifluoroacetic acid washes of the resin, concentrated 
under reduced pressure, and treated with cold ether to precipitate the crude product.  
 
Purification and Characterization: 
  The crude peptide so obtained was purified by reversed phase HPLC (Hewlett-
Packard Series 1050) on a semipreparative Waters µ-Bondapack C18 (19 × 300 mm) 
column with detection at 220 nm. The crude product (50 mg) was dissolved in about 4 
mL of aqueous acetonitrile (20%) containing 0.025% TFA, applied to the column, and 
eluted with a linear gradient of water/acetonitrile containing 0.025% TFA (0-70% 
acetonitrile over 2 h at a flow rate of 5 mL/min). The fractions were collected and 
analyzed at 220 nm by reversed phase HPLC (Hewlett-Packard Series 1050) on an 
analytical Waters µ-Bondapack C18 (3.9 × 300 mm) column. Fractions of over 99% 
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homogeneity were pooled and subjected to lyophilization. The purity of the final peptide 
was assessed by analytical HPLC using two different solvent systems (10-55% 
acetonitrile gradient, 15 min, with 0.025% trifluoroacetic acid; and 50-80% methanol 
gradient, 30 min, with 0.025% trifluoroacetic acid), amino acid analysis (Biopolymer lab, 
Brigham and Women's Hospital, Cambridge, MA), and electrospray ionization mass 
spectrometry (ESI-MS Peptido Genic Inc., Livermore, CA).  
 
Growth Arrest (Halo) Assay:  
 Solid MLT medium [yeast nitrogen base without amino acids (Difco), 6.7 g/L; 
casamino acids (Difco), 10 g/L; glucose, 20 g/L; adenine sulfate, 0.058 g/L; arginine, 
0.026 g/L; asparagine, 0.058 g/L; aspartic acid, 0.14 g/L; glutamic acid, 0.14 g/L; 
histidine, 0.028 g/L; isoleucine, 0.058 g/L; leucine, 0.083 g/L; lysine, 0.042 g/L; 
methionine, 0.028 g/L; phenylalanine, 0.69 g/L; serine, 0.52 g/L; threonine, 0.28 g/L; 
tyrosine, 0.042 g/L; valine, 0.21 g/L; and uracil, 0.028 g/L] [11] was overlaid with 4 mL 
of S. cerevisiae DK102pNED cell suspension (2.5 × 105 cells/mL of Nobel agar). Filter 
disks (sterile blanks from Difco), 8 mm in diameter, were impregnated with 10 µL 
portions of peptide solutions at various concentrations and placed onto the overlay. The 
plates were incubated at 30 ˚C for 24-36 h and then observed for clear zones (halos) 
around the disks. The data were expressed as the diameter of the halo including the 
diameter of the disk. A minimum value for growth arrest is 9 mm, which represents the 
disk diameter (8 mm) and a small zone of inhibition. All assays were carried out at least 3 
times with no more than a 2 mm variation in halo size at a particular amount applied for 
each peptide. The values reported represent the mean of these tests.  
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Effect of α-Factor Analogs on Gene Induction: 
  S. cerevisiae LM23-3AZ carries a FUS1 gene that is inducible by mating 
pheromone and which is fused to the reporter gene β-galactosidase. Cells were grown 
overnight in MLT at 30 ˚C to 5 × 106 cells/mL, washed by centrifugation, and grown for 
one doubling at 30 ˚C. Induction was performed by adding 15 µL of peptide at various 
concentrations to 135 µL of concentrated cells (2 × 108 cells/mL) in a 96 well microtiter 
plate. The mixtures were placed at 30 ˚C with shaking for 2 h. After this time, cells were 
harvested by centrifugation, and each pellet was resuspended in Z-Buffer containing β-
mercaptoethanol [22] and assayed for β-galactosidase production (expressed as Miller 
units) in triplicate. Each experiment was carried out at least 3 times with the results 
similar in each assay. As cells were suspended in liquid medium, any contribution of 
diffusion through agar potentially present in the halo assay was eliminated in the gene 
induction assay.  
 
Binding Competition Assay with [3H]α-Factor:  
 This assay was performed using strain DK102pNED and tritiated α-factor 
prepared by reduction of [dehydroproline8, Nle12]α-factor as described previously [20]. 
In general, cells were grown at 30 ˚C overnight and harvested at 1 × 107 cells/mL by 
centrifugation at 5000g at 4 ˚C. The pelleted cells were washed 2 times in ice-cold buffer 
[PPBi: 0.5 M potassium phosphate (pH 6.24) containing 10 mM TAME, 10 mM sodium 
azide, 10 mM potassium fluoride, 1% BSA (fraction IV)] and resuspended to 4 × 107 
cells/mL. The binding assay was started by addition of [3H]α-factor and various 
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concentrations of nonlabeled peptide (140 µL) to a 560 µL cell suspension so that the 
final concentration of radioactive peptide was 6 × 10-9 M (20 Ci/mmol). Analogue 
concentrations were adjusted using UV absorption at 280 nm and the corresponding 
extinction coefficients. After 30 min incubation, triplicate samples of 200 µL were 
filtered and washed over glass fiber filtermats using the Standard Cell Harvester (Skatron 
Instruments, Sterling, VA) and placed in scintillation vials for counting. Each experiment 
was carried out at least 3 times with the results similar in each assay. Binding of labeled 
α-factor to filters in the absence of cells was less than 20 cpm. The Ki values were 
calculated by using the equation of Cheng and Prusoff, where Ki = EC50/(1 + [ligand]/Kd) 
[23].  
 
Synthesis of Iodinated α-Factor Peptides: 
  Peptides were iodinated with Iodogen tubes from Pierce, Inc., using conditions 
recommended by the manufacturer. Briefly, Iodogen tubes were pre-wet with 2× Tris 
Iodination Buffer (TIB: 50 mM Tris, pH 7.5, 0.8 M NaCl). The TIB was decanted, 100 
µL of fresh TIB was added directly to the bottom of the Iodogen tube, and either 10 µL 
of Na127I (1.86 mg/mL) or 10 µL of Na125I (100 µCi/µL, pH 10, ICN) was added and 
incubated for 15 min with gentle swirling every 30 s. Activated iodide was transferred to 
a siliconized microfuge tube containing 100 µL of the peptide (0.5 mmol/L in TIB) and 
incubated for 20 min with gentle mixing every 30 sec. Scavenging buffer (50 µL at 10 
mg/mL tyrosine in TIB) was added and incubated for 5 min with mixing at minutes 1 and 
4. Following incubation, 1 mL of TIB containing 5 mM EDTA was added. The 
remaining unreacted iodine was separated from peptide using a Waters Sep-Pak C18 
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minicolumn. The eluted products were separated by HPLC using water/acetonitrile/ 
0.025% TFA with an acetonitrile percentage of 20-35% over 30 min at 1.4 mL/min on a 
Waters µBondapak C18 reversed phase analytical column (3.9 × 300 mm). 127I-labeled 
peptides were quantitated by UV spectrophotometry using their extinction coefficients. 
Radioiodinated peptides were labeled using carrier-free Na125I, and the resulting 
monoiodinated peptides were quantitated by converting total dpm associated with the 
HPLC-purified peptide to millimoles of peptide using the specific activity of carrier-free 
Na125I (2159 Ci/mmol).  
 
Synthesis of [Bpa1, Lys7(ε-biotinyl-β-alanyl)]α-Factor:  
 This analogue was synthesized by first adding Boc-β-alanine hydroxysuccinimide 
ester and then hydroxysuccinimido biotin ester to [α-Fmoc-Bpa1]α-factor that had been 
prepared by solid-phase peptide synthesis. After removal of all protecting groups, the 
final peptide was purified to near-homogeneity by reversed phase HPLC. Its molecular 
weight was determined by electron spray mass spectrometry to be 2028.0 (theoretical = 
2028.35). This compound was a full agonist in the growth arrest assay and exhibited a 
binding affinity close to that of α-factor.  
 
Binding Assays with 125I-Labeled α-Factor:  
 DK102 pNED1 cells (grown in MLT medium) [17] and DK102 cells (grown in 
MLT medium supplemented with tryptophan) were harvested at 1 × 107 cells/mL by 
centrifugation and resuspended to 6.25 × 107 cells/mL in PPBi buffer (pH 6.24) and 
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placed at 4 ˚C. In competition binding assays, [Bpa1, (125I)Tyr3, Arg7, Phe13]α-factor (2.4 
× 10-9 M final concentration) was premixed with various concentrations of cold 
competitor. In saturation binding assays, radiolabeled α-factor analogs were diluted with 
cold analogue to obtain the peptide concentrations used in the assay. Cells in PPBi were 
then added to peptide solutions to a final density of 6.25 × 106 cells/mL and incubated for 
45 min at room temperature. Following incubation, the suspension was transferred (3 × 
200 µL) to wells of a 0.45 µm MultiScreen-HV, 96 well plate (Millipore MHVBN4510) 
preblocked with PPBi. Samples were vacuum-filtered, washed with PPBi (2 × 200 µL), 
and counted on an LKB-Wallac CliniGamma 1272 gamma counter. Using this 
methodology, nonspecific binding of radiolabeled peptide to the filter was at background 
levels. Specific binding was determined by subtracting counts associated with the DK102 
(ste2) strain from counts bound to the DK102pNED1 (STE2) strain.  
 
Cross-Linking of [Bpa1, (125I)Tyr3, Arg7, Phe13]α-Factor to Ste2p: 
  BJ2168pNED1 membranes (220 µg of protein) [17] were incubated with 975 µL 
of PPBi buffer (with 0.1%BSA) in siliconized microfuge tubes for 10 min at ambient 
temperature. [Bpa1, (125I)Tyr3, Arg7, Phe13]α-factor (10 and 20 million cpm) was added, 
and the reaction was incubated for 2 h at room temperature with gentle mixing. The 
reaction mixture was aliquoted into 3 wells of a chilled 24 well plastic culture plate 
preblocked with PPBi (0.1% BSA). Separation of the reaction mixtures into separate 
wells kept the depth of the samples minimal (~2 mm) for efficient UV penetration of the 
sample. The samples were held at 4 ˚C and irradiated without the culture plate lid at 365 
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nm for 1 h at a distance of 12 cm in a Stratlinker (Stratagene, La Jolla, CA). Membrane 
samples were recombined in siliconized microfuge tubes and washed twice by 
centrifugation (14000g) with PPBi (0.1% BSA). Membrane pellets were dissolved in 2 × 
sample buffer (0.25 M Tris-HCl, pH 8.8, 0.005% bromphenol blue, 5% glycerol, 1.25% 
β-mercaptoethanol, 2% SDS). Samples were heated to 37 ˚C for 10 min and separated by 
SDS-PAGE (10% gel; 30 mA). In competition cross-linking experiments, cold α-factor 
was added together with radioiodinated peptide. For subsequent receptor digestion 
analysis, the gel was exposed to a phosphorimager screen (STORM, Molecular 
Dynamics), and the band of radioactivity corresponding to Ste2p was excised and placed 
into dialysis tubing (15 000 molecular weight cutoff) with buffer (0.2 M Tris-acetate, pH 
7.4, 1.0% SDS, 100 mM dithiothreitol). Electroelution was performed by placing dialysis 
tubing containing the gel in a horizontal electrophoresis chamber with running buffer (50 
mM Tris-acetate, pH 7.4, 0.1% SDS, 0.5 mM sodium thiogylcolate). Elution was carried 
out at 100 V for 3 h. The buffer in the dialysis tubing was transferred to a Millipore 
Ultrafree-15 centrifuge filter device (30 000 molecular weight cutoff) and concentrated 
by centrifugation. Concentrated sample was washed 3 times with 50 mM Tris-HCl, pH 
7.5. Half of the sample was further treated with PNGaseF (Glyco) according to the 
supplier's instructions.  
 
Digestion of Cross-Linked Ste2p:  
 Cross-linked samples were digested with BNPS-skatole, CNBr, or trypsin. For 
BNPS-skatole digestions, samples were dissolved in 70% acetic acid, and approximately 
10 mg of BNPS-skatole was added. For CNBr digestion, samples were dissolved in 70% 
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formic acid, and a few crystals of CNBr were added. For trypsin digestion, samples were 
dissolved in trypsin digestion buffer (Promega), and 20 µg of trypsin (Sequencing Grade 
modified trypsin, Promega) was added. All digestion reactions took place under nitrogen 
and complete darkness. After digestion, samples were dried by vacuum centrifugation, 
resuspended in 50 µL of 0.5 M Tris, pH 8.25, and re-dried. BNPS-skatole and CNBr 
samples were then dissolved in Tris-tricine sample buffer from Novex (San Diego, CA) 
and run on 16% and 10-20% tricine gels (Novex). Trypsin-digested samples were 
dissolved in loading buffer (Invitrogen) and run on 12% Bis-tris gels with MES running 
buffer (Invitrogen). Gels were dried and exposed to a phosphorimager screen for 1-4 
days.  
 
Cross-Linking of Biotinylated α-Factor to Ste2p-T7:  
 [Bpa1, Lys7(ε-biotinyl-β-alanyl)]α-factor was used in cross-linking studies with 
strain BJS21-pJL147 membranes. Receptors cross-linked with the biotinylated probe as 
described above were digested with trypsin for 18 h with addition of fresh trypsin after 12 
h at 30 ˚C. Digested samples were run on two separate gels (18% SDS-PAGE), 
transferred to Immobilon-P, and blocked with 5% milk-TBS for 1 h. One blot was probed 
with NeurtAvidin-HRP (Pierce Chemical) and detected with Western Lightning 
Chemiluminescence Reagent plus (WLCR+, PerkinElmer). The second blot was probed 
with T7-HRP antibody (Novagen) according to manufacturer's instructions, and detected 
by WLCR+.  
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CHAPTER 3 
Results 
 
Synthesis of α-Factor Analogs:  
 The automated solid-phase synthesis of most of the α-factor analogs yielded 
crude peptides which were 60-70% homogeneous. Lower purities (<50%) were observed 
with the peptides containing diiodoTyr. In previous studies, we obtained better 
incorporation of diiodotyrosine into α-factor when arginine replaced lysine in the seventh 
position [24, 25]. Therefore, all α-factor analogs synthesized in this investigation 
contained Arg7. [Arg7]α-Factor was previously shown to have the same activity and 
binding affinity as α-factor [20]. The crude peptides were all purified by reversed phase 
HPLC to over 99% homogeneity based on analytical HPLC in both an 
acetonitrile/water/TFA and a methanol/water/TFA gradient system. All peptides were 
subjected to amino acid analysis and electrospray ionization mass spectrometry. 
Physicochemical data for peptides containing both Bpa and Tyr substitutions are 
summarized in Table 1. Similar characterization of the series containing only the Bpa 
substitution was also carried out (data not shown). Amino acid analysis and mass 
spectrometry verified the purity and composition of the synthetic α-factor analogs used in 
this study.
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Table 1: Physicochemical properties of photo activatable peptides 
a Calculated monoisotopic molecular weight. 
b Molecular mass determined using electron ionization mass spectroscopy (ESI-MS). 
c K is defined as (Vp - Vf)/Vf where Vp = the elution volume for the peptide and Vf = the breakthrough volume.  
K-values (a) were determined on a C18 µ-Bondpack column using a 10-55% acetonitrile gradient (0.025% trifluoroacetic 
acid) over 15 min and (b) were determined using 50-80% methanol gradient (0.025% trifluoroacetic acid) over 30 min. 
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Receptor Affinities of Bpa-Scanned α-Factor Analogs:  
 To attain efficient cross-linking of a ligand into a receptor binding site, it is 
necessary to employ ligands that bind tightly to the receptor. To ascertain the positions at 
which Bpa replacements would be tolerated, introduction of this residue throughout the 
peptide backbone was tested. As seen in Figure 1, Bpa replacements at positions 1 (Trp), 
3 (Trp), 5 (Gln), 7 (Lys), 8 (Pro), 12 (Met), and 13 (Tyr) were well tolerated, exhibiting 
decreases in Ki from 4-fold to 45-fold in comparison to α-factor (Figure 1). In contrast, 
substitutions at positions 2, 4, 6, 10, and 11 resulted in 100-fold to greater than 1500-fold 
decreases in affinity. Based on these data and our working model for pheromone binding 
to receptor [26], analogs with Bpa at positions 1, 3, 5, and 13 were chosen for further 
evaluation as photo-cross-linkable α-factors. 
  
Bioactivities of Iodinatable Bpa Analogs of α-Factor:  
 To determine cross-link points between a ligand and its binding protein, tags are 
useful to reveal the covalent linkage point of the ligand. The most powerful tag available 
in terms of sensitivity is 125I [26, 27]. Previous studies showed that iodination of the C-
terminal residue (Tyr13) resulted in biological inactivation of α-factor [28]. Another 
report by Masui et al. [29] suggested that Tyr13 in α-factor was essential and could not be 
substituted by other amino acids without loss of activity. However, it was recently 
demonstrated that Tyr13 was replaceable by Phe with little to no effect on biological 
activity or binding affinity of α-factor [25, 30]. Therefore, α-factor analogs [Bpax, Phe13]  
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Figure 1: Binding affinity of Bpa-substituted α-factor analogs. The binding affinities 
of Bpa-scanned α-factor analogs were measured using [3H]α-factor and the binding 
competition assay described under Materials and Methods. The figure shows the 
calculated Ki (23) for each analogue. The numbers on the abscissa represent the position 
of the Bpa replacement. Each measurement was carried out at least 3 times with an error 
of not more than 10% for each value shown. The number above each bar represents the Ki 
value (×108) of that analogue. 
WT   1    2    3    4    5    6    7    8  10   11  12  13 
Residue # of Bpa Replacement  
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(where x = 1, 3, or 5) and [Bpa13]α-factor analogs in which Tyr residues were substituted 
at other positions were evaluated. Based on the occurrence of Trp in positions 1 and 3 of 
the native α-factor structure, analogs 1-8 were synthesized (Table 1).  
 Growth arrest assays and FUS1 gene induction assays were performed to 
determine the biological activity of these analogs (Table 2). Semi-logarithmic plots of 
halo diameter versus amount of peptide applied to the disk were all linear and exhibited 
similar slopes (data not shown). All analogs used in this assay were stable to enzymatic 
cleavage under the conditions tested as strains used in this analysis lacked the Bar1p 
protease that cleaves α-factor. Therefore, the growth arrest data were indicative of the 
relative agonist activity of each peptide. The data show that peptides containing Bpa1 
with either Tyr3 (compound 1) or (I2)Tyr3 (compound 5) retain good agonist activity, 
requiring about 2.3-fold and 4-fold more of the pheromone derivative, respectively, to 
trigger the receptor. In contrast, tyrosine substituted analogs with Bpa3 (2 and 6), with 
Bpa5 (3 and 7), or with Bpa13 (4 and 8) had little or no activity in the growth arrest assay. 
In the solution-phase, gene induction assay, compound 1 caused 50% of the maximal 
gene induction at only 33% higher concentration than α-factor, and compound 5 required 
a 4-fold higher concentration. These results correlated with those of the growth arrest 
assay. Several of the peptides that were not active at the highest tested amount (10 
µg/disk) in the halo assay were agonists in the gene induction assay. In fact, all four 
iodinated compounds (5-8) had comparable activities in this assay. None of the α-factor 
analogs 
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Table 2: Biological activity of α-factor analogs 
 
 
a Values represent micrograms of peptide necessary to produce a halo with a diameter of 
15 mm. Each assay was done in duplicate at least 3 times with a standard error of ±0.1. 
b Values represent nanomolar concentration of ligand to give 50% maximal activity in a 
FUS1-lacZ gene induction assay. Each assay was done in duplicate 3 times with a 
standard error of about 10% for each value shown. 
c Binding affinities were determined by calculation of Ki in competition binding assays 
using [(125I)Y1R7F13]α-factor. Each assay was done in duplicate 3 times with a standard 
error of about 10% for each value shown. 
d The zone of growth inhibition was partially filled in, giving the halo a fuzzy 
appearance. 
Peptide 
(compound no.) 
Growth arresta 
(µg of peptide) 
FUS1-lacZb induction 
potency (nM) 
Binding affinity,c 
Ki (nM)  
α-factor  0.4  3.1  9  
Bpa1Y3R7F13 (1)  1.0  4.4  127  
Y1Bpa3R7F13 (2)  inactive  149  157  
Y1Bpa5R7F13 (3)  >10  184  150  
Y1R7Bpa13 (4)  inactive  inactive  132  
Bpa1(I2)Y3R7F13 (5)  1.5  14  199  
(I2)Y1Bpa3R7F13 (6)  7.3d  19  216  
(I2)Y1Bpa5R7F13 (7)  >10  26  22  
(I2)Y1R7Bpa13 (8)  inactive  33  315 
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induced growth arrest or FUS1-lacZ activation in a mutant lacking Ste2p, confirming that 
the α-factor receptor was required for the biological activity of these peptides. Overall, 
the bioassays demonstrate that α-factor analogs containing both Bpa and iodotyrosine can 
induce Ste2p-dependent signaling. 
  
Binding Affinities of α-Factor Analogs:  
 Binding affinities of the peptides were determined by competition and saturation 
binding assays as described under Materials and Methods. Representative competition 
binding data for α-factor, and 1, 3, and 5 are presented in Figure 2. For most analogs, 
substitution of Bpa at positions 1, 3, 5, and 13 resulted in only 15-17-fold reduction in 
binding affinity versus native α-factor (Table 2). With the exception of [(I2)Tyr1, Bpa5, 
Arg7, Phe13]α-factor which showed increased binding, di-iodination of the Bpa analogs 
resulted in a slight reduction (1.5-2.4-fold) in binding compared to the noniodinated 
peptides.  
 
Iodination and Purification of α-Factor Analogs:  
 Several of the Bpa-containing analogs were chosen for radioiodination based on 
the criteria that they had relatively good biological activity and binding affinities in the 
submicromolar range. [Bpa1, Tyr3, Arg7, Phe13]α-Factor, [Tyr1, Bpa5, Arg7, Phe13]α-
factor, and [Tyr1, Arg7, Bpa13]α-factor were successfully iodinated, but the iodination of 
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Figure 2: Competition binding assay of various α-factor analogs vs. [(125I)Tyr1, 
Arg7, Phe13]α-factor. Competitors were α-factor (○), compound 1 (▲), compound 5 
(∇), and compound 7 (♦). 
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 [Tyr1, Bpa3, Arg7, Phe13]α-factor led to an unresolvable mixture (Figure 3B). This latter 
result was consistent with the recent observation that certain α-factor analogs are 
resistant to iodination [25]. As seen in Figure 3A, iodination of [Bpa1, Tyr3, Arg7, 
Phe13]α-factor resulted in both the mono- and di-iodinated derivatives. The masses of the 
iodinated peptides were verified by electrospray mass spectrometry (data not shown). 
Based on the relatively high biological activity of [Bpa1, Tyr3, Arg7, Phe13]α-factor (1) 
and its diiodinated homologue (5), the radio-iodinated form of this peptide was chosen 
for photolabeling of Ste2p.  
 
Competition of α-Factor for [Bpa1, ( 125I)Tyr3, Arg7, Phe13]α-Factor Binding to Ste2p: 
 [Bpa1, (125I)Tyr3, Arg7, Phe13]α-Factor was shown to be displaced from Ste2p by 
α-factor in a competition binding assay (Figure 4). The amount of bound peptide was 
expressed in dpm and plotted against the amount of cold competitor added. The binding 
competition was greater than 90%. The shape of the curve is consistent with competitive 
binding inhibition, indicating the radioligand is specific for Ste2p. Similar results were 
also obtained with [Bpa1, (125I2)Tyr3, Arg7, Phe13]α-factor, the di-iodinated form of this 
photoactivatable peptide (data not shown).  
 
Cross-Linking of [Bpa1, (125I)Tyr3, Arg7, Phe13]α-Factor to Ste2p: 
  Membranes were incubated with [Bpa1, (125I)Tyr3, Arg7, Phe13]α-factor, and 
cross-linking was carried out using light at 365 nm. A portion (20 µL) of the reaction 
mixture was removed following irradiation and tested for incorporation of radioactivity 
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Figure 3: HPLC analysis of products from iodination of tyrosine-substituted α-
factor analogs. α-Factor analogs were chemically iodinated using Iodogen reagent and 
products separated by HPLC. (Panel A) Iodination of [Bpa1, Tyr3, Arg7, Phe13]α-factor: I, 
noniodinated peptide; II, mono-iodinated peptide; III, di-iodinated peptide. (Panel B) 
Iodination of [Tyr1, Bpa3, Arg7, Phe13]α-factor. 
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Figure 4: Competition binding of [Bpa1, (125I)Tyr3, Arg7, Phe13]α-factor by 
nonradiolabeled α-factor. Data were analyzed using a single-site competition binding 
equation. Error bars on some points were contained within the symbol and cannot be 
seen. 
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by processing over Multiscreen durapore membranes [26]. The radioactive counts of the 
samples with and without competitor reveal a 76% reduction in cross-linked product in 
the presence of 100-fold excess α-factor (Figure 5). The remainder of the reaction 
mixture was analyzed by SDS-PAGE, and a cross-linked product (54 kDa) which 
migrated to the expected size of Ste2p (52 kDa) + probe (2 kDa) was detected by 
autoradiography (Figure 6). No cross-linked products were observed with samples that 
were not UV-irradiated (Figure 6, lanes 3 and 4). Co-incubation of membranes with 
radiolabeled probe and cold α-factor resulted in a decrease in cross-linked product, 
showing that the cross-linking to Ste2p was specific (Figure 6, lane 1 vs. lane 2). Western 
analysis using anti-Flag antibodies to detect Ste2p showed that all lanes had equivalent 
amounts of the receptor (data not shown).  
 
Fragmentation Analysis of Cross-Linked Ste2p: 
  Based on the specific cross-linking of [Bpa1, (125I)Tyr3, Arg7, Phe13]α-factor to 
Ste2p, digestion of the receptor was initiated to identify the cross-linked fragment(s) of 
the receptor. Chemical cleavage with CNBr and BNPS-skatole was performed. These 
methods take place under strongly acidic conditions, which should result in unfolding of 
the receptor, thereby making it more accessible to cleavage [17]. Chemical digestion of 
the receptor was carried out on native and deglycosylated Ste2p prepared by treatment of 
Ste2p with PNGaseF. Deglycosylation of the receptor was verified by SDS-PAGE with 
the deglycosylated receptor migrating with a molecular mass that was approximately 2 
kDa smaller than the native receptor (data not shown). Similar results of deglycosylation 
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Figure 5: Total radioactive counts of [Bpa1, (125I)Tyr3, Arg7, Phe13]α-factor bound to 
membranes following cross-linking in the presence and absence of nonradiolabeled 
α-factor. Bars represent amount of ligand associated with membranes. Cross-linking was 
carried out in the presence (open bar) or absence (shaded bar) of nonlabeled α-factor. The 
experiment was performed 3 times, and the error bars represent the variance observed. 
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Figure 6: Autoradiograph of SDS-PAGE analysis of UV-irradiated DK102pNED 
membranes in the presence of [Bpa1, (125I)Tyr3, Arg7, Phe13]α-factor. Membranes 
containing Ste2p were incubated with [Bpa1, (125I)Tyr3, Arg7, Phe13]α-factor and 
irradiated at 365 nm as described under Materials and Methods. Control samples either 
were not irradiated or contained α-factor as a competitor. Lane 1, UV irradiated plus 100-
fold excess nonradiolabeled α-factor; lane 2, UV irradiated; lane 3, 100-fold excess 
nonradiolabeled α-factor without UV irradiation; lane 4, without excess nonradiolabeled 
α-factor and without UV irradiation; lane 5, molecular weight markers. 
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 of Ste2p were obtained previously by others [31, 32]. In certain gels, Ste2p appeared as a 
diffuse band and sometimes appeared as a doublet. This is most likely due to the fact that 
strain BJ2168pNED1 expresses both a native chromosomal copy of STE2 which codes 
for a 50 kDa protein when glycosylated, and an epitope-tagged, episomally expressed 
STE2 which contains two epitope tags and codes for a 52 kDa protein when glycosylated.  
BNPS-skatole, which cleaves at tryptophan residues, theoretically fragments the 
receptor into four pieces [IA: 9.5 kDa (7.5 kDa for residues 1-70 of Ste2p plus glycosyl 
groups of 2.5 kDa), IIA: 25 kDa (71-295), IIIA: 15 kDa (296-424), and IVA: 3.6 kDa 
(425-457)] (Figure 7A). Western analysis of native receptor with polyclonal antibodies 
against residues 1-60 revealed that, after 2 min incubation with the BNPS-skatole 
reagent, a broad band at approximately 35 kDa began to appear (Figure 8, lane B). The 
size of this band contains glycosylated and deglycosylated forms of a fragment consisting 
of residues 1-295 (fragments IA + IIA). After 24 h incubation with the BNPS-skatole 
reagent, two fragments of 7.5 and 9.5 kDa, corresponding to glycosylated and 
deglycosylated forms of fragment IA, were detectable (Figure 8, lane D) by a similar 
Western analysis. Thus, 24 h incubation was required to ensure complete digestion of the 
Ste2p under the conditions used. 
Ste2p containing cross-linked [Bpa1, (125I)Tyr3, Arg7, Phe13]α-factor was digested 
for 24 h with BNPS-skatole, dissolved in tricine sample buffer, and run on gradient 
tricine gels. Phosphorimaging of the gels revealed two fragments of approximately 27 
and 6 kDa (Figure 9, panel B). The 27 kDa fragment corresponds to that expected for 
complete BNPS-skatole cleavage of Ste2p (25 kDa fragment IIA, Figure 7A), plus 2 kDa 
for the probe. The 6 kDa fragment appears to be anomalous (see Discussion). In this 
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Figure 7: Schematic representation of chemical and enzymatic cleavage of Ste2p. 
These figures represent the BNPS-skatole, CNBr, and trypsin cleavage sites for the Ste2p 
receptor. Ste2p receptor is shown here using snake diagrams to represent the putative 
transmembrane domains. (Panel A) Cleavage of the receptor by BNPS-skatole results in 
four fragments labeled IA (residues 1-70 of Ste2p), IIA (71-295), IIIA (296-424), and 
IVA (425-458) with their respective molecular masses given in parentheses. Fragment IA 
contains the putative N-linked glycosylation sites as represented by the goalpost symbols. 
The oligosaccharides add 2 kDa of mass to fragment IA. Panel B represents the peptides 
resulting from a complete CNBr cleavage of Ste2p. Panel C represents the peptides 
resulting from a complete trypsin cleavage of Ste2p.  
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Figure 8: Western blot analysis of BNPS-skatole-digested membranes. Membranes 
were digested with BNPS-skatole, and at various time points, portions of the reaction 
mixture were removed and dried under vacuum centrifugation. Samples were then 
dissolved in tricine sample buffer and run on gradient tricine gels. Protein was transferred 
to Immobilon P membranes and probed with polyclonal antibodies specific for the first 
60 amino acids of Ste2p. Lanes A and C were loaded with undigested membrane protein 
with intact Ste2p indicated in the figure. Lane B represents a 2 min digestion, and lane D 
shows a 24 h digestion with BNPS-skatole. The sizes of the detected fragments were 
indicated by arrows. Detected bands above 52 kDa are routinely observed in Western blot 
analysis of Ste2p and are widely believed to represent multimeric or aggregate structures 
of Step2 [32]. 
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Figure 9: Autoradiograph of SDS-PAGE 10-20% tricine gel analysis of membranes 
photolabeled with [Bpa1, (125I)Tyr3, Arg7, Phe13]α-factor. (A) Photo-cross-linked 
membranes, untreated, and (B) photo-cross-linked membranes treated with BNPS-skatole 
and PNGaseF to remove N-linked oligosaccharides. Arrows denote cross-linked Ste2p 
receptor (lane A) and receptor fragments (lane B). Detected bands above 52 kDa are 
routinely observed in Western blot analysis of Ste2p and are widely believed to represent 
multimeric or aggregate structures of Step2 [32].  
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gel and subsequent ones, an unidentified, low molecular weight form of radioactive 
iodine was readily discernible in the portion of the gel corresponding to a molecular size 
less than 4 kDa. 
 Complete cleavage of the cross-linked receptor with CNBr yielded one labeled 
fragment of ~6 kDa (Figure 10, panel I, lane B). Total cleavage of Ste2p labeled with 
[Bpa1, (125I)Tyr3, Arg7, Phe13]α-factor could result in several possible radioactive 
fragments with a molecular mass of 6 kDa. Therefore, a partial CNBr digestion of cross-
linked Ste2p was performed. This resulted in fragments of 35, 22, 9, and 6 kDa (Figure 
10, panel II, lane B). All of these fragments can be rationalized in terms of theoretical 
CNBr cleavage points in Ste2p (Table 3). For example, the 35 kDa band (Figure 7B) 
could correspond to fragments IVB through XB (32.5 kDa) plus ligand (2 kDa). The 
smaller bands [23 (fragments VIIB-IXB plus ligand), 10 (fragments VIIB-VIIIB plus 
ligand), and 6 kDa (fragment VIIIB plus ligand)] could all result from cleavages at Met 
residues within the 35 kDa peptide (Table 3). PNGaseF treatment of the mixture of 
fragments obtained by partial CNBr degradation did not result in any shifts in the band 
sizes (Figure 10, lane C). This was interpreted as ruling out fragment IB (glycosylated) in 
any of the cross-linked fragments detected.  
 Digestion of the cross-linked receptor with trypsin revealed one band of 
approximately 9 kDa corresponding to fragment XC (Figure 7C). It should be noted that 
cleavage at the Arg residue within the α-factor analogue does not occur because Arg is 
followed by a Pro residue. Cross-linking of ligand into VIIIC or IXC (Figure 7), two 
fragments of trypsin-hydrolyzed Ste2p that could correspond to fragments of CNBr- 
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Figure 10: Autoradiographs of membranes photo-cross-linked with [Bpa1, 
(125I)Tyr3, Arg7, Phe13]α-factor and treated with CNBr. Samples run on an SDS-
PAGE 10-20% tricine gel. I: lane A, photo-cross-linked membranes; lane B, complete 
digestion of photo-cross-linked membranes with CNBr. Arrows indicate photolabeled 
Ste2p and 6.7 kDa cleavage fragment of Ste2p. II: lane A, photo-cross-linked 
membranes; lane B, incomplete digestion of photo-cross-linked membranes; lane C, 
PNGaseF treatment of membranes from lane B.
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Table 3: Peptides of CNBr-digested Ste2p 
 
a Peptides are named in order from the N-terminus to the C-terminus of Ste2p. Peptides of only one or two amino 
acids resulting from CNBr cleavage are not included in the table. 
b The residue within Ste2p of the first amino acid of this CNBr fragment. 
c The residue within Ste2p of the last amino acid of this CNBr fragment. 
d The total molecular mass of all fragments within a possible partial digest. For example, in the first column, 
fragments IB through IIIB have a molecular mass of 17.8 kDa. 
e The carboxyl terminus of Ste2p used in this study contained a His-tag and a FLAG tag (see Materials and Methods). 
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digested Ste2p, would have led to a much smaller band of radioactivity (approximately 
3.5-4.5 kDa). Taken together, examination of all the digestion maps [BNPS-skatole 
(Figure 7A), CNBr (Figure 7B), and trypsin (Figure 7C)] indicated that the cyanogen 
bromide fragment VIIIB (Figure 7B, residues 251-294) was the smallest common cross-
linked fragment. This portion of Ste2p corresponds to transmembrane domain 6, the 
extracellular loop between transmembrane domains 6 and 7, and transmembrane domain 
7.  
 The position of cross-linking on Ste2p and the probe was further examined using 
an epitope-tagged Ste2p (Ste2p-T7) and biotinylated, photoactivatable [Bpa1, Lys7(ε-
biotinyl-β-alanyl)]α-factor. The T7 epitope, introduced between residues 303 and 304 at 
the C-terminal end of the tryptic fragment that spans TMD6 and TMD7, was fully 
tolerated by Ste2p [16]. Trypsin digestion of Ste2p-T7 results in fragments similar to the 
wild-type Ste2p receptor (Figure 11), but fragment XC (Figure 7C) is tagged with the T7 
epitope (1.1 kDa), allowing identification of this receptor fragment by western blotting 
with anti-T7 antibodies. Ste2p-T7 was cross-linked with [Bpa1, Lys7(ε-biotinyl-β-
alanyl)]α-factor, digested with trypsin (18 h, 30 ˚C), run on SDS-PAGE, and probed with 
T7 antibodies to detect the epitope or probed with NeutrAvidin to detect biotin of the 
cross-linked α-factor analogue (Figure 12). The 14 kDa band corresponds to a partial 
trypsin digestion product containing IXC, IL3, and XC (Figure 7C) covering TMD5- 
TMD7 plus the cross-linked ligand (2.0 kDa) and the T7 epitope (1.1 kDa), and the 11 
kDa band corresponds to fragment XC (Figure 7C) plus the cross-linked ligand and the 
T7 epitope. These fragments of cross-linked Ste2p-T7 were detected in lanes probed with 
either anti-T7 antibody or NeutrAvidin. In a parallel experiment (data not shown), the 
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Figure 11: Autoradiograph of membranes photo-cross-linked with [Bpa1, (125I)Tyr3, 
Arg7, Phe13]α-factor and treated with trypsin. Samples run on SDS-PAGE 12% Bis-
Tris with MES buffer. Lane B, cross-linked receptor before trypsin digestion; lane D, 
after trypsin digestion; lanes A and C, molecular mass markers with sizes indicated in the 
left and right margins. 
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Figure 12: Western blot analysis of [Bpa1, Lys7(ε-biotinyl-β-alanyl)]α-factor cross-
linked membranes. [Bpa1, K7(ε-biotinyl-β-alanyl)]α-factor was cross-linked into Ste2p-
T7, treated with trypsin, and run on 18% SDS-PAGE. Lane A, before trypsin digestion 
probed with NeutrAvidin-horseradish peroxidase (NA-HRP); lane B, after trypsin 
digestion probed with NA-HRP; lane C, after trypsin digestion probed with anti-T7-HRP 
conjugate.  
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same two bands at 11 and 14 kDa were detected when a single gel blot was probed with 
anti-T7 antibody and then stripped and reprobed with NeutrAvidin. These results indicate 
that one fragment corresponding to XC contained the T7 epitope and the cross-linked 
[Bpa1, Lys7(ε-biotinyl-β-alanyl)]α-factor.  
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CHAPTER 4 
Discussion 
 
 Photoaffinity labeling with Bpa has been shown to be a useful tool in elucidating 
direct contacts between ligands and their cognate receptors [4-11]. These photoaffinity 
studies, which include work on the parathyroid, secretin, and nociceptin receptors, have 
used receptor digestion analysis to elucidate fragments of the receptor that were cross-
linked to the photo-activatable ligand probe. It should be noted, however, that receptor 
fragments may move anomalously on polacrylamide gels and that molecular weights of 
small fragments are difficult to determine accurately. In favorable cases, specific residues 
involved in cross-linking were identified [5-7, 9]. Site-directed mutagenesis studies can 
then be used to corroborate the importance of such residues in the binding of the ligand to 
the receptor.  
 This part (Part II) of the dissertation detailed the synthesis and testing of α-factor 
analogs containing Bpa for use as photoprobes to elucidate binding sites on the Ste2p 
receptor. Results from the Bpa-scanned α-factor series (Figure 1) allowed the conclusion 
that residues at positions 1, 3, 5, and 13 could be replaced with the photoactivatable 
amino acid without severe decreases in binding affinity. Based on previous structure-
activity analyses [18-20, 24, 27-29], analogs containing iodinatable tyrosine residues at 
positions 1 or 3 with phenylalanine at position 13 were designed. Bioassay and receptor 
binding studies indicated that these analogs triggered biological responses characteristic 
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of Ste2p activation, and retained Ste2p-specific submicromolar binding affinities for this 
receptor (Table 2).  
 One of the analogs tested, [Bpa1, Tyr3, Arg7, Phe13]α-factor, was iodinated and 
exhibited relatively good agonistic activity in two standard pheromone response assays 
(growth arrest and FUS1-lacZ). Binding of [Bpa1, (125I)Tyr3, Arg7, Phe13]α-factor was 
found to be specific for the Ste2p receptor based on the ability of native α-factor to 
displace [Bpa1, (125I)Tyr3, Arg7, Phe13]α-factor in a competition binding assay (Figure 4). 
SDS-PAGE analysis of photolabeling experiments with [Bpa1, (125I)Tyr3, Arg7, Phe13]α-
factor resulted in detection of one major radiolabeled product which migrated at the 
expected size of Ste2p covalently attached to the probe (54 kDa). The amount of 54 kDa 
product was reduced by >70% in the presence of excess cold α-factor, indicating that 
cross-linking was occurring at the pheromone binding site of Ste2p. These findings 
showed that the radioiodinated probe had biological and binding characteristics similar to 
native α-factor and cross-linked specifically to Ste2p. Thus [Bpa1, (125I)Tyr3, Arg7, 
Phe13]α-factor can be used to determine the binding site contacts between α-factor and its 
receptor.  
 Receptor cross-linked with the radiolabeled probe was purified by SDS-PAGE, 
eluted from the gel, and treated with various cleavage agents to identify a fragment(s) 
that covalently attached to the radioprobe. It was expected that cleavage at the Trp 
residues of Ste2p with BNPS-skatole would break the receptor into four fragments 
(Figure 8A: fragments IA, IIA, IIIA, and IVA). Previous studies by others have shown 
that the intracellular C-terminal tail of Ste2p has no effect on binding of α-factor and can 
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actually be removed without loss of α-factor binding to Ste2p [31, 32]. Based on this 
information, fragments IIIA and IVA were eliminated as possible sites for cross-linking 
as they make up the intracellular C-terminal tail of the receptor and are not accessible to 
α-factor. SDS-PAGE analysis with high percentage tricine gels resulted in identification 
of two major radiolabled products of 27 and 6 kDa in size. The 27 kDa fragment 
corresponded to fragment IIA (25 kDa) plus the probe (2 kDa). The 6 kDa fragment was 
unexpected in that it does not correspond to a cross-linked form of fragment IA which 
would have an expected size of approximately 11 kDa (7.5 kDa + 2 kDa for the probe +2 
kDa for the polysaccharides = 11.5 kDa). The unexpected 6 kDa fragment most likely 
corresponds to cleavage of receptor fragment IIA at methionines and/or cysteines due to 
reagent contamination. It has been reported that slight impurities in BNPS-skatole can 
result in cleavage at methionines and cysteines [33]. These impurities can arise from 
incomplete removal of N-bromosuccinimide (NBS) substrate during the synthesis of 
BNPS-skatole. However, NBS contamination is usually only a small fraction of the total 
reagent. As a result, Trp residues were cleaved fast by BNPS-skatole while the Met and 
Cys residues were cleaved at a slower rate. Based on this information, it is believed that 
the 6 kDa fragment was generated by cleavage at sites other than Trp in the 27 kDa 
fragment and would explain why the fragment was not detected in Western analysis by 
anti-N-terminal Ste2p antibodies following BNPS cleavage. This argument is 
strengthened by the observation that complete cleavage of Ste2p by CNBr at methionines 
also resulted in a 6 kDa fragment.  
 Complete cleavage of the cross-linked receptor with cyanogen bromide resulted in 
the identification of a single labeled band ~6 kDa in size. Based on the BNPS-skatole 
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results, the band should be part of fragment IIA (Figure 7A). Complete CNBr cleavage of 
Fragment IIA should yield six fragments [IIIB: 10.6 kDa (residues 72-165 of Ste2p), 
IVB: 1.6 kDa (166-180), VB: 1.0 kDa (181-189), VIB: 3.2 kDa (190-218), VIIB: 3.8 
kDa (219-250), and VIIIB: 4.5 kDa (251-294)] (Figure 7B). Of these, fragments VIB, 
VIIB, and VIIIB when cross-linked to the probe would give sizes similar to the 
identified radiolabeled fragment. Incomplete digestion of the cross-linked receptor with 
CNBr yielded four fragments (Figure 10, panel II, lane B). Digestion of the cross-linked 
receptor with trypsin revealed one band (Figure 11) of approximately 9 kDa 
corresponding to fragment XC (Figure 7C). Taken together, the results of the two 
chemical cleavages and trypsin cleavage indicated the receptor was labeled between 
residues 251 and 294. This portion of Ste2p corresponds to transmembrane domain 6, the 
extracellular loop between transmembrane domains 6 and 7, and transmembrane domain 
7.  
 To verify that the 9 kDa fragment in Figure 11 was composed of a portion of 
Ste2p and the cross-linked α-factor analogue, a receptor containing an epitope tag was 
utilized. This receptor, Ste2p-T7, carried the T7 epitope (Met-Ala-Ser-Met-Thr-Gly-Gly-
Gln-Gln-Met-Gly) introduced between Ste2p residues 303 and 304. The epitope is thus 
N-terminal to a trypsin-sensitive Lys residue at position 304. In this manner, the XC 
fragment (Figure 7C) and any fragments resulting from partial digestion of Ste2p-T7 
containing this portion of the receptor could be detected by antibody to T7. The Ste2p-T7 
receptor was utilized successfully by Dube, DeConstanzo, and Konopka [16] previously 
to determine interactions between TMD5 and TMD6. Using Ste2p-T7 and a biotinylated, 
photoactivatable α-factor analog, [Bpa1K7(ε-biotinyl-β-alanyl)]α-factor, detection of the 
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cross-linked fragment was carried out by anti-T7 antibody and a biotin probe. Two bands 
at 11 and 14 kDa, corresponding respectively to XC with the T7 epitope plus the α-factor 
and to IXC-IL3-XC with the T7 epitope and the α-factor were observed. The detection 
of both bands by the two probing methods indicated that the bands contained cross-linked 
[Bpa1K7(ε-biotinyl-β-alanyl)]α-factor and a portion of Ste2p-T7. The increase in size 
from 9 kDa (Figure 11, Ste2p cross-linked to iodinated, photoaffinity probe) to 11 kDa 
(Figure 12, Ste2p-T7 cross-linked with biotinylated, photoaffinity probe) is consistent 
with the extra mass due to the ε-biotinyl-β-alanyl modification and the T7 epitope. These 
results strongly indicate that the region of the receptor cross-linked by a Bpa1-
photoactivatable probe, either iodinated or biotinylated, corresponded to residues 251-
294 of Ste2p. The fact that the only two bands found on the protein blots were revealed 
by both epitope and biotin probes was strong evidence for the position of the cross-
linking in the receptor. Although other 11 and 14 kDa fragments might occur during 
trypsin cleavage, they would not react with the anti-T7 antibodies.  
 The determination of a contact between the position 1 side chain of α-factor and 
residues of Ste2p allows us to refine our current working model for the placement of α-
factor into the active site of this receptor. Based on site-directed mutagenesis and 
synthetic analogs, evidence was recently presented for a contact between the side chain of 
residue 10 (Gln) of α-factor and residues 47 and/or 48 at the extracellular interface of the 
first transmembrane domain of the receptor [26]. Fluorescence spectroscopy studies 
indicate that the side chain of Lys7 most likely faces toward a pocket formed by the 
extracellular loops and that this pocket has both apolar and polar character [34]. In 
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addition, the side chain of Trp3 is in a hydrophobic cavity based on fluorescence analyses 
(Ding, Becker, and Naider, unpublished results), and previous studies with position 1 
analogs also indicate a strong preference for a large hydrophobic residue at the amino-
terminal position of the pheromone [35]. This latter result taken together with the present 
photolabeling analysis suggests that cross-linking occurs with residues that are at, or 
slightly below, the extracellular interface of transmembrane helices 6 and/or 7 of Ste2p. 
Finally, biophysical evidence exists supporting a bend around the Pro-Gly center of α-
factor as the biologically relevant conformation of the pheromone. In total, these results 
allow us to develop a crude two-dimensional model for fitting the tridecapeptide into the 
pheromone binding site. The working model has a contact of Gln10 with residues S47 
and/or T48, a contact of residues 1 and 3 with F262 and/or Y266, and a β-turn around the 
Pro-Gly sequence in the center of α-factor. Recent studies indicate that F262 and Y266 
are important for α-factor binding and activity [36]. Additional features of the bound 
structure should be forthcoming as further refinements of side chain contacts using the 
other photoactivatable analogs and site-directed mutagenesis studies currently carried out 
in our laboratory progresses.  
 The results presented in this part represent the first direct evidence of contact 
between the α-factor ligand and a domain of the Ste2p receptor. Additionally, this is the 
first study to use Bpa photo-cross-linkable probes to study ligand-receptor interaction in 
class IV GPCRs. Future studies should allow for identification of a residue or residues 
that cross-link to the α-factor probe used in this study. These results along with planned 
studies to use a series of α-factor probes that will place cross-linkable moieties at various 
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positions in the pheromone should allow for mapping of the ligand binding site of the 
Ste2p receptor. Results from such studies have the potential to provide key insight into 
peptide ligand mediated activation of GPCRs by identifying contact residues. 
Identification of the contact residues would be useful in assigning structure-function 
relationships between the α-factor pheromone and Ste2p and compare the results to 
information gained from other classes of GPCRs.  
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PART III 
 
 
Identification of Ligand Binding Regions of the Saccharomyces 
cerevisiae α-factor Pheromone Receptor (Ste2p) by Photo-affinity 
Cross-linking 
 101
 
 
 
 
 
 
 
Part III presents collaborative work with Dr. Fred Naider’s laboratory at the City 
University of New York, Staten Island. Cagdas D. Son performed all the studies in th 
is part with the exception of synthesis of the peptides used in this study. The peptide 
syntheses were carried out by Hasmik Sargsyan in Dr. Naider’s laboratory.  This part, 
excluding the portions describing optimization of cross-linking and site-directed 
mutagenesis of Ste2p residues 54-58, has been submitted for publication in Biochemistry. 
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CHAPTER 1 
Introduction 
 
The yeast Saccharomyces cerevisiae is a sexual organism that manifests a 
conjugative response when opposite mating type cells, MATa and MATα, are mixed 
together (For Reviews see [1-5]). The mating reaction is initiated by stimulation of cell 
surface receptors on each cell type by a polypeptide pheromone secreted from cells of the 
opposite mating type. Ste2p is a G protein-coupled receptor (GPCR) expressed on the 
surface of haploid cells of mating type MATa, which is involved in this initiation event. 
Binding of the α-factor tridecapeptide mating pheromone (Trp-His-Trp-Leu-Gln-Leu-
Lys-Pro-Gly-Gln-Pro-Met-Tyr), secreted by the mating type MATα, to Ste2p activates 
the pheromone-signaling pathway by promoting dissociation of a coupled heterotrimeric 
G protein into its constituent α subunit and βγ subunit complex on the cytoplasmic side 
of the plasma membrane. The activation of the receptor leads to a series of events 
including G1 growth arrest, cellular elongation, gene induction, agglutinin biosynthesis 
and ultimately cell fusion with the opposite mating type MATα cells. 
 GPCRs constitute a major family of human proteins [6]. To date more than 1,000 
GPCRs have been identified, and these proteins recognize diverse signaling molecules 
including neurotransmitters, sensory molecules and chemotactic agents [7].  The 
ubiquitous nature of GPCRs together with their highly specific ligand recognition makes 
them an important target for therapeutic agents [8, 9].  Among the most important GPCR 
ligands are peptides including hormones, growth factors, and pheromones.  
 103
Understanding the molecular mechanism of peptide recognition by their cognate GPCRs 
may lead to design of novel peptide analogs for treatment of disorders involving 
defective ligands and/or mutant receptors.  
 Although there has been considerable literature on the GPCR ligand binding sites 
for small molecules like biogenic amines [10], relatively less information exists 
concerning the binding sites of peptide-responsive GPCRs.  Photoreactive cross-linking 
studies, using 4-benzoyl-L-phenylalanine (Bpa)-containing peptide ligands, are a 
powerful complement to site-directed mutagenesis studies for mapping peptide-receptor 
interaction(s). Studies reported on parathyroid hormone (PTH), opioid receptor (ORL1) 
[11-17], substance P [18-20], cholecystokinin [21], and vasopressin [22] showed that 
Bpa-containing peptides can be successfully used for identification of receptor fragments 
that are interacting with photoactivatable peptide analogs. Recent work on human PTH 
receptor [23, 24], the secretin receptor [25], the ORL1 receptor[26] and human 
angiotensin type I receptor [27], showed that specific contact residues can be mapped 
after photoaffinity labeling by sequencing of the cross-linked fragment and site-directed 
mutagenesis in the region of cross-linking. A new method called the methionine 
proximity assay took advantage of modified analogs of Bpa, e.g. p-nitro-benzoyl-
phenylalanine (NO2Bpa), that have selectivity for methionine residues [28]. This unique 
property allowed the identification of a contact site by methionine scanning of the 
putative contact residues of three GPCRs, followed by analysis of the cross-linked 
receptor.  All of these studies using Bpa-analogs revealed that generation of covalently 
linked ligand-receptor conjugates has become a valuable tool for the identification of the 
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cross-linked domains  allowing mapping of the interface between a peptide ligand and its 
GPCR [29].  
In part II of this dissertation, a general approach to directly identify the interaction 
between position 1 of α-factor and a region between residues 251-294 of the receptor 
Ste2p was reported [30]. However, this study was limited to the use of only one Bpa-α-
factor analog. Similarly in this part (part III) the evaluation of a series of biotinylated 
photoactivatable analogs containing Bpa at various positions throughout the α-factor 
pheromone was described. An important aspect of the present part is the use of biotin as a 
tag allowing detection of cross-linking using avidin based chromophores and eliminating 
problems previously encountered with radioactive iodine [30]. Four analogs studied were 
selectively cross-linked into the α-factor binding site of Ste2p. Chemical and enzymatic 
fragmentation of the cross-linked receptor allowed the identification of contacts between 
the position 3 and 13 side chains of the pheromone and Ste2p residues in the EL2-TM5 
and/or TM6-EL3-TM7 region and first transmembrane domain, respectively. In addition, 
interaction of position 1 of α-factor with a region of Ste2p covering residues 251-294 
was confirmed.   
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CHAPTER 2 
Materials and Methods 
 
Organisms:  
 S. cerevisiae DK102 [MATa ste2::HIS3 bar1 leu2 ura3 lys2 ade2 his3 trp1] 
transformed with pNED1[STE2] [31] was used in binding studies and in the growth arrest 
assays of various α-factor analogs. Strain BJ2168 was used as parental strain to construct 
BJS21 by deleting STE2 using the kanamycin deletion cassette according to a standard 
protocol [32]. BJS21 [MATa ste2::KanR, prc1-407, prb 1-1122, pep4-3, Leu2, trp1, ura 
3-52] strain transformed with pNED1 [STE2] was used in cross-linking studies. Strain 
LM102 [33] [MATa ste2::HIS3 bar1 leu2 ura3 lys2 ade2 his3 trp1] transformed with 
pGA314.Cys-less.STE2.FT.HT [34] was used for generating site directed Ala mutations 
between residues M54 and R58 of Ste2p. All strains used had similar binding of α-factor. 
However, the BJS21 pNED strain lacked several peptidases, so it was used to increase the 
yield of Ste2p in experiments involving cross-linking.  
 
Chemical Reagents: 
  All reagents and solvents used for the solid-phase peptide synthesis of the 
photoactivatable peptides were analytical grade and were purchased from Advanced 
Chem. Tech. (Louisville, KY), VWR Scientific (Piscataway, NJ), or Aldrich Chemical 
Co. (Milwaukee, WI). High-performance liquid chromatography (HPLC) grade 
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dichloromethane (CH2Cl2), acetonitrile (ACN), methanol (MeOH), and water were 
purchased from VWR Scientific and Fisher Scientific (Springfield, NJ). 
 
Synthesis of N-α-Fmoc-Protected α-factor Analogs: 
  N-α-Fmoc-protected α-factor analogs needed for the preparation of their 
biotinylated derivatives were synthesized by solid-phase peptide synthesis on an Applied 
Biosystems 433A peptide synthesizer (Applied Biosystems, Foster City, CA) starting 
with N-α-Fmoc-Tyr(OBut) - or N-α-Fmoc-Bpa-Wang resin (0.7 mmol/g substitution, 
Advanced ChemTech, Louisville, KY). In all of the peptides, L-norleucine (Nle), which 
is isosteric with L-methionine, was incorporated at position 12 to replace the naturally 
occurring L-methionine to prevent oxidation of the sulfur atom of this amino acid during 
peptide synthesis and purification. Replacement of Met by Nle was shown previously to 
result in an analog with equal activity and receptor affinity to that of the native 
pheromone [35]. Since all analogs have Nle in place of Met12, this residue is eliminated 
from the abbreviated names for simplicity. The 0.1 mmol FastMoc chemistry of Applied 
Biosystems was used for the elongation of the peptide chain with an HBTU/HOBt/DIEA-
catalyzed, single coupling step using 10 equiv of protected amino acids for 30 min. Upon 
completion of chain assembly the N-α-Fmoc group was not removed from the peptide 
chain. 
 
 
 
 107
Cleavage, Purification and Characterization of Peptides: 
  Cleavage, purification and characterization of the peptides were carried out as 
detailed in material methods chapter, Part II of this dissertation. Briefly, the N-α-Fmoc-
protected peptidyl resin was washed thoroughly with 1-methyl-2-pyrrolidinone and 
dichloromethane and dried in vacuum. The peptide was cleaved from the resin support 
with simultaneous side chain deprotection using a cleavage cocktail at room temperature 
for 1.5 hour with the omission of 1,2-ethanedithiol in the cleavage reaction, to transform 
Bpa-containing peptides to cyclic dithioketal derivatives [36]. The filtrates from the 
cleavage reaction were collected, combined with trifluoroacetic acid washes of the resin, 
concentrated under reduced pressure, and treated with cold ether to precipitate the crude 
product. 
 The crude peptide so obtained was purified by reversed phase HPLC (Hewlett-
Packard Series 1050) on a semi-preparative Waters µ-Bondapack C18 (19 x 300 mm) 
column with detection at 220 nm. The fractions were collected and analyzed at 220 nm 
by reversed phase HPLC (Hewlett-Packard Series 1050) on an analytical Waters µ-
Bondapack C18 (3.9 x 300 mm) column. Fractions of over 99% homogeneity were pooled 
and subjected to lyophilization. The purity of the final peptide was assessed by analytical 
HPLC using two different solvent systems (10- 55% acetonitrile gradient, 15 min, with 
0.025% trifluoroacetic acid; and 50-80% methanol gradient, 30 min, with 0.025% 
trifluoroacetic acid) and ESI-MS (Hunter College, CUNY). 
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Biotinylation of N-α-Fmoc- protected α-factor analogs:  
 Biotinylation of N-α-Fmoc-protected α-factor analogs was carried out using 
biotinylamidocaproate-N-hydroxysuccinimide ester (Sigma). The N-α-Fmoc-protected 
α-factor analog (10.0 mg, 5 µmol) was dissolved in 0.5 ml of cold (0 ˚C) DMF, then the 
same volume (0.5 ml) of cold buffer (Na2B4O7, pH 9.5, 50mM) was added. The solution 
was stirred at 0 ˚C (ice bath) for 2 min., and 10.0 mg (20 µmol) of biotinylamidocaproate-
N-hydroxysuccinimide ester (Sigma) dissolved in 0.5 ml of cold DMF (0 ˚C) was added 
very slowly. Reaction was monitored by analytical reversed phase HPLC using a linear 
gradient of 20-70 % ACN in 30 min and when the starting peptide disappeared (20-40 
min) 0.5ml of a 20% solution of piperidine in DMF was added, and the reaction mixture 
was stirred at room temperature for 30 min until the Fmoc-group was fully deprotected, 
as monitored by analytical HPLC. The reaction mixture was neutralized with acidified 
buffer (0.2 M HCl), and injected immediately onto a preparative HPLC column 
(conditions for preparative HPLC: 20-70% ACN in 150 min, column; Waters µ-
Bondopack C18, 19x300 mm). The main fraction was collected and lyophilized. The 
purity of the biotinylated peptide was > 99 % by analytical HPLC and the molecular 
weight of peptide was confirmed by mass spectral analysis. The overall recovery of 
purified biotinylated peptide was 85-90%. 
 
Site-directed mutagenesis: 
  Oligonucleotide-directed mutagenesis of single-stranded phagemid DNA of 
pGA314.Cys-less.STE2.FT.HT [STE2 gene with the wild-type cysteine residues (Cys59 
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and Cys292) replaced by alanine and containing the FLAG® and 6xHis tags on the C-
terminus] was constructed as described previously [37, 38]. This construct was shown to 
have full wild-type Ste2p activity as determined by binding and biological activities. 
Briefly, single-stranded DNA was prepared by infecting E.coli strain CJ236 (ung-, dut-) 
carrying the pGA314.Cys-less.STE2.FT.HT with the helper phage M13KO7 [39]. In 
vitro mutagenesis was performed on the single-stranded DNA using mutagenic 
oliogonucleotides according to standard protocols.  The product of the mutagenesis 
reaction mixture was transformed into DH5α (Invitrogen) E. coli strain, and 
transformants were selected on ampicillin-containing plates. Plasmids were then isolated 
from transformants using the Wizard Miniprep kit (Promega). After sequencing of the 
isolated plasmids to confirm correct incorporation of the intended mutations, constructs 
were transformed into yeast strain LM102 (ste2 deletion strain), and transformants were 
selected by their growth on medium lacking tryptophan.  
 
Growth Arrest (Halo) Assay: 
  Solid MLT medium[40] as detailed in material and methods of Part II was 
overlaid with 4 mL of S. cerevisiae DK102pNED cell suspension (2.5 x 105 cells/mL of 
Nobel agar). Filter disks (sterile blanks from Difco), 8 mm in diameter, were presoaked 
with 10 µL portions of peptide solutions at various concentrations and placed onto the 
overlay. The plates were incubated at 30 ˚C for 24-36 h and then observed for clear zones 
(halos) around the disks. The data were expressed as the diameter of the halo including 
the diameter of the disk. A minimum value for growth arrest is 9 mm, which represents 
the disk diameter (8 mm) and a small zone of inhibition. All assays were carried out at 
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least 3 times with no more than a 2 mm variation in halo size at a particular amount 
applied for each peptide. The values reported represent the mean of these tests. 
 
Binding Competition Assay with [3H]α-Factor: 
  Competition binding assay was performed using strains DK102pNED and 
tritiated α-factor prepared by reduction of [dehydroproline8, Nle12]α-factor as described 
previously [35]. In general, cells were grown at 30 ˚C overnight and harvested at 1 x107 
cells/mL by centrifugation at 5000g at 4 ˚C. The pelleted cells were washed 2 times in 
ice-cold buffer [PPBi: 0.5 M potassium phosphate (pH 6.24) containing 10 mM TAME, 
10 mM sodium azide, 10 mM potassium fluoride, 1% BSA (fraction IV)] and 
resuspended to 4 x 107 cells/mL. The binding assay was started by addition of [3H]α-
factor (6 nM) and various concentrations of non-labeled peptide (140 µL) to a 560 µL 
cell suspension. Analog concentrations were adjusted using UV absorption at 280 nm and 
the corresponding extinction coefficients (Table 1). After 30 min incubation, triplicate 
samples of 200 µL were filtered and washed over glass fiber filtermats using the Standard 
Cell Harvester (Skatron Instruments, Sterling, VA) and placed in scintillation vials for 
counting. Each experiment was carried out at least 3 times with the results similar in each 
assay. The Ki values were calculated by using the equation of Cheng and Prusoff, where 
Ki = IC50/(1 + [ligand]/Km) [41]. 
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Binding Saturation Assay with [3H]α-Factor:  
 LM102 pGA314.Cys-less.STE2.FT.HT and various Ala mutants in this 
background strain were used in the saturation binding assay. In these assays, various 
concentrations of [3H]α-factor were added to the cell suspension prepared as described in 
competition binding assay part. Specific binding was determined by subtracting counts 
associated with the LM102 (STE2 deletion) strain from counts bound to the strains 
harboring WT or mutant receptors. Each experiment was carried out at least three times 
with similar results. Nonspecific binding of labeled α-factor to filters in the absence of 
cells was less than 20 counts/min. Data curves for competition and saturation binding 
assays were fitted from at least eight triplicate data points using PrismTM software 
(GraphPad) with nonlinear regression one site saturation hyperbola equation. 
 
Optimization of Cross-linking conditions:  
 10 µl of membranes (22 mg/ml of total protein, prepared according to protocols 
previously described, see PART II of this dissertation) derived from cells with a deletion 
in the α-factor receptor encoding gene STE2 (BJS21) and membranes from these same 
cells transformed with a plasmid (pNED) encoding Ste2p (BJS21 pNED) were incubated 
with 975 µL of PPBi buffer (with 0.1%BSA) in siliconized microfuge tubes for 10 min at 
ambient temperature. Various concentrations (0, 0.3, 5.0, 10.0, and 20 µg/ml) of Bpa-
scanned biotinylated α-factor analogs were added, and the reaction was incubated for 30 
min at room temperature with gentle mixing. The reaction mixture was aliquoted into 3 
wells of a chilled 24 well plastic culture plate preblocked with PPBi (0.1% BSA). 
 112
Division of the reaction mixtures into separate wells kept the depth of the samples 
minimal for efficient UV penetration of the sample. The samples were held at 4 °C and 
irradiated without the culture plate lid at 365 nm for 5, 15, 20, 25, 45, 60, and 90 min at a 
distance of 12 cm in a Stratlinker (Stratagene, La Jolla, CA). Membrane samples were 
recombined in siliconized microfuge tubes and washed twice by centrifugation (14000g) 
with PPBi (0.1% BSA). Membrane pellets were dissolved in 5µl sample buffer (0.25 M 
Tris-HCl, pH 8.8, 0.005% bromphenol blue, 5% glycerol, 1.25% ‚β-mercaptoethanol, 2% 
SDS). Samples were heated to 37 °C for 10 min and separated by SDS-PAGE (10% gel; 
30 mA). After transfer to a PVDF membrane blots were analyzed with NA-HRP 
conjugate (from Pierce). 
 
Cross-Linking of α-factor analogs to Ste2p:  
 Membranes (220 µg/ml of total protein) from BJS21, BJS21 pNED strains [31], 
and LM102 pGA314.Cys-less.STE2.FT.HT strains carrying various Ala mutants were 
incubated with 975 µL of PPBi buffer (with 0.1%BSA) in siliconized microfuge tubes for 
10 min at ambient temperature. Bpa scanned biotinylated α-factor analogs (10 to 20 nM) 
were added, and the reaction was incubated for 30 min at room temperature with gentle 
mixing. The reaction mixture was aliquoted into 3 wells of a chilled 24 well plastic 
culture plate preblocked with PPBi (0.1% BSA). Division of the reaction mixtures into 
separate wells kept the depth of the samples minimal for efficient UV penetration of the 
sample. The samples were held at 4 °C and irradiated without the culture plate lid at 365 
nm for 1 h at a distance of 12 cm in a Stratlinker (Stratagene, La Jolla, CA). Membrane 
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samples were recombined in siliconized microfuge tubes and washed twice by 
centrifugation (14000g) with PPBi (0.1% BSA). Membrane pellets were dissolved in 5µl 
sample buffer (0.25 M Tris-HCl, pH 8.8, 0.005% bromphenol blue, 5% glycerol, 1.25%‚ 
β-mercaptoethanol, 2% SDS). Samples were heated to 37 °C for 10 min and separated by 
SDS-PAGE (10% gel; 30 mA). In competition cross-linking experiments, 100x cold α-
factor was added together with biotinylated peptide. For subsequent receptor digestion 
analysis, the band between 45 and 60 kDa covering cross-linked Ste2p mass was excised 
and placed into dialysis tubing (30000 molecular weight cutoff) with buffer (0.2 M Tris-
acetate, pH 7.4, 1.0% SDS, 100 mM dithiothreitol). Electro-elution was performed by 
placing dialysis tubing that contains the gel in a horizontal electrophoresis chamber with 
running buffer (50 mM Tris-acetate, pH 7.4, 0.1% SDS, 0.5 mM sodium thiogylcolate). 
Elution was carried out at 100 V for 3 h. The buffer in the dialysis tubing was transferred 
to a Millipore Ultrafree-15 centrifuge filter device (30 000 molecular weight cutoff) and 
concentrated by centrifugation. Concentrated sample was washed 3 times with 50 mM 
Tris-HCl, pH 7.5. The cross-linked samples were resolved with SDS-PAGE, transferred 
to a PVDF membrane and assayed for the detection of proteins that are covalently linked 
with biotinylated analogs with NeutrAvidin-HRP conjugate (NA-HRP) (Pierce). All the 
gels used in these blots were analyzed by staining with coomassie blue to ensure efficient 
transfer of the protein to the membrane. 
 
Digestion of Cross-Linked Ste2p:  
 Cross-linked samples were digested with CNBr, trypsin, or BNPS-skatole. For 
CNBr digestion, samples were dissolved in 70% formic acid, and 200 mg/ml of CNBr 
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were added. For trypsin digestion, samples were dissolved in trypsin digestion buffer 
(100 mM Tris-HCl, pH 8.5), and 6.25 µg of trypsin (Sequencing Grade modified trypsin, 
Roche) was added to 250µg of total proteins. After 6 hr of incubation a second batch of 
trypsin (6.25 µg) is added to achieve complete digestion. Ste2p contains a lysine residue 
(K269) followed by a proline residue (P270) in the extracellular loop 3, which makes it 
less likely to be digested by trypsin. Nevertheless, we found that this region is 
reproducibly susceptible to trypsin digestion under the conditions described above. For 
BNPS-skatole digestion, samples were dissolved in 50% acetic acid with addition of 
10mg/ml BNPS-skatole. To prevent anomalous cleavage of Ste2p at histidine and 
tyrosine residues, tyrosine at 100-fold molar excess was added to the reaction mixture 
during BNPS-skatole digestion [42]. Deglycosylated samples for BNPS-skatole digestion 
were prepared by treatment with PNGaseF (500 units/µl, BioLabs). Briefly, ~ 10 µl of 
partially purified Ste2p-containing membrane proteins (1µg/µl) was incubated with 5 µl 
of 10x glycoprotein denaturing buffer (5% SDS, 10% β-mercaptoethanol) at 100 ˚C for 
10 min. After 10 min, 5 µl of 10x G7 buffer (0.5M sodium phosphate, pH=7.5) and 5 µl 
of 10% NP-40 were added. Finally, 5µl PNGase F and 20µl of water was added (total 
volume, 50µl) and incubated at room temperature overnight.  All digestion reactions took 
place under nitrogen and complete darkness at 37°C. After digestion, samples were dried 
by vacuum centrifugation, resuspended in 50 µL of 0.5 M Tris, pH 8.25, and re-dried. 
The digested samples were dissolved in loading buffer (Bio-Rad) and resolved on 12% 
NuPAGE Bis-tris gels with MES running buffer (Invitrogen). 
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CHAPTER 3 
Results 
 
Synthesis of α-factor analogs: 
N-α-Fmoc protected α-factor analogs containing Bpa1, Bpa3, Bpa5, Bpa8, or Bpa13 
were prepared by automated solid phase synthesis using standard coupling and 
deprotection protocols. During several of the syntheses we noted partial Fmoc removal 
occurred using the “complete wash protocol” of the Applied Biosystems 433A 
synthesizer. This problem was eliminated by washing only with DCM. N-α-Fmoc-
protected Bpa-containing α-factor analogs were purified by semi-preparative HPLC 
(Waters µ-Bondopack C18, 125Å, 19x300mm, gradient 20-60% acetonitrile in 150 min). 
After lyophilization they were used in the synthesis of the corresponding biotinyl-
amidocaproate (BioACA) derivatives. Thus all biotinylated analogs used in this part of 
the dissertation were biotinylated at the epsilon amine of Lys7 and a spacer was used to 
ensure that the biotin group was available to the avidin detection protein. The final 
products containing both Bpa and biotin were more than 99% pure as determined by 
analytical reversed-phase HPLC and had the expected molecular weight (Table 1). 
 
Receptor Affinities of Bpa-Scanned Biotinylated α-factor analogs: 
α-factor analogs that bind tightly to the pheromone receptor (Ste2p) were 
essential to achieve an efficient cross-linking. Studies detailed in part II showed that Bpa 
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a The extinction coefficients were calculated by the DNASTAR™ program (Lasergene, Madison, WI) on the basis of the 
peptide sequence. 
b Mass-spectral analysis of biotinylated analogs were performed by Dr.Cliff Soll, Hunter College,CUNY  
c This synthesis was not optimized. 
Table 1: Βiotinylation yield for α-factor analogs. Table represents yields of biotinylation and results of mass spectral 
analysis 
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replacements were well tolerated at positions 1(Trp), 3(Trp), 5(Gln), 7(Lys), 8(Pro), 
12(Met), and 13(Tyr) of α-factor pheromone with Ki  values indicating poorer binding 
from 4-fold to 45-fold in comparison to α-factor [30]. Based on these data and our 
current working model for pheromone binding to receptor [43], we chose photo-cross-
linkable analogs with Bpa at positions 1, 3, 5, 8, and 13 to determine contact points 
between the peptide and its receptor. This placed potential crosslink sites in side chains 
throughout the pheromone. The position seven side-chain was used for the biotin tag for 
detection purposes [44].  
Binding affinities of the Bpa-scanned biotinylated α-factor analogs were 
determined by measuring their ability to compete with [3H]α-factor as described under 
Experimental Details. Analogs containing Bpa1 and Bpa5 exhibited only a 3- to 4-fold 
reduction in binding affinity compared to native α-factor (Figure 1). The binding affinity 
for Bpa13 was relatively poor (~12 fold lower than wild type). [Bpa8]α-factor showed 
very poor competition and did not compete fully at the highest concentration tested 
making the binding affinity for this analog only an estimate. [Bpa3]α-factor exhibited a 
comparatively intermediate binding of ~40 nM, although this is also only an estimate as 
full competition did not occur at the highest concentration tested.      
 
Bioactivities of Bpa-Scanned Biotinylated α-factor analogs: 
For the cross-linking studies to relate to a biologically relevant receptor-ligand 
interaction it is important to determine whether the ligand has biological activity. 
Therefore, the ability of the Bpa-scanned biotinylated α-factor analogs, used in this part 
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Figure 1: Competition binding assay of various α-factor analogs vs. tritiated α-
factor. Competitors were cold α-factor (■), Bpa1 (▲), Bpa3 (▼), Bpa5 (♦), Bpa8 (●), 
and Bpa13 (□). 
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of the dissertation, to cause growth arrest in MATa as tested by growth arrest assay 
(Figure 2, Table 2). Semi-logarithmic plots of halo diameter versus amount of peptide 
applied to the disk were all linear and exhibited similar slopes (data not shown). All 
analogs used in this assay were stable to enzymatic cleavage under the conditions tested 
as strains used in this analysis lacked the Bar1p protease that cleaves α-factor. Therefore, 
the growth arrest data are indicative of the relative agonist activity of each peptide. The 
data show that the biotinylated peptides, where Bpa is at position 1, 3, 5, and 13 retained 
detectable agonistic activity, although the Bpa3, Bpa5, and Bpa13 pheromones had 
relatively low ability to trigger signal transduction (Table 2). On the other hand 
biotinylated [Bpa8]α-factor did result in a small halo (~2 mm around the filter disk) at the 
highest concentration (20 µg/disk) used in this assay. None of the α-factor analogs 
induced growth arrest in a mutant lacking Ste2p (BJS21), confirming that the α-factor 
receptor was required for the biological activity of these peptides.  
 
Optimization of Cross-linking of Bpa-Scanned Biotinylated α-factor analogs: 
 The cross-linking reaction between the photoactivatable Bpa group and the 
receptor is affected by the concentration of the reactants, temperature, and time. 
Throughout this study, temperature and the concentration of the receptor were kept 
constant, while the concentrations of Bpa-containing α-factor analogs and the time of UV 
irradiation varied. Following cross-linking under these various conditions, the yield was 
determined by the comparison of the signal intensities detected by NA-HRP blots.  
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Figure 2: Halo assay with Bpa-scanned biotinylated α-factor analogs. Various 
amounts (labeled on the disks [µg]) of α-factor analog were spotted on sterile filter disks 
placed on solid agar media and the growth arrest was quantified by measuring the 
diameter of the halo formed after 48 hr incubation  at 30 ˚C.
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Table 2: Summary of receptor affinities and biological activities for Bpa-scanned 
biotinylated α-factor analogs. 
Position of 
Bpa WT Bpa1 Bpa3 Bpa5 Bpa8 Bpa13 
Ki [nM] 6 20 ~40 25 ~160 75 
Biological 
Activitya 0.4 1.5 3.5 9.4 ~50
b 9 
% affinity 100 30 15 24 ~4 8 
% activity 100 23 10 4 <1 5 
  
a Amount of analog (µg) needed to form 15 mm halo of growth arrest.  
b Out of linear range the highest amount (20µg) tested in this assay gave only 13mm halo. 
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Figure 3a and 3b showe representations of these studies carried out with the [Bpa1]α-
factor analog. Results for all the Bpa-containing analogs are summarized in table 3.   
 
Cross-linking of Bpa-Scanned Biotinylated α-factor analogs to Ste2p: 
The membranes derived from cells with a deletion in the α-factor receptor 
encoding gene STE2 (BJS21) and membranes from these same cells transformed with a 
plasmid (pNED) encoding Ste2p (BJS21 pNED) were incubated with Bpa-scanned 
biotinylated α-factor analogs, and cross-linking was carried out using UV light (365 nm). 
BJS21 membranes were used as control in this experiment to check the possible 
interference from endogenous biotin signal and/or non-specific cross-linking products. 
Aliquots from each reaction mixture were removed following cross-linking and tested for 
incorporation of the biotinylated ligand to Ste2p by western blot analysis probed with 
NA-HRP (Figure 4). The cross-linked product (54 kDa), which migrated to the expected 
size of Ste2p (52 kDa) + α-factor analog (2 kDa) was detected in all lanes that contain 
cross-linked BJS21 pNED membranes, although the [Bpa8]α-factor analog exhibited a 
low degree of cross-linking consistent with its low biological activity and poor binding 
data. During the scanning of the film for preparation of the figure, a doublet seen for 
Ste2p on the original gels faded into the broader single band seen at ~54 kDa.  No 
detectable signal was present on lanes loaded with BJS21 membranes (that lack Ste2p). 
In addition no cross-linked products were visible with samples that were not UV-
irradiated (data not shown).  
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Figure 3: Optimization of the [Bpa1]α-factor analog concentration and time for 
cross-linking. A) Different concentrations of [Bpa1]α-factor analog were incubated with 
the membranes from BJS21 pNED strain (45 min. UV irradiation). B) Duration of UV 
irradiation was varied at constant concentration (10µg/ml) of [Bpa1]α-factor analog. 
After cross-linking the samples were solubilized in sample buffer and resolved by 10% 
SDS-PAGE. Following the transfer of proteins to PVDF membranes cross-linking was 
identified by NA-HRP conjugate, which detected the biotin tag on the ligands. 
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Table 3:  Summary of the cross-linking optimization with Bpa scanned α-factor 
analogs. 
Position of Bpa Bpa1 Bpa3 Bpa5 Bpa8 Bpa13 
Time for XL (min) 45 45 60 ND 30 
Amount of Bpa Analog 
(µg/ml) 5 5 10 ND 3 
  
ND: Due to the low binding affinity and poor biological activity this analog was not used 
in the optimization studies. 
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Figure 4: Western blot analysis of BJS21 pNED (expresses Ste2p), and BJS21 (∆ 
Ste2p) photo-cross-linked membranes. Membranes photo-cross-linked with various 
Bpa containing α-factor analogs were dissolved in Tricine sample buffer and resolved by 
Nu-PAGE 12% Bis-Tris gel. Proteins were transferred to a PVDF membrane and probed 
with NA-HRP to detect the biotin signal on the analog.
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In a follow up experiment, the BJS21 pNED membranes were co-incubated with Bpa-
scanned biotinylated α-factor analogs and 100-fold molar excess of wild type α-factor 
pheromone (Figure 5). Results indicated that in the presence of excess α-factor 
pheromone the cross-linking of the biotinylated analogs was greatly diminished 
indicating that the cross-linking to Ste2p with the Bpa-scanned biotinylated α-factor 
analogs occurs at the α-factor binding site. Cross-linking of [Bpa8]α-factor was not 
blocked by addition of 100-fold molar excess of α-factor (data not shown). We 
concluded that the low amount of cross-linking observed with the Bpa8 analog (Figure 4) 
may not reflect interaction with the α-factor binding site. This conclusion is supported by 
the relatively poor competition of this analog for α-factor binding (Figure 1) and the poor 
biological activity of this analog (Table 2).  Therefore, further investigations with this 
probe were discontinued. Cross-linking of [Bpa5]α-factor was blocked by excess α-
factor, however, the amount of cross-linked product was very low in comparison to the 
amount of cross-linked product using Bpa1, Bpa3, and Bpa13 analogs (Figure 5). 
Therefore, experiments using this analog were also discontinued. Cross-linking efficiency 
for Bpa1, Bpa3, and Bpa13 analogs was estimated to be around 50% by comparison of the 
chemiluminescence signals from two different blots, one probed with NA-HRP (to detect 
cross-linked Ste2p by the reaction with the biotinylated analog) and the other probed with 
a FLAG® antibody detected by anti-mouse IgG HRP (Promega, to detect the total FLAG-
tagged Ste2p; data not shown). 
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Figure 5: Western blot analysis of BJS21 pNED photo-cross-linked membranes in 
the presence or absence of excess α-factor. Membranes photo-cross-linked with various 
Bpa containing α-factor analogs either in the presence or in the absence of 100x excess 
wt. ligand and resolved by Nu-PAGE 12% Bis-Tris gel. Proteins were transferred to a 
PVDF membrane and probed with NA-HRP to detect the biotin signal on the analog. 
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Fragmentation Analysis of Cross-linked Ste2p:   
 Membranes containing Ste2p (BJS21 pNED) cross-linked with various Bpa-
scanned analogs described in this part were resolved by preparative SDS-PAGE. Cross-
linked Ste2p was electro-eluted from the gel and was treated with various cleavage agents 
to identify a fragment that covalently attached to the biotinylated ligand. Fragments of the 
cross-linked receptor were analyzed after Trypsin, CNBr and BNPS-skatole digestion to 
identify a putative Bpa1, Bpa3, and Bpa13 cross-linked fragment(s). Trypsin digestion of 
the cross-linked receptor was carried out with sequencing grade trypsin at 37 ˚C for 16 hr. 
To monitor trypsin digestion, we used a T7 epitope-tagged Ste2p [45] and detected a ~4 
kDa band (residues 270-303 +T7 tag) by T7 antibody instead of a ~8kDa band (residues 
240-303 + T7-tag), indicating that the Lys-Pro site in the 3rd extracellular loop was 
susceptible to complete trypsin digestion under current digestion conditions (data not 
shown). A similar unexpected trypsin digestion at a Lys-Pro bond was observed by others 
[46]. Chemical cleavage was performed by CNBr or BNPS-skatole under strongly acidic 
conditions. BNPS-skatole digestion was carried out on native and deglycosylated Ste2p 
prepared by treatment of Ste2p with PNGase-F. These methods were previously used in 
our laboratory and applied by other groups in studies on Ste2p [30, 47, 48].  
 Trypsin digestion resulted in fragments around 5 kDa for both Bpa1 and Bpa3 α-
factor analogs whereas ~10 and ~8 kDa bands for Bpa13 α-factor were detected on the 
same blot (Figure 6). The theoretical digestion of Ste2p by trypsin shows multiple 
possible fragments that might correspond to 5 kDa after cross-linking with Bpa1 or Bpa3 
(Figure 7A). CNBr digestion of the cross-linked receptor was carried out to narrow down 
the putative cross-linked regions. Following CNBr digestion a band approximately 6 kDa  
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Figure 6: Western blot analysis of Trypsin digested BJS21 pNED photo-cross-linked 
membranes. Membranes photo-cross-linked with various Bpa containing α-factor 
analogs were digested with Trypsin and resolved by Nu-PAGE 12% Bis-Tris gel. 
Proteins were transferred to a PVDF membrane and probed with NA-HRP to detect the 
biotin signal on the analogs. Membranes, cross-linked with α-factor, were used as 
negative control, and ligand alone was used for positive control. 
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Figure 7: Schematic representation of receptor fragments after chemical or 
enzymatic cleavage of Ste2p. These figures represent the theoretical BNPS-skatole, 
Trypsin, and CNBr cleavage sites for the Ste2p receptor. For simplicity purposes the 
cytoplasmic tail is not represented in these cartoons. (Panel A) Represents the peptides 
resulting from a complete Trypsin digestion of Ste2p. (Panel B) Represents the receptor 
fragments generated after a complete CNBr cleavage of the receptor. (Panel C) Cleavage 
of the receptor by BNPS-skatole results in four fragments three of which represented IC 
(residues 1-70 of Ste2p), IIC (71-295), and IIIC (296-424). Molecular weights are 
represented on the figure in kDa. N-terminus fragments IA, IB, and IC contains two 
known N-linked glycosylation sites which adds ~2 kDa to these fragments thus the 
molecular weights for these fragments indicated as approximations.  
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was detected for both Bpa1 and Bpa3 (Figure 8). This result in combination with the 
trypsin digestion narrows the possible cross-linking to two regions: VIB (190-218), or 
VIIIB (251-294) (Figure 7B), where the latter is in agreement with our previous findings 
for Bpa1 [30] . CNBr digestion of Bpa13 cross-linked Ste2p resulted in a ~3 kDa band 
(Figure 8). The overlapping region of the two digestions (Trypsin and CNBr) 
corresponded to the region of Ste2p between residues F55 to R58 for Bpa13 cross-linking.  
Further analysis of Bpa13 cross-linked Ste2p with BNPS-skatole was carried out.  
Digestion of the cross-linked native receptor resulted in two detectable bands around 12 
and 10 kDa (Figure 9). Similar digestion with the deglycosylated receptor resulted in a 
single band around 10 kDa indicating that Bpa13 cross-linked to a glycosylated region of 
Ste2p represented by IC (region 1 to 70 of Ste2p) (Figure 9, Figure 7C).  As a control to 
determine whether anomalous cleavage occurred with the BNPS-skatole reagent, we 
subjected the Bpa1-cross-linked receptor to fragmentation under similar conditions. In 
this case only one band (~27 kDa) was observed (Figure 9).  Although one might predict 
that the BNPS-skatole reagent would cleave inside the peptide ligand thus releasing this 
ligand, we believe that the proximity of the cross-linked site (position one) to Trp3 in the 
analog might significantly slow down this reaction. 
 
Site-directed Ala mutations between residues M54 and R58 of Ste2p: 
 After assignment of a region of interaction for [Bpa13]α-factor analog by cross-
linking studies, site-directed Ala mutations in this region were carried out to identify a 
possible contact point. Five individual alanine mutations were introduced in the region of 
Ste2p between M54 and R58. Additionally two mutants (R58D and R58E) generated by
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Figure 8: Western blot analysis of CNBr digested BJS21 pNED photo-cross-linked 
membranes. Membranes photo-cross-linked with various Bpa containing α-factor 
analogs were digested with CNBr and resolved by Nu-PAGE 12% Bis-Tris gel. Proteins 
were transferred to a PVDF membrane and probed with NA-HRP to detect the biotin 
signal on the analogs. Membranes, cross-linked with α-factor, were used as negative 
control, and ligand alone was used for positive control. 
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Figure 9: Western blot analysis of BNPS-skatole digested BJS21 pNED photo-cross-
linked membranes. Bpa1 and Bpa13 cross-linked BJS21 pNED membranes [native (-) 
or deglycosylated (+)]were digested with BNPS-skatole (Pierce) for 16 hr @ 37 °C, then 
resolved by 12% Bis-Tris gel (Invitrogen) and transferred to PVDF membrane. 
Membranes were probed with NA-HRP conjugate to detect the biotin signal on the Bpa1 
and Bpa13 analogs. A) ~27 kDa band corresponding to a region of Ste2p between 
residues 71 to 295 (25 kDa) plus the ligand (2 kDa) B) Left lane is the BNPS-skatole 
digest of the native (-) membranes and generates two bands (~12 and ~10 kDa), right lane 
is the BNPS-skatole digest of the PNGaseF treated [deglycosylated (+)] membranes.  
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Ayca Akal-Strader and a double mutant F55A-R58A were used in these experiments.  
Halo assays indicated that the biological activity for the mutant receptors, except F55A-
R58A double mutant and G56A mutant, were similar or slightly reduced as compared to 
the wild type receptor (Table 4). The G56A mutant was previously characterized by 
Blumer et al. with similar results [49].  This study concluded that G56 residue was 
involved in receptor dimerization forming a GXXXG motif like that found in glycophorin 
A; mutation at this residue resulted a 3-5 fold lower response to α-factor induced growth 
arrest as detected by the halo assay.  
 Binding affinities for the mutant receptors, detected by saturation binding assay, 
showed that receptors carrying a mutation at the R58 position had poor binding to the α-
factor indicated by a large decrease in the Ki (Figure 10, Table 4). Other mutant receptors 
had similar or slightly lower binding affinities to α-factor. The combination of our 
previous results for position 13 α-factor analogs [50] (Table 5) and the current findings 
by cross-linking and site-directed mutagenesis suggested that position 13 of α-factor 
might be interacting with R58 of Ste2p. In order to further validate this hypothesis cross-
linking experiments were carried out with the five Ala mutants generated in this study. 
Western blot analysis detecting the FLAG tag on Ste2p showed that all of the mutants 
were expressed in the membrane (data not shown). Detection of biotin tag on the 
[Bpa13]α-factor analog by NA-HRP showed that cross-linking of [Bpa13]α-factor analog 
to the R58A mutant was highly diminished. Similarly a lower amount of cross-linking 
was observed to the M54A mutant (Figure 11). Unlike R58A and M54A, the remaining 
Ala mutants (F55A, G56A, and V57A) showed relatively equal amounts of biotin signal. 
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Table 4: Summary of the binding affinities and biological activities of Ala mutants.      
Receptor Binding affinity  (Ki, nM) 
% Biological activity 
(Halo assay) 
Wild type 2.7 ±0.5 100 
M54A 3.6  ±0.3 ~80 
F55A 7.6  ±1.4 ~70 
F55A & R58A >100a ~50 
G56A 3.7  ±1.1 ~20 
V57A 2.7  ±0.5 ~70 
R58A 20.4 ±5.5 ~80 
R58D >100a ~70 
R58E 20.9 ±6.7 ~70 
 
a Saturation curve was linear under the tested concentrations, thus the Ki is only an 
estimation. 
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Figure 10: Saturation binding assay with R58 mutants. Site-directed mutagenesis of 
the R58 residue in Ste2p (to Ala, Glu, and Asp) was carried out and the binding affinities 
of the mutants were determined by a saturation binding assay. (■)Wild type receptor, 
(▲)R58A mutant, (▼)R58E mutant, and (∆)R58D mutant.  
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Table 5: Summary of the binding affinities and biological activities of position 13 α-
factor analogs.  
Peptide Binding affinity (Ki, nM) 
% Biological activity 
(Halo assay) 
α-factor 11 ±3 100 
Phe13 22 ±3 120 
p-F-Phe13 16 ±3 110 
m-F-Phe13 59 ±6 86 
p-NO2-Phe13 58 ±7 94 
Ala13 >1000 40 
Ser13 >1000 55 
 Table adapted from S. Liu et al. [50]  
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Figure 11: Western blot analysis of photo-cross-linked Ala mutant BJS21 
pGA314.Cys-less.STE2.FT.HT membranes. Membranes carrying five individual Ala 
mutants of Ste2p (M54A, F55A, G56A, V57A and R58A) were photo-cross-linked with 
biotinylated [Bpa13]α-factor analog and resolved by 10% SDS-PAGE. Proteins were 
transferred to a PVDF membrane and probed with NA-HRP to detect the biotin signal on 
the analog. 
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CHAPTER 4 
Discussion 
 
This part of the dissertation details the synthesis and characterization of a new set 
of α-factor analogs containing Bpa as a photoactivatable cross-linker and biotin as a tag 
for detection. Photoaffinity labeling of receptor residues with Bpa has been used as a 
powerful tool to obtain constraints to better understand the molecular basis of ligand 
binding and activation of receptors [11-13, 15-17, 25, 26, 29, 51]. Most of these studies 
used 125I as a tag to track the cross-linking efficiency and detect the resulting cross-linked 
fragment after various chemical and enzymatic digestions for mapping the contact region. 
Previous studies described in part II showed that iodination of Bpa-scanned α-factor 
analogs except Bpa at position 1, resulted in either loss of function due to multiple 
iodination or drastic decrease in binding affinity, which made it impractical for cross-
linking studies [30]. Although biotin detection uses an indirect method that includes 
transfer to membrane, probing with NA-HRP and detection by a colorimetric enzymatic 
reaction compared to direct detection of radioiodine, the relatively unstable nature and 
high hydrophobicity of the 125I tagged ligand raised additional problems during 
comparison of consecutive experiments. Furthermore, in future investigations 
biotinylated peptide fragments generated by chemical or enzymatic degradation can be 
isolated by affinity purification procedures and subjected to mass spectrometry. 
Therefore, in this part (part III) of the dissertation the use of biotin instead of 125I as a 
reporting tag with a series of Bpa scanned α-factor analogs was summarized.  
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Early studies on angiotensin II receptor [52]  and recent work on chemotactic 
peptide analogs [53] and  the integrin receptor [54] showed that biotin can be used as a 
reporting tag instead of radioactive isotopes. However, most of these studies were 
hampered by the low affinity of the ligand analogs due to incorporation of biotin as a 
reporter tag. Results presented in this part (part III) indicated that all of the 
Bpa/biotinylated analogs tested except Bpa8 retained binding affinities within 
approximately one order of magnitude of that of α-factor and were agonists (Table 2). 
Detection of the biotin tag was achieved by NeutrAvidin-horse radish peroxidase 
conjugate, which takes advantage of the strong interaction between the biotin and 
NeutrAvidin and a powerful reporting signal from the product of the peroxidase reaction 
thus avoiding the use of iodine at any point in the detection protocol.  
Cross-linking experiments done with the membranes from a Ste2p knock-out 
strain (BJS21) showed that under the conditions tested no nonspecific cross-linking or 
endogenous biotin signal in the region of Ste2p was detected (Figure 4), although some 
higher molecular weight bands were detected (Figure 5). In addition cross-linking of the 
biotinylated Bpa analogs to Ste2p was prevented by mixing 100-fold molar excess of 
wild type pheromone into the reaction mixture prior to UV irradiation (Figure 5). Thus, in 
principle these α-factor analogs can be used to determine contacts between ligand side 
chains and receptor residues involved in binding interactions between α-factor and its 
GPCR Ste2p. 
The [Bpa5]α-factor had good binding affinity but was a weak agonist (Table 2). 
Using an excess of ligand we obtained reasonable cross-linking of this analog (Figure 4). 
However, only limited amounts of cross-linked product were recovered from preparative 
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gels and digestion with both chemical and enzymatic reagents resulted in loss of signal 
(data not shown). Considering our current working model for ligand-receptor 
interactions, residue 5 of α-factor might be exposed to solvent or involved in interactions 
with the extracellular loops. Relative to the trans-membrane (TM) domains, the loops are 
more mobile which might cause the environment around Bpa5 to be more dynamic. Such 
mobility around Bpa5 might influence cross-linking efficiency and thus hinder Bpa5-α-
factor incorporation compared to the other analogs that seem to be interacting with the 
TMs.  Supporting the lack of importance of the position 5 side chain in tight interactions 
with the binding site was our observation that the [L-Ala5]α-factor had the highest 
receptor affinity of any of the alanine scanned α-factors [55]. Thus, further analysis was 
not carried out with [Bpa5]α-factor although we plan to revisit this issue if we can 
optimize cross-linking efficiencies in future studies.  Due to lack of detectable biological 
activity and poor competition  between the [Bpa8]α-factor analog and α-factor for 
receptor binding (Figure 1, Table 2), fragmentation analysis for the receptor cross-linked 
with this analog was not carried out. 
  Trypsin digestion of the cross-linked receptor resulted in a band ~5 kDa for both 
[Bpa1]α-factor and [Bpa3]α-factor analogs (Figure 6). The presence of multiple possible 
trypsin digestion fragments that could gave a band around 5 kDa (IIIA, IVA, VA, VIA, 
VIIIA, IXA, and XA, Figure 5A, when cross-linked to the 2 kDa Bpa1 or Bpa3 analogs 
would give a ~5 kDa fragment) made it very difficult to assign a cross-link region for 
Bpa1 and Bpa3 with only these results. On the other hand, when these results were 
combined with the CNBr digestion data, the region of the Ste2p interacting with [Bpa1]α-
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factor and [Bpa3]α-factor analogs was narrowed down to two possibilities: a region 
covering part of EL2 and an extracellular portion of TM5 (Figure 7B, VIB) or part of 
TM6, EL3 and part of TM7 (Figure 7B, VIIIB). In part II, it has been determined that 
[Bpa1]α-factor cross-linked to a portion of Ste2p comprising TM6-EL3-TM7 [30] in 
agreement with the second possibility mentioned above. If both N-terminal tryptophan 
residues of α-factor interact with the same portion of Ste2p, then [Bpa3]α-factor might 
interact as well with the TM6-EL3-TM7 region.  However, based on the present 
experimental results, we can not rule out the interaction of [Bpa3]α-factor with EL2-
TM5.  
Trypsin digestion of the Bpa13-cross-linked receptor resulted in bands of ~8 and 
~10 kDa (Figure 6). After  complete trypsin digestion of cross-linked Ste2p there  is  only 
one theoretical Ste2p region that could give these bands with the cross-linked ligand: the 
glycosylated and unglycosylated N-terminus of the receptor (residues 1-58; Figure 7A, 
fragment IA) [56]. Additional digestions with CNBr and BNPS-skatole were carried out 
to further probe the cross-linking. Detection of a ~3 kDa band after CNBr digestion 
(Figure 8) in combination with two bands, ~12 kDa (presumably the glycosylated N-
terminal ~10 kDa fragment plus ligand) and ~10 kDa (the unglycosylated N-terminal plus 
ligand) after BNPS-skatole digestion (Figure 9),  strongly indicated that the N-terminus 
of the receptor was the region cross-linked with [Bpa13]α-analog. The higher intensity of 
the lower molecular weight band observed in figure 9 (middle lane) suggests one of two 
explanations: glycosylation may interfere with either cross-linking efficiency or detection 
by NA-HRP.  To further test whether the ~12 kDa, BNPS-skatole fragment, was 
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glycosylated, deglycosylation of the cross-linked receptor followed by BNPS-skatole 
digestion was carried out. Results showed that upon deglycosylation only a single band 
~10 kDa was detected (Figure 9). Thus, we conclude that the [Bpa13]α-analog interacts 
with the junction between the N-terminus of Ste2p and the start of TM1. The smallest 
overlapping region between the three different digestions (trypsin, CNBr, and BNPS-
skatole) carried with Ste2p cross-linked with [Bpa13]α-analog indicated that cross-linking 
occurs at a region between residues F55 to R58. Although the [Bpa13]-analog had a 
relatively higher loss in affinity and efficacy, almost complete competition with the wild 
type ligand in a receptor binding assay, detection of biological activity by the halo assay, 
and prevention of cross-linking by an excess of α-factor indicated that this analog 
interacted with the receptor in a similar manner as the wild type ligand. Thus information 
gathered from this ligand will be helpful to interpret the possible contact(s) of position 13 
of α-factor with its receptor Ste2p.  Nevertheless, it is conceivable that the presence of the 
large diphenylketone group in the position 13 side-chain does result in a reorientation of 
the peptide in the binding site. The identification of contacts between the position 1, 3 
and 13 side chains of α-factor and specific regions of Ste2p leads refinement of the 
current working model  [30] for the placement of the pheromone into its binding pocket 
on the receptor.  Results presented herein indicate that the [Bpa1]α-factor analog and the 
[Bpa3]α-factor analog interact with a region of Ste2p covering EL2-TM5 or TM6-EL3-
TM7. Results reported in part II using an iodinated [Bpa1]α-analog showed a contact 
between position one of the ligand and TM6-EL3-TM7 [30]. Taken together, the present 
and previous results suggested that the N-terminus of the pheromone interacts with a 
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binding domain consisting of residues from the extracellular ends of TM5, TM6, and 
TM7 and portions of EL2 and EL3 close to these TMs. These conclusions are consistent 
with a previously proposed model [57] for α-factor bound to Ste2p.  Nevertheless, it is 
important to emphasize that the cross-linking results do not preclude other portions of 
Ste2p participating in the binding domain for the N-terminus of α-factor.   
This part also presented a direct interaction between the [Bpa13]α-analog and a 
region of Ste2p at the extracellular end of TM1. Supporting this interaction are studies 
from our laboratory demonstrating that changes at both residue 58 in TM1 and position 
13 of the ligand exhibit a similar phenotype (Tables 3 and 4). Site-directed mutagenesis 
studies in TM1 showed that mutation of the R58 residue (R58A, R58D, or R58E) results 
in a 25-100 fold decrease in binding affinity of the wild type pheromone (Figure 10) and 
only 20-30% decrease in the biological activity determined by halo assay (Table 4). 
Similarly, previous work reported by Liu et al. [50] showed that position 13 analogs of α-
factor, where Tyr was replaced by Ala or Ser had very poor binding affinities, but 
showed relatively good biological activity (Table 5). Thus, data from pheromone-receptor 
cross-linking studies, receptor mutagenesis analysis, and the structure-activity 
relationships of α-factor analogs would be consistent with an interaction between 
position 13 of the pheromone and TM1. However, this conclusion conflicts with a 
previously reported hypothesis on a possible interaction between position 13 of α-factor 
and F204 (located at the extracellular end of TM5) of Ste2p [57]. This hypothesis was 
mainly based on site-directed mutagenesis (F204C) resulting in a  receptor defective in α-
factor binding, and previous studies from our laboratory [55] showing defective binding 
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of position 13 α-factor analogs. Considering the current working model and results 
presented in this part (part III) of the dissertation, an interaction between position 13 of 
α-factor and TM5 of Ste2p is unlikely. 
Cross-linking analyses, presented in this part of the dissertation, suggested that 
Trp1, Trp3 and Tyr13 of the pheromone interact with TM6-EL3-TM7, EL2-TM5 or TM6-
EL3-TM7, and TM1 regions of Ste2p, respectively. These findings have led the 
refinement of the working model for fitting the tridecapeptide into the pheromone 
binding site (Figure 12). This model has a contact of Tyr13 of the pheromone with Ste2p 
residues between F55 to R58, an interaction between pheromone residue Gln10 with 
receptor residues S47 and/or T48, contacts of residues Trp1 and Trp3 of α-factor with 
Y266 and F204 of Ste2p, and a β-turn around the Pro-Gly sequence in the center of α-
factor allowing the middle of the pheromone to interact with extracellular loops. 
Additional constraints of the bound structure should be forthcoming as further 
refinements achieved by cross-linking studies with Bpa3 and Bpa5 analogs and 
sequencing analysis of the cross-linked fragments by mass spectrometry currently in 
progress in our laboratory.       
Understanding how G protein-coupled receptors are activated by ligand binding is 
an important goal of workers in the GPCR field.  A de novo computer model of Ste2p in 
the resting state (G. Nikiforovich, unpublished data) suggests that R58 and Y98 are in 
close enough proximity to be involved in a cation-pi interaction. An interaction between  
the Tyr13 of the pheromone and R58 of Ste2p, as described in the binding model 
presented herein, would disturb this cation-pi interaction leading to a conformational 
change that might facilitate a receptor shift to a more active state. Mutational studies on 
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Figure 12: Working model for the fitting of α-factor pheromone into the ligand 
binding site on its GPCR, Ste2p. α-factor and the loops are represented by the grey 
curve and dotted lines respectively. Contact residues determined in this study and 
previous studies indicated by a star symbol with the residue number of the pheromone.  
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Y98 showed that replacing this residue with a histidine resulted in a receptor that was 
weakly constitutive and supersensitive to pheromone [59], which supports the idea that 
Y98 is important for stabilizing the inactive state of Ste2p, perhaps by interacting with 
R58. Additional studies on this GPCR system should lead to valuable insights into the 
mechanism of GPCR activation by a peptide ligand.       
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PART IV 
 
 
Purification of Cross-linked Receptor Fragments  
and Mass Spectrometry Analysis 
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CHAPTER 1 
Introduction 
 
 Photoaffinity labeling is one of the few direct experimental strategies used to 
identify ligand-binding sites in biomolecules like GPCRs (see reviews [1-5]). Since the 
introduction of this technique, researchers have used tagged photoaffinity reagents 
(mostly radioactively labeled) and purified photolabelled fragments by conventional 
purification techniques. These fragments are usually further analyzed either by amino 
acid sequence analysis or fragmentation studies with chemical or enzymatic reagents. 
Although valuable information may be gained, many of these studies had limited 
resolution due to the size of the digested photolabelled fragments (in the order of several 
kDa in most cases) [6-9] or resistance to classical sequencing techniques [2]. Site-
directed or random mutagenesis experiments have contributed to the identification of 
receptor regions that are important in agonist selectivity or affinity, however these studies 
lack direct structure information about the agonist-receptor complexes.  
 Mass spectrometry (MS) is becoming the method of choice to overcome problems 
caused by limited sample yields for labeled peptide fragments produced in small 
quantities and to obtain better resolution in sequencing. In addition to the development of 
methods for the identification of post-translational modifications (for example, 
glycosylation and phosphorylation), electrospray (ES) [10-15] and matrix-assisted laser-
desorption ionization (MALDI) MS [16-18] have been used for studies on ligand-
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receptor interactions, suicide inhibitors and affinity labels. Recent progress in MS enables 
detection and sequencing of peptides in sub-picomolar quantities (see reviews [19-22]).  
Identification of a cross-linking site generated by photoaffinity labeling often 
requires the sequencing of the cross-linked fragment. Sequencing could be performed in 
the conventional fashion by Edman degradation or with exoproteases, however the 
amount of sample requirement is much greater than that needed for MS (>100 pmol) [23] 
and neither method is useful for membrane proteins due to low yields in purification and 
inadequate digestion by proteases [2]. Recently, several MS methods, including post-
source-decay MALDI-time of flight (MALDI-TOF) MS [24-26] and tandem MS 
(MS/MS) [27-30], have been used to analyze the sequence of a peptide fragment.   
A few groups have reported successful identification of the specific amino acids 
labeled in a protein using photoaffinity labeling combined with MALDI-TOF MS, such 
as the study on NK-1 receptor by Sachon et al. [31]. Leite et al. [32]used benzophenone 
based photo-probes and employed on-line liquid chromatography/tandem mass 
spectrometry (LC-MS/MS) with an ion trap to identify the photolabeled peptides and 
amino acid residues in the nicotinic acetylcholine receptor.  Although the sample amount 
and handling is minimal with these methods, determination of the primary sequence from 
the fragmentation pattern of a branched peptide can be quite difficult due to the 
complexity of the fragmentation process [33, 34]. Frequently, a proteolytic digest of a 
cross-linked protein includes multiple species: cross-linked peptides, linear peptides, and 
modified peptides thus making it difficult to identify and analyze the desired labeled 
fragments at normal instrument resolution. Furthermore presence of complete and 
incomplete digest fragments increases the number of possible cross-linked peptides in the 
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complex mixture. While all these cross-linked peptides will not be observed due to 
chemical preference and proper geometric orientation of the cross-linker and the target 
residue(s), all possibilities must be considered in interpreting experimentally observed 
mass/charge (m/z) values. Despite the fact that there are a few computer programs used 
for the analysis of mass spectra obtained from digested cross-linked proteins[35-38], 
careful examination of the data manually is often required.     
Several methods have been described for distinguishing cross-linked peptides in 
mass spectra of cross-linked and digested proteins. Some of these methods use 
isotopically labeled cross-linkers [39, 40] or proteins [41] that yield a distinctive 
signature in the mass spectrum. These techniques rely on the observation of a 
characteristic pattern in the mass spectrum or tandem mass spectrum of the analyte 
mixture. However, if the signal-to-noise ratio of the cross-linked species yielding this 
pattern is insufficient, the pattern cannot be reliably distinguished.   
The few successful examples mentioned above, where mass spectrometry was 
used to identify photoaffinity labeled residues, revealed that an efficient purification of 
the cross-linked peptide from a complex mixture is essential prior to MS analyses. 
Inadequate purification further complicates the collision induced dissociation (CID)-MS, 
thus making it almost impossible to identify the modified residue. Therefore, a separation 
method for enriching the cross-linked species from the analyte mixture would be useful 
for reducing levels of complexity caused by the non-cross-linked peptides. An affinity 
separation provides such an advantage, as described by Trester-Zedlitz et al. [42]. This 
part of the dissertation mainly describes the use of avidin-biotin interaction to purify the 
biotinylated α-factor analogs and the cross-linked receptor fragments from a yeast 
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membrane digest. It has been previously shown that a similar approach aided analysis of 
biotinylated fragments of avian skeletal muscle troponin C (TnC) from various mixtures 
of biotinylated TnC, BSA and equine cytochrome c following different enzymatic 
digestions [43].   
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CHAPTER 2 
Materials and Methods 
 
Chemical Reagents: 
 Immunopure immobilized monomeric avidin and streptavidin beads were 
purchased from Pierce (Rockford, IL). The acetone, water, and acetonitrile used in all 
HPLC applications and sample purifications were HPLC grade and obtained from 
Burdick & Jackson (Muskegon, MI). The 98% formic acid used in these applications was 
purchased from EM Science (an affiliate of MERCK KgaA, Darmstadt, Germany). 
Buffer components and salts were from Sigma (St. Louis, MO). Alpha-Cyano-4-
hydroxycinnamic acid (CHCA) and Sinapinic acid were purchased from Aldrich 
(Milwaukee, WI). CHCA was re-crystallized from ethanol before use. Immobilon NC 
Pure nitrocellulose was obtained from Millipore. Sequencing grade modified trypsin was 
used as supplied by Roche Diagnostics (Indianapolis, IN). Bovine serum albumin (BSA) 
and CNBr were from ICN Biomedicals (Aurora, OH). Dialysis tubing was from 
Spectrapor (Annex, LA). Immobilized-metal affinity chromatography (IMAC) was 
carried out either with Nitrilotriacetic acid pre-charged with Ni2+ (Ni-NTA) from Qiagen 
(Valencia, CA), or with HiTrap chelating column charged with Cu2+ from Amersham 
Biosciences (Piscataway, NJ). 
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Photoaffinity cross-linking: 
 Photoaffinity cross-linking was carried out with various 4-benzoyl-L-
phenylalanine (Bpa)-containing α-factor analogs as described in Part II and III. Briefly 
BJS21 pNED membranes (220 µg/ml of total protein) were incubated with PPBi buffer 
(total volume 1ml, with 0.1%BSA) in siliconized microfuge tubes for 10 min at ambient 
temperature. Bpa-scanned biotinylated α-factor analogs (10 to 20 nM) were added, and 
the reaction was incubated for 30 min at room temperature with gentle mixing. The 
reaction mixture was aliquoted into 3 wells of a chilled 24 well plastic culture plate pre-
blocked with PPBi (0.1% BSA). The samples were held at 4 °C and irradiated without the 
culture plate lid at 365 nm for 1 hour at a distance of 12 cm in a Stratlinker (Stratagene, 
La Jolla, CA). Membrane samples were recombined in siliconized microfuge tubes and 
washed twice by centrifugation (14000g) with PPBi (0.1% BSA). Then membrane pellets 
were stored at -80 ˚C for further experiments. 
    
Purification of intact cross-linked Ste2p:  
 Immobilized-metal affinity chromatography (IMAC), and size exclusion 
(preparative gel extraction) were used to partially purify the cross-linked Ste2p prior to 
further analysis. Partial purification before fragmentation and affinity purification helped 
to increase the yield and decreased the complexity in mass spectrometry analysis. The 
purification efficiency was tested by western blot analysis of the fractions collected from 
the columns and total protein in each elution was checked with Silver or Coomassie 
staining of the protein bands after SDS-PAGE.  
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a.  Hi-Trap column:  
 HiTrap chelating HP from Amersham Biosciences was used for IMAC. This 
column is composed of highly-cross-linked agarose beads to which iminodiacetic acid 
(IDA) has been coupled by stable ether groups via a spacer arm. The column is charged 
with 0.1 M CuSO4 and used by following the supplier’s protocol with the following 
modifications: The membranes containing Ste2p from BJS21 pNED (cross-linked or not, 
~ 1.5 mg/ml total protein) were solubilized in 6M urea (pH = 8.0) for at least 5hr (final 
volume 1 ml) followed by direct injection to a HiTrap column. The column was then 
connected to a high performance liquid chromatography (HPLC) instrument (Hewlett 
Packard, 1100 series). A wash step was then carried out with 50 mM ammonium 
bicarbonate buffer (pH=8.0), containing 50 mM imidazole and 6M urea. Elution of the 
bound proteins was achieved by the same buffer with 200 mM imidazole.        
b. Ni-NTA column: 
 Ni-NTA agarose from Qiagen was used as an alternative metal-chelating matrix. 
This column is composed of Ni-NTA coupled to Sepharose® CL-6B and offers high 
binding capacity and minimal nonspecific binding.  The protocol was adapted from a 
previous Ste2p purification study by David et al. [44]. Briefly, the membranes (5-
10mg/ml total protein) were solubilized in solubilization buffer (1% Dodecyl β 
Maltoside, 10% glycerol, 150 nM NaCl in 50 mM HEPES, pH=7.5, plus protease 
inhibitors;final volume 2 ml)   and were incubated with 1ml Ni-NTA (pre-equilibrated 
with equilibration buffer: 10% glycerol, 500 nM NaCl in 50 mM HEPES, pH=7.5, plus 
protease inhibitors) overnight (o/n) by end-to-end mixing. The flowthrough was collected 
from the column as the resin packed. The column was washed with 5 column volumes of 
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equilibration buffer, followed by 10 column volumes of wash buffer (10% glycerol, 150 
nM NaCl, 50 mM imidazole in 50 mM HEPES, pH=7.5, plus protease inhibitors). 
Column-bound material was then eluted with 5 column volumes of elution buffer (10% 
glycerol, 150 nM NaCl, 300 mM imidazole in 50 mM HEPES, pH=7.5, plus protease 
inhibitors). Fractions were concentrated with Microcon® YM-30 (Millipore, MW cutoff = 
30,000 Da.) before further analysis.     
c. Preparative Gel extraction: 
 BJS21 pNED membranes and cross-linked membranes (~1.5 mg total protein) 
were dissolved in 400 µl 1x loading buffer (BIO-RAD tricine sample buffer) for at least 
an hour. The dissolved membranes were then loaded on a preparative 10% SDS gel and 
resolved for 80 min at 25 mAmp. After the proteins resolved according to size, a 10 mm 
wide strip around the 50 kDa marker was cut out of the gel. The strip was then placed in 
dialysis tubing (MW cutoff = 25,000 Da.) with transfer buffer (25 mM Tris, 0.2 M 
Glycine and 20% methanol) and electro-eluted for 3 hr at 400 mAmp in a vertical transfer 
apparatus (Hoefer Scientific Inst.). Following electro-elution the dialysis tubing (20 ml) 
was placed in a 4 liters beaker filled with 25 mM ammonium bicarbonate. The buffer was 
changed every hour for three hours and then kept o/n at 4 °C. 
      
Digestion of cross-linked Ste2p: 
 Chemical and enzymatic digestions were carried out after the partial purification 
of the cross-linked samples. The fragmentation was achieved as described in parts II and 
III. In brief, the concentrated samples (~0.1-0.2 mg/ml) were either re-suspended in 70% 
formic acid for CNBr digestion or in buffer (100 mM Tris-HCl, pH 8.5) for trypsin 
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digestion. All digestions were carried out in complete darkness, under nitrogen gas, and 
at 37 °C for at least 24 hr. All digests were concentrated by vacuum centrifugation 
(SpeedVac) and analyzed by SDS-PAGE or mass spectrometry.         
 
Test of avidin purification: 
 Immunopure immobilized monomeric avidin and streptavidin beads were tested 
for the efficiency of capturing biotinylated peptides from simple and complex mixtures. 
The compatibility of these beads with MALDI-TOF was analyzed and compared. Ten µl 
of the biotinylated α-factor analog (Bpa8, 0.1µg/µl) was mixed with an equal volume of 
beads. The mixture was incubated at room temperature with continuous agitation for an 
hour. After the incubation the beads were washed with 50 µl PBS (0.1 M sodium 
phosphate, 0.15 M NaCl, pH = 7.2) 4 times, followed by washing with 50 µl water (5 
times). The beads were then left to settle and the supernatant was withdrawn after 
approximately 15 min.. The pellet was re-suspended in a minimal amount of water (10 
µl) and used in a MALDI-TOF experiment.  
 Capture of biotinylated α-factor analog from a simple and a complex mixture was 
carried out by applying a similar protocol. Preparation of a simple and a complex mixture 
of [Bpa8]α-factor analog was achieved by mixing with an equal amount of α-factor (0.1 
µg/µl, 10 µl final volume) or CNBr digested BJS21 pNED membranes (~300µg total 
protein), respectively. Ten µl of these mixtures were incubated with the beads as 
described above. After the wash steps the beads were directly analyzed by MALDI-TOF.  
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CNBr digested BJS21 pNED membranes cross-linked with various Bpa-scanned 
biotinylated α-factor analogs were examined under similar conditions.  
       
Purification of cross-linked Ste2p fragments with Monomeric avidin column: 
 After the fragmentation of the cross-linked membranes (~0.1-0.2 mg/ml) with 
CNBr or Trypsin, the digests were loaded onto a 1 ml packed monomeric avidin column. 
The column was washed with at least 5 column volumes of PBS followed by a second 
wash with 10 column volumes of 10% methanol, 50 mM ammonium bicarbonate. The 
bound biotinylated fragments were eluted with 5 column volumes of 50% acetonitrile, 
0.4% TFA [45]. The elutions were then pooled and concentrated by vacuum 
centrifugation to a final volume of 100 µl and analyzed by mass spectrometry.    
 
Mass spectrometry: 
 All of the mass spectrometry experiments were carried out in collaboration with 
the Biological Mass Spectrometry group in Oak Ridge National Laboratory (ORNL). 
Sample preparation and cleanup was done at the University of Tennessee and analysis 
was accomplished at ORNL. Two main mass spectrometry techniques were applied as 
described below:  
a. Matrix-assisted laser desorption ionization time-of-flight mass spectrometry 
(MALDI-TOF-MS): 
MALDI-TOF experiments were performed on a PerSeptive Biosystems Voyager 
Elite MALDI-TOF, equipped with a 337 nm nitrogen laser, operating in the positive ion 
mode (delayed extraction/linear mode). Spectra were obtained in reflector mode, with 
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+20 kV total acceleration voltage, +18 kV applied to the grid, +10 V applied to the guide 
wire, and 210 ns acceleration delay. Spectra were averaged from up to 256 individual 
laser pulses, obtained from several locations on each sample spot. Sample aliquots were 
applied to a pre-spotted thin-layer matrix. CHCA was prepared by dissolving 40 mg of 
CHCA in 1 ml of 2-propanol: acetone (50:50, v/v). Nitrocellulose was prepared by 
dissolving 10 mg in 1 ml 2-propanol: acetone (50:50, v/v). An equal volume of CHCA 
and nitrocellulose were mixed to give 20 mg/ml CHCA and 5 mg/ml nitrocellulose. A 0.5 
µl aliquot was dispensed onto the MALDI plate and allowed to dry. One-half µl volume 
of samples were applied to the thin layer and allowed to dry. Sinapinic acid (SA) was 
prepared by dissolving 10 mg SA in acetonitrile: 0.1% aqueous TFA (50:50, v/v). 
Samples were applied as described above. External calibration of the m/z axis was 
performed using gramicidin S and bovine insulin β-chain. Expected masses were 
calculated using Protein Prospector [46].  
Direct application of the avidin beads to MALDI plate was carried out by the 
protocol adapted from Li et al. [47]. Briefly, a layer of CHCA or SA (dissolved in 
acetone, 25 mg/ml) was applied to the MALDI plate, forming a dense layer of small 
crystals to allow adsorption of the beads. One µl of the bead slurry was then added and 
allowed to dry partially. An aliquot of a second matrix solution (CHCA or SA dissolved 
in aceteone, >50mg/ml) then was applied to allow solubilization of adsorbed peptides 
from the beads into the matrix solution. Upon complete drying, the beads were blown off 
with a stream of dry nitrogen leaving un-adsorbed peptides within the matrix ready for 
MALDI-TOF analysis. A schematic of the sample preparation procedure is shown in 
Figure 1.     
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Figure 1: Schematic representation of the MALDI procedure with avidin beads. 
Avidin beads were used to capture biotinylated peptides from simple or complex 
mixtures. Beads were spotted directly on the MALDI matrix for analysis (figure adapted 
from [47]). 
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b. Nanospray mass spectrometry (NS-MS):  
NS-MS was performed on a LCQ-DECA instrument (Thermo Finnigan) operating in 
the positive ion mode. Nanospray voltage was set to 2.0kV (Thermo Finnigan nanospray 
source) and the heated capillary was set at 200°C.  A 20µm id fused silica was directly 
connected to a liquid junction (Thermo Finnigan), which was connected to a 10µm id 
uncoated fused silica tip (New Objective, Woburn, MA). The MS was operated with 5 
microscans averaged for full scans and MS/MS scans, 5 m/z isolation widths for MS/MS 
isolations and 35% collision energy for collision-induced dissociation. For all 
experiments, the MS was operated in the data dependent MS/MS mode, where the four 
most abundant peaks in every full MS scan were subjected to MS/MS analysis. To 
prevent repetitive analysis of the same intense peptides, dynamic exclusion was enabled 
with a repeat count of 2. The exclusion duration was set to 1 minute. LC-MS/MS 
experiments were performed on an integrated Famos/Switchos/Ultimate 1D/2D HPLC 
system (LC Packings, a division of Dionex, San Francisco, CA) directly coupled to a 
quadrupole ion trap mass spectrometer (LCQ-DECA Thermo Finnigan, San Jose, CA) 
outfitted with a Finnigan nanospray (NS) source.  The entire system was fully automated 
and under direct control of the Xcalibur software system (Thermo Finnigan). For all 
reverse phase separations, gradients were run from 100% Solvent A (95% H2O/ 5% 
ACN/ 0.1% formic acid) to 100% Solvent B (30% H2O/ 70% ACN/ 0.1% formic acid), 
followed by a wash with 100% Solvent B and a 20 minute equilibration back to Solvent 
A before the next run (run times dependent upon experiment type). The loading solvent 
used in the 1D LC-MS/MS experiments was 100% H2O with 0.1% formic acid. For all 
nano mode reverse phase separations the flow rate was set at 200nL/min. The reverse 
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phase separations were carried out by a VYDAC C18 column (Part No. 218MS5.07515; 
75µm id x 15cm, 300Å with 5µm particles). All injections were made by an autosampler 
(Famos) onto a 50µL loop and flushed onto a LC Packings C18 precolumn (300µm id x 
5mm, 100Å with PepMap C18 5µm particles), and eluted after desalting onto the VYDAC 
C18 column. The outlet from the resolving column was directly connected to the NS 
source with a short piece of fused silica (20µm id for NS). 
The theoretical masses of the fragment ions were calculated by Prowl web site 
“http://prowl.rockefeller.edu/”. This site considers the common modifications to amino 
acids during fragmentation such as homoserine lactone formation at methionine residues 
after CNBr digestion (-48 Da)  
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CHAPTER 3 
Results 
 
Purification of intact cross-linked Ste2p:  
 Membranes obtained from BJS21 strain transformed with pNED (an over 
expression vector carrying the STE2 gene) [44] were used in the purification experiments. 
The α-factor receptor encoded by this plasmid is tagged at its C-terminus with an epitope 
tag (FLAG) and a 6xHis tag. Two of the methods applied in this study took advantage of 
the 6xHis affinity tag, which facilitates binding to metal ions. Immobilized-metal affinity 
chromatography (IMAC), based on this principle, was first used to purify proteins in 
1975 by Porath et al. [48]. The method was further optimized by other groups to purify a 
variety of different proteins and peptides [49].  
 Two different IMAC beads were used to purify the Ste2p (Ste2p.FT.HT) as 
detailed in Material and Methods. The HiTrap Chelating column from Amersham 
Biosciences was used by connecting it to a HPLC system. Various concentrations of 
imidazole (0, 25, 50, and 75 mM) in the wash buffer were tested to optimize the elution 
of non-specifically bound proteins. Results indicated that most of the protein was washed 
from the column in the flow-through (Figure 2, fractions 1-10; Figure 3, fractions 2, 4, 
and 6) and that 50 mM imidazole in the wash buffer effectively removed the proteins that 
are non-specifically attached to the resin as indicated by the absorbance of fractions 17-
30 (Figure 2). Western blot analysis (probed with anti-FLAG antibody) of the fractions 
showed that elutions with 200 mM imidazole released the bound 6xHis tagged Ste2p in 
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Figure 2: Elution of Ste2p.FT.HT from HiTrap column. HPLC elution profile (Abs. 280nm) of BJS21 pNED membranes from 
Cu2+ charged HiTrap column is plotted. The inset shows the western blot of the selected fractions probed with anti-FLAG 
antibody. Lanes labeled with the fraction number (indicating the elution time in minutes).
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Figure 3: Silver stained SDS-PAGE gel loaded with HiTrap elutions. First lane is the 
molecular weight markers, other lanes labeled with the fraction number (indicating the 
elution time in minutes). 
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fractions 42, 43 and 44. The higher molecular weight bands in fractions 42-44 were due 
to aggregation of Ste2p in the absence of detergents.  The high absorbance observed after 
fraction 45 was due to the 200 mM imidazole in these fractions.  
Similarly proteins solubilized from BJS21 pNED membranes that had been 
subjected to cross-linking with biotinylated [Bpa1]α-factor were also partially purified by 
a HiTrap column.  Figure 4 illustrates that cross-linked Ste2p could be eluted with 200 
mM imidazole and detected on a blot probed with NA-HRP. Most of the proteins eluted 
in the flow-through as indicated by the abundance of proteins in the flow-through 
fractions indicated by high absorbance (Figure 4) and in a silver-stained gel (data not 
shown).  In addition, the lack of bands in the NA-HRP probed blots (Figure 4) indicated 
that the cross-linked Ste2p was not eluted in these fractions. Washing the column with 50 
mM imidazole removed loosely bound proteins leading to a slight increase in absorption. 
The cross-linked Ste2p was eluted after increasing the imidazole concentration to 200 
mM. Both the increase in the absorption and bands detected by the NA-HRP blot 
indicated that fractions 52-54 contained biotinylated protein. Washing the column with 
500 mM imidazole after the elution did not lead to further release of tagged proteins. The 
overall yield of cross-linked Ste2p (Figure 4) was lower than that obtained from uncross-
linked membranes (Figure 2).  
 The second matrix used for IMAC was Ni-NTA from Qiagen, which is a Ni2+-
charged Sepharose resin. Fractionation of proteins solubilized from the cross-linked 
membranes was performed by following the supplier’s protocol with the modifications 
described in Materials and Methods. Elutions from the Ni-NTA column were analyzed 
after concentrating with vacuum centrifugation. Briefly, proteins were resolved by SDS- 
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Figure 4: Elution of cross-linked Ste2p.FT.HT from HiTrap column. HPLC elution profile (Abs. 280nm) of cross-linked 
BJS21 pNED membranes from Cu2+ charged HiTrap column is plotted. The inset shows the western blot of the selected fractions 
probed with NA-HRP. Lanes labeled with the fraction number (indicating the elution time in minutes).
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PAGE and transferred to PVDF membrane for western blot analysis. Blots were probed 
with either Konopka antibody (this antibody was obtained from Prof. James Konopka, 
SUNY Stony Brook; the antibody reacts specifically to the N-terminal 100 amino acids 
of Ste2p) or NA-HRP to detect the presence of Ste2p.FT.HT and cross-linked 
Ste2p.FT.HT, respectively (Figure 5). Analysis of both blots (Figure 5 A and B) showed 
that elution 2 (E2) contained a protein of approximately 54 kDa that was biotinylated 
(Figure 5A) and reacted with a specific antibody that recognized Ste2p (Figure 5B). 
Retention of this protein through the wash steps indicated that it interacted with the 
column tightly (due to the presence of a 6xHis tag). This blot also showed that a small 
amount of Ste2p was present in the flow-through and washes 1 (W1) suggesting that 
either the column was slightly over loaded or there was a small population of Ste2p 
which lost the 6xHis tag during sample preparation. Detection of these bands with NA-
HRP was not observed, probably due to a lower sensitivity of this detection compared to 
the Konopka antibody. Elutions from the Ni-NTA column were analyzed by silver 
staining to determine the presence of other proteins that co-eluted with the bound Ste2p 
(Figure 6). The presence of multiple bands revealed that several other membrane proteins 
retained on the column after the 50 mM imidazole wash. Comparison of the two IMAC 
matrices will be detailed in the Discussion part (Chapter 4). 
An alternative approach for purification of intact Ste2p was based on size 
exclusion. This method involved very little sample handling potentially giving higher 
yield. Briefly, proteins solubilized from cross-linked membranes were dissolved in 
loading buffer and resolved by 10% SDS-PAGE. After separation of proteins a 10 mm-
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Figure 5: Western blot analysis of the fractions from Ni-NTA column. Fractions collected from a Ni-NTA column loaded 
with cross-linked BJS21 pNED membranes were concentrated and resolved by 10% SDS-PAGE. After transferred to PVDF 
membranes blot A) probed with NA-HRP to detect biotin signal, and blot B) probed with Konopka antibody to detect Ste2p.
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Figure 6: Silver stained SDS-PAGE gel loaded with Ni-NTA column elutions. Cross-
linked BJS21 pNED membranes resolved by 10% SDS-PAGE and protein bands detected 
by silver staining.    
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wide region of the gel around the 50 kDa band was removed, and proteins were electro-
eluted. Following dialysis the samples were concentrated by vacuum centrifugation and 
assayed with western blot analysis and silver staining (Figure 7). The results showed that 
there was no other detectable biotinylated protein in the purified sample. Also no 
aggregation or degradation products were observed. Analysis of the silver stained gels 
indicated the presence of a few other proteins in the partially purified sample (Figure 
7A).          
 
Analysis of partially purified Ste2p with Nanospray-MS (NS-MS):  
 Following the partial purification of Ste2p the compatibility of the purified 
sample with tandem mass spectrometry was analyzed. For this assay FLAG-tagged, 
6xHis tagged Ste2p was partially purified by a HiTrap column as described above (Figure 
2). Following the purification step the concentrated sample (Fractions 42-44, Figure 2) 
was re-suspended in 70% formic acid and digested with CNBr for 18hr at 37 °C. Digests 
were then dried by vacuum centrifugation and neutralized with 50 mM ammonium 
bicarbonate buffer (final volume ~ 100 µl). Analysis of the neutralized sample was 
carried out with LCQ-DECA (Thermo Finnigan) operating in the positive ion mode. The 
total ion spectrum obtained from this sample indicated that there were several ion packets 
throughout the spectrum, indicating the presence of many peptides (Figure 8). Manual 
analysis of the MS/MS data showed that at least 10% sequence coverage for Ste2p was 
obtained. Representative spectra of two such fragments are shown in Figure 9. In one 
spectrum (Figure 9A), a sequence of AAALTLIVM was clearly obtained allowing 
assignment to the CNBr theoretical peptide FGVRCGAAALTLIVM.  However, the 
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Figure 7:  Partial purification of cross-linked Ste2p by gel extraction. A) Silver 
stained gel to show the total proteins present. Lane one is the unpurified cross-linked 
BJS21 pNED membranes, lane two is after gel extraction. B) NA-HRP blot of the same 
samples to detect the biotin tag (from the analog) on Ste2p. Lane 1 is the total membrane 
and lane 2 is the partially purified sample. 
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Figure 8: Total ion spectrum of CNBr digested HiTrap elution from LCQ-DECA. Multiple ion packets were observed 
through out the chromatogram. Most of the peptides start eluting after 25 min. 
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YFVSAVKGM (181-189) 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: MS/MS spectrums of CNBr digested HiTrap elution from LCQ-DECA. 
Two representatives for MS/MS spectrums revealing sequence information of CNBr 
digested Ste2p fragments A) covering residues 55-69 and B) covering residues 181-189.  
* Cleavage at methionine causes loss of 48 Da (formation of homoserine lactone).
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sequence coverage and the presence of many other peptides in the CNBr-digested HiTrap 
elution necessitated the use of an alternative purification method to enrich cross-linked 
Ste2p fragment(s). 
 
Optimization of avidin purification and MALDI analysis: 
 As an alternative purification method, biotinylated samples were enriched by an 
affinity capture method modified from Li et al. [47] and analyzed with MALDI-TOF. 
This method allowed high sensitivity while minimizing sample handling by taking 
advantage of the extremely strong interaction between avidin and biotin (having 
dissociation constant on the order of 10-15) and incorporating this property into mass 
spectrometry. Two types of immunopure immobilized avidin beads (monomeric avidin 
and streptavidin from Pierce) were used and compared in this study. Biotinylated 
[Bpa8]α-factor analog was used as the probe throughout the method optimizations, 
carried out with uncross-linked samples, for mass spectrometry analysis. Capture and 
detection of the biotinylated ligand from a simple (a 1:1 mixture of the probe with α-
factor) and a complex (a 1:300, 1:30, and 1:6 mixture of the probe with CNBr digested 
BJS21 pNED membranes) mixture was tested.  
Analysis of mass spectra from the monomeric avidin beads after incubation with 
the biotinylated [Bpa8]α-factor analog alone indicated that this peptide was captured on 
the beads, ionized from the matrix during MALDI-TOF analysis, and detected as a 
2159.11 m/z ion (theoretical, 2159 Da) (Figure 10). The mixture of α-factor and 
biotinylated [Bpa8]α-factor showed that two peptides were detected in washes, designed  
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Figure 10: Capture of biotinylated peptides from a simple mixture with monomeric 
avidin beads. A) Biotinylated [Bpa8]α-factor mixed with monomeric avidin beads, B) 
washes from the monomeric avidin beads after incubation with a mixture of biotinylated 
[Bpa8]α-factor and α-factor (1:1), C) analysis of the washed monomeric avidin beads.   
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to remove peptides not bound to avidin from the beads (Figure 10B). The detected 
masses for these two peptides, 1668.19 and 1503.52 Da, matched the theoretical masses 
for α-factor (1668 Da) and an autolysis product that was missing Tyr13 (1504 Da). There 
were a few minor peaks around 2158 m/z indicating that a very small quantity of the 
biotinylated probe was eluted in the wash. Spectra from material adsorbed on the washed 
beads (Figure 10C) had one main peak at 2160 m/z corresponding to biotinylated 
[Bpa8]α-factor (theoretical = 2159 Da) and a neighboring peak possibly due to two 
sodium (2x22 Da) adduct, observed as 2204.08 Da. 
Following the testing of the monomeric avidin beads, streptavidin beads were also 
tested for the ability to capture biotinylated peptides. The control experiment to confirm 
the binding to the beads was carried out by incubating the beads with biotinylated 
[Bpa8]α-factor alone. Similar to monomeric avidin beads, analysis of the streptavidin 
beads resulted in detection of a single peak around 2160 m/z (data not shown). However, 
analysis of the washes from streptavidin beads showed that these samples contain 
relatively more biotinylated [Bpa8]α-factor as revealed by the detection of peaks at 
2159.93 and 2219.19 (a sodium + potassium adduct = +60 Da) m/z (Figure 11A). This 
result indicated that the streptavidin beads did not bind this ligand as tightly as the 
monomeric avidin beads. Spectra from washed streptavidin beads (Figure 11B) showed a 
lower signal at 2161m/z as compared to the signal at this mass obtained from monomeric 
avidin beads (Figure 10C). In addition, there were other peaks at lower m/z, perhaps due 
to the presence of residual α-factor.  Due to relatively lower binding of the biotinylated 
peptide to streptavidin beads as compared to monomeric avidin bead, further experiments  
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Figure 11: Capture of biotinylated peptides from a simple mixture with streptavidin 
beads.  A) Washes from the streptavidin beads incubated with mixture of biotinylated 
[Bpa8]α-factor and α-factor (1:1), B) analysis of the washed streptavidin beads. 
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 involving purification of biotinylated [Bpa8]α-factor from complex mixture was only 
carried out with monomeric avidin beads. 
Analysis of monomeric avidin beads, mixed with CNBr-digested membranes, 
showed that a major peak at 4418.53 m/z was detected (Figure 12). This peak was likely 
due to an endogenously biotinylated protein in yeast membranes. Such biotinylated 
proteins are detected in blots of yeast membranes probed with NA-HRP (See part III of 
this dissertation).  The 4418 m/z peak was detected in all samples (Figure 12 A, B, and 
C).  This mass was excluded from subsequent spectral analyses in this dissertation. 
Examination of various complex mixtures containing different ratios of biotinylated 
peptide and membranes digested with CNBr suggested that even at a 1:300 mixture (by 
weight) the biotinylated [Bpa8]α-factor analog (2166 m/z) was captured and identified by 
MALDI-TOF analysis of monomeric avidin beads (Figure 12B). The 2166 m/z ion 
detected in this experiment did not coincide exactly with the theoretical 2159 Da peptide. 
This was attributed to an inaccurate assignment of the m/z ion in a dilute sample with a 
low signal to noise ratio.  A more accurate mass detection was obtained when the mixture 
had a relatively higher amount of biotinylated probe in the mixture (ratio of biotinylated 
[Bpa8]α-factor to membrane digest approximately 1:30, w/w) (Figure 12C). The 
discrepancy between the theoretical mass of 2159 Da and the obtained 2161 m/z ion 
might be due to an inexact calibration of the mass spectrometer. 
Following these analyses, CNBr-digested cross-linked membranes were examined 
under the same conditions. Cross-linking experiments were carried out, as detailed in 
materials and methods chapter of Part III of this dissertation, with biotinylated [Bpa1]α- 
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Figure 12: Capture of biotinylated peptides from a complex mixture with 
monomeric avidin beads. CNBr-digested membranes were mixed with various amounts 
of biotinylated [Bpa8]α-factor and the beads were analyzed with MALDI-TOF after 
several washes. A) Beads incubated with CNBr-digested membranes alone, B) beads  
incubated with[Bpa8]α-factor mixed with membrane digest (ratio,1:300 by weight), C) 
beads incubated with [Bpa8]α-factor with membrane digest (ratio,1:30 by weight).  
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factor analog.  Analysis of the CNBr-digested membranes prior to cross-linking resulted 
in detection of a peak at 4417.95 m/z (Figure 13A), the endogenous, biotinylated CNBr 
fragment in yeast membranes, similar to the fragment found in previous experiments 
(Figure 12A).  The spectrum from the beads that were incubated with CNBr-digested 
cross-linked membranes had three main peaks, 2071.98, 4413.49, and 6863.9 m/z (Figure 
13B). As biotinylated [Bpa1]α-factor (theoretical mass = 2070 Da) was used in the cross-
linking reaction, the 2071.98 ion corresponded to uncross-linked ligand. The peak at 
4413.49 was assigned to the endogenously biotinylated peptide and did not match the 
mass of any cross-linked Ste2p fragments. In addition a peak at 6863.9 m/z was 
observed. In order to identify a possible cross-linked fragment that could give a signal in 
this range the theoretical CNBr digestion map of Ste2p was examined. The closest 
fragment that could generate a signal at this m/z is the region of Ste2p between residues 
251 and 294 that gave a mass of 6639 upon cross-linking with biotinylated [Bpa1]α-
factor .The region of Ste2p between residues 251 to 294 was previously identified as the 
cross-linking region for [Bpa1]α-factor analogs as described in part II and III of this 
dissertation.  The 6639 theoretical mass was about 224 Da lower than the observed m/z. 
A literature search on MALDI adducts showed that an adduct of 224 Da from the matrix 
(SA) used in the MALDI-TOF experiment was observed [50]. If this adduct was indeed 
associated with the ion found in the experiment (Figure 13), then the experimental mass 
minus the adduct would match the theoretical mass for biotinylated analog cross-lined to 
the region of Ste2p covering residues 251 to 294.   
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Figure 13: Capture of cross-linked fragments with monomeric avidin beads. A) 
CNBr digested yeast membranes were incubated with monomeric avidin beads and 
analyzed with MALDI-TOF. B) Membranes cross-linked with biotinylated [Bpa1]α-
factor analog were digested with CNBr, biotinylated fragments captured by monomeric 
avidin beads and analyzed with MALDI-TOF.  
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Purification and cleanup of biotinylated samples for Nanospray-MS (NS-MS): 
 Although the information obtained from MALDI-TOF was much more accurate 
then calculating peptide masses from SDS-PAGE, sequencing was not possible with this 
method. In order to identify the Ste2p residue(s) where the cross-linking takes place, 
sequencing the cross-linked fragments is necessary. Tandem mass spectrometry analyses 
were carried out, with a LCQ DECA instrument, to obtain sequence information from 
biotinylated [Bpa8]α-factor and cross-linked Ste2p fragments. A column containing 
monomeric avidin beads was used to purify biotinylated fragments prior to tandem NS-
MS analysis. The protocol was first tested with a complex mixture of CNBr-digested 
yeast membranes and biotinylated [Bpa8]α-factor (300:1 mixture, w/w). Elutions from 
the column were analyzed with the LCQ-DECA instrument. The results (Figure 14) 
showed that there were relatively few peaks in the total ion spectra in comparison to the 
HiTrap elutions previously analyzed with the same method (Figure 8). 
MS/MS analysis of the main ions at 53 minutes covered almost the complete 
sequence of biotinylated [Bpa8]α-factor (Figure 15). This spectrum also showed that the 
biotin tag attached to Lys7 of the analog can be cleaved during fragmentation inside the 
ion trap.  This experiment showed that a monomeric avidin column could be used to 
capture biotinylated peptides of sufficient purity for sequence analysis by tandem MS. 
 Following these results a similar purification protocol was applied to membranes 
cross-linked with various biotinylated Bpa-scanned α-factor analogs (Bpa1, Bpa3, Bpa5 
and Bpa13). Cross-linked Ste2p was first partially purified with gel extraction from the 
solubilized membranes. This initial purification was required to get rid of the uncross-  
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Figure 14: Analysis of elutions from monomeric avidin column with LCQ-DECA.  
A) The total ion spectrum of the elutions from monomeric avidin column which was 
incubated with a complex mixture (CNBr digested yeast membranes + biotinylated 
[Bpa8]α-factor), B) the full MS spectra at 53rd minute indicating detection of a peptide 
with a mass of ~2160 Da. 
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Figure 15: MS/MS analysis of the 1080.79 m/z ion at 53rd minute. The main ion at 53rd min was selected and analyzed after 
fragmentation by CID. 
WHWLQLK(biotin)BpaGQPNleY 
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linked ligand that would decrease the purification yield from avidin column. The 
concentrated electro-elution samples were then re-suspended in 70% formic acid and 
digested with CNBr. Concentrated digests were neutralized and loaded on a monomeric 
avidin column to enrich the biotinylated fragments. Analysis of the elutions with LCQ-
DECA showed that the total ion spectra contained a few main ion packets as shown in a 
representative spectrum obtained from biotinylated [Bpa5]α-factor cross-linked 
membrane digests (Figure 16A). Unfortunately, the fragmentation spectra for these ions 
were too complex to analyze by hand and a proper software was not available to analyze 
the data automatically. Manual analysis of the total ion spectra obtained from these 
experiments revealed identification of a few peptide masses. For example the full MS 
spectrum for biotinylated [Bpa5]α-factor cross-linked sample suggested that a 4678 Da 
peptide was eluted at 37th minute of the MS analysis. The ion packet observed in figure 
16B showed that this peptide is highly charged, thus the fragmentation spectrum could 
contain multiply charged ions. Examination of the theoretical fragments from cross-
linked Ste2p  illustrated that the CNBr fragment covering residues 166-189 had the 
closest mass (fragment mass 2488.23 + ligand mass 2128 = 4616.23 Da) to the mass 
observed. The difference between the theoretical and observed masses was 61 Da, which 
could be due to a sodium + potassium adduct (60 Da) during the sample preparation. A 
similar adduct of 60 Da was observed when the biotinylated Bpa8 scanned ligand was 
analyzed by MALDI-TOF (Figure 11A). Although an MS/MS sequence was obtained for 
the major ions at this time point (data not shown), the sensitivity of the instrument was 
not great enough to deconvolute the charge states of the fragment ions to identify the 
sequence. However, the observed mass implied cross-linking of biotinylated [Bpa5]α- 
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Figure 16: Analysis of monomeric avidin column purified CNBr digested cross-
linked membranes with LCQ-DECA. A) The total ion spectrum of the elutions from 
monomeric avidin column loaded with CNBr digested membranes, cross-linked with 
biotinylated [Bpa5]α-factor analog B) the full MS spectra at 37th minute showing the 
multiple charge states of 4678 Da peptide. 
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factor analog to a region of Ste2p covering residues 166-189 (TM4) with the assumption 
of a 60 Da adduct as discussed above.   
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CHAPTER 4 
Discussion 
 
In order to determine the Ste2p residue where the cross-linking of biotinylated 
Bpa scanned α-factor analogs takes place, accurate mass detection is crucial. Recent 
developments in mass spectrometry combined with a proper affinity purification make 
this technique an invaluable method for detection of peptide masses with very high 
accuracy and sensitivity [63-65].  
Although purification techniques have been previously optimized to purify α-
factor pheromone receptor (Ste2p) [44], application of these methods to cross-linked 
membranes and compatibility of the elutions with mass spectrometry have not been 
tested. This part of the dissertation outlined the use of different affinity chromatography 
methods to purify intact Ste2p or biotinylated cross-linked fragments from a complex 
membrane mixture, and a size exclusion protocol applied to partially purify Ste2p. Also 
two mass spectrometry techniques were used to identify cross-linked regions on the α-
factor pheromone receptor. 
 Currently, many affinity purification techniques are commonly used to purify 
various proteins. In this study a 6xHis tagged Ste2p construct was used to take advantage 
of the immobilized-metal affinity chromatography (IMAC). The FLAG tag present in the 
same construct was used for detection purposes.  After comparing two different metal 
chelating resins as described in the results, the HiTrap column from Amersham 
Biosciences was shown to be preferable to the Ni-NTA resin from Qiagen under the 
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conditions tested. The main difference between the two resins is their interaction with the 
metal ions. While the HiTrap column uses iminodiacetic acid (IDA) to interact with the 
metal ions, Ni-NTA resin carries nitrilotriacetic acid (NTA), which provides an 
additional interaction site for the metal ion (Figure 17A). The supplier of this resin claims 
that this extra interaction with the metal ion increases the stability of the charged column 
thus binding to 6xHis tagged proteins would be tighter than IDA matrices. However, 
occupation of four out of six binding sites of (+2) charged metal ion leaves only two 
possible sites for the interaction with His from 6xHis tag (Figure 17B). On the other hand 
IDA matrices could interact with the 6xHis tag at the remaining 3 contact sites potentially 
yielding higher specificity.  
 Results from purification with both resins showed that Ste2p.FT.HT could be 
captured and partially purified from yeast membrane preparations. Elutions from both 
resins carried a few non-specifically bound proteins detected by silver stain (Figure 3&6). 
When the specifications of these two resins were compared, the main differences were 
the ability of the HiTrap column to withstand higher flow-rates and back pressure, thus 
allowing coupling to a HPLC instrument. Due to this reason and the flexibility in the 
choice of metal ions that could be used to charge the resin, HiTrap columns were 
preferred throughout this study for partial purification of Ste2p.FT.HT.  
 Besides the IMAC, electro-elution from preparative SDS gels was also applied for 
partial purification of cross-linked Ste2p. Following cross-linking (UV exposure), many 
proteins in membrane preparations aggregate, causing a decrease in their solubility. 
Unless treated with denaturants like urea or guanidine-HCl, use of these samples with an 
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Figure 17: Comparison of the interaction of different metal chelating matrices with 
nickel ion. A) Shows how the two metal chelating matrices, NTA and IDA, interact with 
metal ions, B) an illustration of how two His could interact with the NTA bound Ni2+ 
(Figures adapted from “A handbook for high-level expression and purification of 6xHis-
tagged proteins” available online at 
“http://www1.qiagen.com/literature/handbooks/PDF/Protein/Expression/QXP_QIAexpre
ssionist/1024473_QXPHB_0603.pdf”) 
A 
B 
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affinity chromatography (like IMAC) is not feasible. Although most of the affinity 
columns are compatible with many of the denaturants, additional sample cleanup is often 
necessary, which in most cases could cause low yield. In order to decrease sample 
handling, a simple and efficient gel extraction method was applied to partially purify 
cross-linked Ste2p. As detailed in results, this technique was particularly good at 
removing the aggregates or degradation products that usually co-purified by affinity 
chromatography (Figure 4 inset). The presence of multiple forms of the cross-linked 
Ste2p in the purified sample would complicate the fragmentation and the analysis of the 
fragments afterwards. One disadvantage of gel extraction is the requirement of a dialysis 
step after the electro-elution to remove the excess detergent and buffer components from 
the SDS-PAGE. The purity (Figure 7A, lane 2) and the ease of sample handling by gel 
extraction were comparable to the IMAC method.  
 The IMAC and gel extraction methods were satisfactory for analysis of cross-
linked Ste2p fragments, following chemical or enzymatic digestion, with western blot 
analysis. On the other hand use of highly sensitive mass spectrometric techniques like 
MALDI-TOF, or NS-MS requires much purer and enriched samples. For this purpose, 
during the synthesis of the Bpa-scanned α-factor analogs incorporation of a biotin tag 
was included to take advantage of the well-studied avidin-biotin chemistry [51, 52]. The 
extremely strong interaction between the avidin and biotin was useful for both detection 
and affinity purification [53, 54]. Two different immunopure immobilized avidin beads 
(monomeric avidin and streptavidin from Pierce) were used and compared in this study.  
Streptavidin, immobilized on beaded agarose, is an avidin-like protein that carries 
four binding sites for biotin, each with a similar binding affinity (dissociation constant ~ 
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10-15). Unlike avidin this protein has a lower pI (5-6) and is not a glycoprotein, therefore 
it is postulated to be less prone to nonspecific binding [51]. Monomeric avidin, 
immobilized on beaded agarose, has only one binding site for biotin (dissociation 
constant ~ 10-8). Both beads were incubated with a simple mixture containing a 
biotinylated α-factor analog and the wild type α-factor pheromone in a 1:1 mixture. 
Analysis with MALDI-TOF showed that capture of the biotinylated analog from this 
simple mixture with monomeric avidin beads was more efficient compared to the 
streptavidin beads. A similar study by Gitlin et al. [70] suggested that the biotin binding 
site of streptavidin could be buried more deeply compared to monomeric avidin [55] 
requiring a long-chain spacer arm between the analyte and biotin tag for efficient binding. 
Thus depending on these analyses, monomeric avidin beads were preferred for further 
experiments.  
Following the success in capturing a biotinylated analog from a simple mixture, 
monomeric avidin beads were tested with a complex mixture that mimics the actual 
digests containing cross-linked Ste2p fragment(s). Briefly, yeast membranes carrying 
Ste2p (~300µg total protein) were digested with CNBr and mixed with a biotinylated α-
factor analog. Mixtures containing various ratios of ligand to membrane digest were then 
incubated with monomeric avidin beads and subjected to several washes as described in 
Materials and Methods. Results showed that biotinylated analog can be captured even 
from a mixture where the ligand to total membrane digest ratio is 1:300 by weight. There 
was only one main contamination peak probably originating from an endogenously 
biotinylated protein. At the lowest ratio tested, peak broadening and adducts were 
observed. However analysis of higher intensity signals (from 1:30 mixture) revealed an 
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experimental mass for the biotinylated analog, which was only 2 Da higher than the 
theoretical weight (Figure 12C).  
 Although these results suggested that for lower concentration samples, like cross-
linked fragments, there could be deviations from mass accuracy, the method was much 
more sensitive than calculating masses from relative mobility on SDS-PAGE. Therefore 
the method was applied to a sample where a CNBr digested cross-linked membrane was 
used (membranes were cross-linked with biotinylated [Bpa1]α-factor). Detection of three 
main peaks, including a peak at 4417 Da, previously observed in membrane only assay 
(Figure 12A), was quite promising. Analysis of the masses obtained from these peaks 
suggested the presence of uncross-linked free ligand (theoretical mass = 2070) and 
another peptide with observed weight of 6863.9 Da. This observed mass was 224.51 Da 
higher then the theoretical weight of a possible cross-linked fragment resulting from 
linking of the biotinylated [Bpa1]α-factor analog (2070 Da) to a region of Ste2p covering 
residues 251-294 (4569.39 Da) generated by CNBr digestion. Even though this difference 
is very big considering the mass accuracy of MALDI-TOF, it has been reported that a 
matrix adduct from sinapinic acid (SA = 224 Da) could be observed in such analyses [47, 
50], which will result in such a mass deviation. Testing of a different matrix, α-Cyano-4-
hydroxycinnamic acid (CHCA), to solve this problem caused the disappearance of signal 
at high m/z region from the sample. CHCA matrix is commonly used for small size (2 to 
3 kDa) peptides and thus might not be effective in the ionization of bigger fragments 
observed with SA matrix. These results showed that although the MALDI-TOF-MS is a 
very sensitive and accurate method to determine masses of peptides, without sequence 
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information, assignment of these masses to possible cross-linked fragments could not be 
done unambiguously.  
 Thus partially purified Ste2p, digested with CNBr, was analyzed with NS-MS to 
obtain sequence information from receptor fragments. Results indicated that IMAC or gel 
extraction alone was not enough to obtain sufficient purity for NS-MS. Although a few 
peptides were detected and sequenced from Ste2p (Figure 9 A and B), the sequence 
coverage was very low (~10% of the receptor sequence). The presence of several 
additional peptides from various other proteins complicated the full MS and MS/MS 
sequences, making it very hard to analyze. Therefore alternative affinity purification 
methods were tested to obtain purer samples before NS-MS analysis.    
A monomeric avidin column was quite successful when tested for purification of 
biotinylated ligands from CNBr digested yeast membranes. Figure 14 shows that the 
main ion in the chromatogram belongs to the biotinylated analog, which was mixed with 
the complex membrane digest. There were only a few other peptides from this mixture 
observed in the total ion spectrum indicating the sample was relatively pure. In addition, 
the MS/MS spectrum from this high intensity ion revealed almost the complete sequence 
for the biotinylated analog (Figure 15). Unfortunately application of this method without 
any modification to the cross-linked membranes was not as successful. The presence of 
uncross-linked ligand in these samples competed against the cross-linked fragments from 
Ste2p during purification with monomeric avidin column. Additionally, the uncross-
linked peptides were smaller in size, thus their ionization in the NS-MS experiments was 
more efficient. The signal from these small peptides masked signal from less abundant 
peptides like the bulky cross-linked fragments. To overcome these problems, application 
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of monomeric avidin column following gel extraction and CNBr digestion of cross-linked 
Ste2p was applied prior to NS-MS analysis. This two-step purification was designed to 
eliminate the uncross-linked ligand prior to monomeric avidin column resulting in better 
enrichment of the biotinylated cross-linked fragments.  
Preliminary results from these experiments suggested that a few peptides could be 
enriched and detected by NS-MS. However the MS/MS spectra of these peptides were 
complicated. Presence of multiple charge states of the fragment ions made it very hard to 
obtain a series of related ions to determine a sequence tag. Due to the resolution limit of 
the mass spectrometer used in this study the identification of the charge states of these 
ions was not possible, thus deconvolution of the sequence information from these 
MS/MS spectra could not be accomplished. In the absence of sequence information, data 
obtained from NS-MS studies was only supportive instead of being informative. These 
problems could be solved with a more sensitive instrument like a Fourier Transform Ion 
Cyclotron Resonance (FT-ICR) that could do MS/MS analysis, or by the use of 
isotopically labeled cross-linkers resulting in doublet ions that would aid identification of 
cross-linked fragments in total ion spectra. The details of these methods are further 
discussed in Part V, Chapter 2 of this dissertation. 
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CHAPTER 1 
General Conclusions and Discussion 
 
This dissertation details how Bpa-scanned α-factor analogs have been used to 
gain insights into structure-function relationships between α-factor, the Saccharomyces 
cerevisiae peptide pheromone, and Ste2p, its G protein-coupled receptor. New detection 
and purification methods were introduced by the use of biotin as an affinity tag attached 
to cross-linkable α-factor analogs. The major findings of the studies, contributions to 
current knowledge of how peptide ligands interact with their GPCRs, and possible future 
experiments that would provide further details on the mechanism(s) of signal 
transduction through GPCRs upon ligand binding are summarized in this final part of the 
dissertation.   
 
Use of Bpa-scanned α-factor Analogs: 
 It has been shown previously that benzoyl-L-phenylalanine (Bpa) can be 
introduced at positions 1, 3, 5, 7, 8, 12 and 13 replacing the native α-factor residues (Trp, 
Trp, Gln, Lys, Pro, Met, and Tyr, respectively) to give potential photo-affinity labels with 
slight decreases in Ki from 4-fold to 45-fold in comparison to α-factor [1]. Based on these 
observations and our working model for pheromone binding to Ste2p [1, 2], iodinatable 
α-factor analogs carrying Bpa at position 1, 3, 5, or 13 were synthesized. Studies with 
these analogs, as detailed in Part II, showed that except for [Bpa1(I2)Y3R7F13]α-factor, 
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iodinated [Bpa3], [Bpa5] and [Bpa13]α-factor analogs had poor biological activity and 
decreased Kis. In addition, chemical iodination of these analogs resulted in multiple 
iodination at Tyr residue and caused further loss of function. Based on these studies, it 
was decided to pursue a different mode of tagging the α-factor analog in order to obtain 
modified analogs with sufficient biological activity and receptor binding to ensure their 
usage for photo-affinity studies. 
Design and syntheses of biotinylated, Bpa-scanned α-factor analogs were 
achieved (covered in Part III). Analysis of these analogs illustrated that, except for the 
[Bpa8]α-factor analog, the presence of a biotin tag on Lys7 had minor effects on 
biological activity and binding affinity. Photo-activated cross-linking of these analogs to 
yeast membranes expressing Ste2p resulted in one major band around 54 kDa detected by 
western blot analysis probed with NA-HRP (NeutraAvidin-Horse Radish Peroxidase 
conjugate). The NA-HRP detected the biotinyl group which was the tag on α-factor that 
was cross-linked into Ste2p. The intensity of the bands was reduced by addition of excess 
α-factor pheromone during the cross-linking reaction. These results indicated that 
biotinylated [Bpa1], [Bpa3], [Bpa5], and [Bpa13]α-factor analogs specifically cross-linked 
to the Ste2p and could be used in identification of contact sites between α-factor and its 
GPCR.  
 
Purification of intact Ste2p and enrichment of biotinylated cross-linked fragments: 
 In order to identify the interaction site(s) between a peptide ligand and its GPCR, 
fragmentation of the cross-linked receptor followed by analysis of the resulting fragments 
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is often applied [3, 4](see review [5]). The use of a reporter tag on the peptide ligand, like 
125I as mentioned in Part II or biotin as discussed in Part III of this dissertation, aids the 
identification and analysis of the cross-linked fragments. In the case of the biotin tag, due 
to the presence of possible endogenously biotinylated proteins in the sample mixture, a 
partial purification of the cross-linked receptor prior to fragmentation is essential. Two 
main approaches (IMAC and size exclusion) for partial purification of the intact cross-
linked Ste2p were detailed in Part IV. Although a single-step purification was sufficient 
for western blot analyses, further enrichment of the cross-linked fragments was necessary 
for the highly sensitive mass spectrometry studies. In order to achieve this goal, 
following partial purification and fragmentation, the cross-linked fragments were 
enriched by using monomeric avidin beads, which takes advantage of the strong 
interaction between biotin and avidin [6, 7]. Results presented in parts III and IV of this 
dissertation showed that purification methods applied were adequate to obtain samples 
pure enough to analyze with either western blots or mass spectrometry analyses.  
             
Identification of Ste2p regions cross-linked with Bpa-scanned α-factor analogs: 
  Following partial purification of the cross-linked Ste2p, chemical and enzymatic 
fragmentation was carried out to identify the cross-linked region(s). Detection of the 
cross-linked fragments was achieved by autoradiography or analysis of protein blots by 
probing with NA-HRP according to the tag attached to the ligand used. Fragmentation of 
the [Bpa1, Tyr3(125I), Arg7, Phe13]α-factor cross-linked Ste2p using CNBr, trypsin, and 
BNPS-skatole reagent resulted in distinct fragmentation patterns as explained in Part II. 
Using these analyses and an epitope tagged Ste2p (Ste2p-T7; [8]) the region of cross-
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linking was localized to residues 251 to 294 of the receptor. This region corresponds to a 
portion of Ste2p comprising the sixth and seventh transmembrane domains and the 
connecting the third extracellular loop.  
 Similarly, Part III of this dissertation details the use of biotinylated Bpa-scanned 
α-factor analogs to identify the contact regions between the peptide ligand and Ste2p. 
Findings from biotinylated [Bpa1]α-factor were in agreement with the results obtained 
from studies using [Bpa1, Tyr3(125I), Arg7, Phe13]α-factor, suggesting an interaction 
between position one of the α-factor side chain and a region of Ste2p covering residues 
251 to 294. In addition, studies with biotinylated [Bpa3]α-factor showed similar 
fragmentation patterns observed from biotinylated [Bpa1]α-factor, revealing that position 
three of α-factor might be interacting with a region of Ste2p covering part of EL2 and an 
extracellular portion of TM5 or the extracellular portions of TM6 and TM7 including the 
EL3. Furthermore, results obtained from biotinylated [Bpa13]α-factor indicated that the 
C-terminus of α-factor is in close proximity to the extracellular portion of TM1, covering 
a region of Ste2p between residues F55 and R58. 
  
Further analysis of the [Bpa13] cross-linked Ste2p region covering residues F55-R58: 
 After identification of cross-linking regions on Ste2p with various Bpa-scanned 
α-factor analogs, the next step was to identify contact residues, which will provide a 
better understanding of agonist-mediated receptor activation. The F55 to R58 residues of 
Ste2p, identified by cross-linking studies using biotinylated [Bpa13]α-factor, were further 
analyzed by site-directed Ala mutagenesis. Binding analyses carried out with the mutants 
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generated in these residues indicated that mutations at residue R58 caused a 10- to 50-
fold poorer binding of α-factor to the mutant receptor compared to the wild type receptor. 
Western blot analyses and biological activity assays with these mutants showed that the 
receptors were expressed on the yeast membranes. Additionally, cross-linking studies 
done with the mutants using biotinylated [Bpa13]α-factor showed that similar biotin 
signal was detected around 54 kDa from all of the Ala mutants (in the region of Ste2p 
between residues M54 to R58), except for the R58A mutant. These results suggested that 
the R58 residue of Ste2p has an important role in ligand binding and that this residue is in 
close proximity to position 13 of α-factor.               
 
Mass spectrometry analysis and preliminary results: 
 An alternative approach to site-directed mutagenesis for identification of contact 
residues between α-factor analogs and Ste2p is the sequencing of the cross-linked 
fragments. Part IV of this dissertation summarized the use of two mass spectrometry 
approaches using MALDI-TOF and LCQ DECA instruments to analyze the cross-linked 
receptor fragments. Although the MALDI-TOF instrument was not used for the 
sequencing of the cross-linked fragments, valuable information was gained during the 
optimization of biotinylated peptide enrichment. Results from this instrument showed 
that a biotinylated peptide ([Bpa8]α-factor analog) could be captured and enriched from a 
complex peptide mixture (CNBr-digested yeast membrane prep.). A protocol adapted 
from Li et al. [9] was used to illustrate the power of an affinity purification combined 
with MALDI-TOF. Analysis of biotinylated [Bpa1]α-factor cross-linked membranes after 
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CNBr digestion with this method revealed the identification of a 6863.9 Da biotinylated 
peptide. With the assumption of a weight shift due to a matrix adduct from sinapinic acid, 
this result was in agreement with previous findings suggesting the interaction of position 
1 of α-factor with a Ste2p region covering residues 251 to 294 as reported in parts II and 
III. 
      Following the optimization of an affinity purification technique to enrich the 
biotinylated cross-linked fragments, nanospray mass spectrometry (NS-MS) analysis was 
carried out by a LCQ DECA instrument. This instrument was preferred due to its 
capabilities of doing tandem mass spectrometry (MS/MS) analysis. The basic principle 
behind these experiments was to obtain pure and enriched cross-linked fragments that 
could be analyzed by NS-MS. Preliminary experiments carried out with biotinylated 
[Bpa8]α-factor in a complex peptide mixture showed that monomeric avidin purification 
was sufficient to capture and enrich enough peptides for sequencing. Similar analyses, 
after a two-step purification of CNBr-digested cross-linked membranes, resulted in 
detection of several clean ion packets representing biotinylated peptide masses. These 
results showed that the optimized purification methods were compatible with the mass 
spectrometric analyses. Previous tries of NS-MS analyses with samples prepared by 
single-step purifications led to a very low signal-to-noise ratio due to the presence of 
many other peptides, buffer components and detergents. Examination of the MS/MS 
spectra from the peptides identified were hampered by the insufficient resolution of the 
instrument used to resolve the charge states of the fragment ions and lack of suitable 
software to aid the analysis. Manual analysis of these spectra did not reveal more than 
two consecutive residues during sequencing, which was not enough to identify a contact 
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residue. Further analysis of the data with specific software would be required to assign 
cross-linking regions or contact residues.     
   
Working model for pheromone binding to Ste2p and receptor activation:    
Although identification of contact residues between the α-factor and its GPCR 
Ste2p was not accomplished by mass spectrometry, invaluable information was gained 
from the photoaffinity cross-linking studies. Data obtained from these studies and others 
including receptor mutagenesis analyses and structure-activity relationships of α-factor 
analogs allowed the proposal of a binding model for the peptide ligand. The model 
(Figure 1) suggests a bend in the α-factor around the Pro8-Gly9 bound [10], with the Lys7 
side chain facing away from the transmembrane domains and interacting with a binding 
pocket formed by the extracellular loops [11]. Studies with position one α-factor analogs 
[12] indicated a strong preference for a large hydrophobic residue at the amino-terminal 
position of the pheromone. In addition fluorescence analyses with Trp3 indicated that the 
side chain of this residue is in a hydrophobic cavity (Ding, Becker, and Naider, 
unpublished results). Based on these studies and cross-linking data presented in this 
dissertation (parts II and III) it is likely that N-terminus of the pheromone interacts with a 
pocket consisting of aromatic residues from the extracellular ends of TM5, TM6, and 
TM7 and the loops EL2 and EL3 attached to these TMs. Depending on the analyses of 
these regions by site-directed mutagenesis studies [2, 13] our binding model suggests that 
Trp1 and Trp3 residues of α-factor could interact with Tyr266 (TM6) and Phe204 (TM5), 
respectively. Furthermore, the C-terminus of the pheromone interacts with the  
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Figure 1: Working model for the fitting of α-factor pheromone into the ligand 
binding site on its GPCR, Ste2p. A) Possible contact residues and their interactions in 
resting state, B) possible interactions between the α-factor (green) and Ste2p (red)  
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extracellular tip of TM1, where Gln10 of α-factor is in  close proximity to residues 47 and 
48 of Ste2p [2] and position 13 localized between receptor residues Arg58 and Tyr98. 
Given the interactions described above, the activity and receptor affinity of 
truncated pheromones [14], and recent studies with fluorescent α-factor analogs [15] a 
multi-step binding and activation of Ste2p upon agonist binding is envisaged. According 
to this hypothesis, first the C-terminus of the pheromone binds to the receptor. Tyr13 
interacts with Arg58 (TM1) disturbing an interaction between this residue and Tyr98 
(TM2), which could destabilize the inactive state of Ste2p. Following this interaction the 
receptor undergoes a conformational change; the active conformation is stabilized by 
interactions between the N-terminus of the pheromone and the hydrophobic pocket 
formed by aromatic residues at the extracellular regions of TM5, TM6 and TM7. Similar 
stepwise mechanisms have been proposed for other GPCRs, where agonists bind and 
initiate movements of transmembrane domains of receptor, thus these movements 
increase the interactions with the various functional groups on the ligand [16-20].        
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CHAPTER 2 
 
Future Studies 
 
Despite the tremendous progress in understanding the structure of GPCRs over 
the last few years including the solving of the crystal structure of rhodopsin [21] only 
partial information is known concerning GPCR binding sites for most molecules 
including peptides. This dissertation summarizes the first steps accomplished in mapping 
the α-factor binding site(s) within Ste2p using benzoyl-L-phenylalanine (Bpa)-containing 
analogs of the pheromone. Work to date has determined several interactions between the 
side chains of α-factor residues and receptor regions as detailed above. However, in order 
to understand the activation mechanism of GPCRs upon agonist binding, further studies 
are necessary to reveal additional details of the ligand-bound structure. This final part of 
the dissertation outlines a few of the methods that could be applied, in our current model 
system, to elucidate the interactions between the α-factor and its GPCR Ste2p. 
 
Cross-linking studies: 
  Photoaffinity cross-linking studies using a benzophenone chromophore (Bpa) 
have been applied successfully throughout this study. Unfortunately, incorporation of the 
Bpa replacing every single residue of α-factor was not possible, due to loss of biological 
activity and poor binding. In order to overcome these problems relatively smaller 
photoactivatable cross-linkers like p-azido-phenylanaline or p-nitro-L-phenylalanine 
could be used to complete the scan through the whole pheromone. These new cross-
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linkers could also be used to confirm the results obtained by Bpa. In cases, when the 
biological activity and binding of a photoaffinity cross-linker was not optimum, as 
discussed in Part III of this dissertation, one always can argue the validity of the results. 
Obtaining similar cross-linking results by using different cross-linkers at the same 
position and comparing the results could resolve these issues.  
 Beside new cross-linkers, α-factor analogs that carry two cross-linkers can be 
designed and synthesized. Such an analog carrying Bpa residues at the first and thirteenth 
positions could be used to lock the receptor in a certain conformation. After cross-
linking, the receptor can be purified and further analyzed to identify the stabilizing 
interactions. A receptor that is locked in the active conformation would be also very 
useful for crystallization studies. As there would be relatively less mobility, such a 
receptor could yield better diffracting crystals.  
 Alternatively, cross-linking studies could be used to analyze the interactions 
between TM domains under certain conditions such as agonist or antagonist bound states. 
Recent studies carried out by Chin et al. [22, 23] described the in vivo incorporation of 
photoaffinity cross-linker (Bpa) into any protein sequence (in response to amber codon 
TAG) by site-directed mutagenesis. These studies made it possible to analyze protein- 
protein interactions or intra molecular interactions by using photoaffinity cross-linking. 
Incorporation of Bpa into Ste2p sequence would be very useful to study the proximity of 
TMs. Following cross-linking the receptor could be digested chemically or enzymatically 
to further analyze which TM is interacting with the residue modified by the cross-linker. 
Also this approach can be used to cross-link the receptor back to the ligand to identify the 
important residues on the receptor that are likely to interact with the α-factor. 
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Combination of results from such cross-linking studies with the results discussed in this 
dissertation could reveal contact residues between the pheromone and Ste2p.     
 
Site-directed mutagenesis: 
 Another way to identify the contact residues between the α-factor and its receptor 
is to carry out site-directed mutagenesis. The regions of Ste2p identified by cross-linking 
studies could be analyzed by site-directed mutagenesis as described in Part III of this 
dissertation. Binding and biological activity assays with these mutants could aid the 
identification of the ligand interacting site(s). However, mutagenesis studies carried out 
by methionine instead of classical alanine mutagenesis would be useful. Insertion of a 
methionine in these regions could be used in combination with further CNBr digestion to 
decrease the size of the region identified by cross-linking. In addition a recent approach 
reported by Rihakova et al. [24] could be used, which takes advantage of a modified Bpa 
analog (NO2Bpa), to determine contact residues. This modified Bpa analog has an 
increased selectivity for methionine and does not cross-link unless a methionine residue 
is in proper distance and orientation. Use of such a cross-linker and a methionine scanned 
receptor will help the identification of contact residues.  
      
Mass Spectrometry: 
 Part IV of this dissertation details the use of mass spectrometry in the analysis of 
cross-linked receptor fragments. However, the data analyses from these studies were 
limited due to relatively low sensitivity of the instruments used, lack of proper algorithms 
to analyze complex fragmentation patterns, natural loses common in peptide ion 
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fragmentation, and unusual and difficult-to-interpret fragmentation of branched peptides. 
In addition, the low signal-to-noise ratio observed in the MS/MS spectra further 
complicated the analysis and determination of sequence information from cross-linked 
peptides.  
 Recent developments in instrument design and computational analyses could help 
to overcome most of these problems. Studies with new instruments, using a combination 
of quadrupolar ion trap and a fourier transform ion cyclotron resonance cell, showed that 
it is possible to obtain very high mass accuracy (below 2 ppm) and do MS/MS analysis at 
the same time [25, 26]. This new strategy suggested that determination of the amino acid 
composition of the peptide prior to sequencing would aid the subsequent peptide 
sequencing which could be performed by a permutation-based scoring algorithm. 
Analysis of the cross-linked fragments by such a powerful instrument and proper 
algorithms could help identification of the contact residues between the α-factor and 
Ste2p. 
  Besides the complexity of the fragmentation spectra and the sensitivity of the 
mass spectrometer used, identification of the cross-linked fragment ions in a total ion 
spectrum was challenging. Specific labeling of the cross-linked fragments by the use of 
α-factor analogs that are identical except from the overall mass would result in twin 
peaks in relative abundance vs. time spectrum (Figure 2). This property could be used to 
identify parent ions from cross-linked fragments in complex mixtures. The idea is based 
on the principle of identifying target peptides by the use of stable-isotope labeling named 
as the isotope coded affinity tag (ICAT)-based protein profiling [27, 28]. Such α-factor 
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Figure 2: Total ion spectrum of two [Bpa1]α-factor analogs, obtained by LCQ DECA. Two analogs containing Bpa at 
position one and had a mass difference of 42 Da were mixed and analyzed by NS-MS. Twin peaks were observed at about 30 min 
of the elution from a C18 column.  
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analogs that carry the cross-linker at the same position and differ by only several Da in 
mass could be designed and used for identification of cross-linked fragments in mass 
spectrometry analysis. Currently in our lab, studies with such peptides that have Bpa at 
position 1 and carry a mass difference of 42 Da (due to different length linkers between 
the biotinyl group and the epsilon amine of lysine at position seven in α-factor) are being 
used to optimize conditions to identify cross-linked fragments (Figure 2). After 
fragmentation, Ste2p cross-linked with analogs that only differ by mass will generate 
cross-linked fragments that are 42 Da apart with the assumption that they cross-link to the 
same fragment. Detection and analysis of twin peaks generated by this method will 
simplify the data analysis, thus increase accuracy.      
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